Notes to Unaudited Condensed Consolidated Financial
Statements
1.
Nature of Business and Basis of
Presentation.
We are
a Delaware corporation, originally incorporated in 1988 under the
name “Terrapin Diagnostics, Inc.” in the State of
Delaware. In 1998, we changed our corporate name to “Telik,
Inc.” and changed our name again to “MabVax
Therapeutics Holdings, Inc.” in 2014. Unless the context
requires otherwise, references to “we,”
“our,” “us,” “MabVax” or the
“Company” in this prospectus mean MabVax Therapeutics
Holdings, Inc. on a condensed consolidated financial statement
basis with our wholly-owned subsidiary, MabVax Therapeutics,
Inc.
Nature
of Business – About Us
MabVax
Therapeutics Holdings, Inc. is a clinical-stage biotechnology
company with a fully human antibody discovery platform focused on
the rapid translation into clinical development of products to
address unmet medical needs in the treatment of cancer and
pancreatitis. We discovered a pipeline of human monoclonal antibody
product candidates based on the protective immune responses
generated by patients who have been vaccinated against targeted
cancers. Our therapeutic vaccine product candidates under
development were discovered at Memorial Sloan Kettering Cancer
Center (“MSK”) and are exclusively licensed to us as
well as exclusive rights to blood samples from patients who were
vaccinated with the same licensed vaccines. We operate in only one
business segment.
Our
lead development product, MVT-5873, is a fully human IgG1
monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an
epitope on CA19-9. MVT-5873 is currently in Phase 1 clinical
trials as a therapeutic agent for patients with pancreatic cancer
and other CA19-9 positive tumors. CA19-9 is expressed in over 90%
of pancreatic cancers and in other diseases including pancreatitis.
CA19-9 plays an important role in tumor adhesion and metastasis and
is a marker of an aggressive cancer phenotype. CA19-9 also has an
important role in the biological pathways that can result in
pancreatitis. CA19-9 serum levels are considered a valuable adjunct
in the diagnosis, prognosis and treatment monitoring of pancreatic
cancer and now pancreatitis. With our collaborators including MSK,
Sarah Cannon Research Institute, Honor Health and Imaging
Endpoints, we have treated more than 56 patients with either our
therapeutic antibody designated as MVT-5873 or our PET imaging
diagnostic product designated as MVT-2163 in Phase 1 clinical
studies, and demonstrated early safety, specificity for the target
and a potential efficacy signal. The Company also has a
radioimmunotherapy product, designated as MVT-1075, that is also in
Phase 1 clinical development. For additional information,
please visit the Company's website,
www.mabvax.com
.
Information on the Company’s
website is not incorporated herein.
Studies
conducted by Cold Spring Harbor Laboratories have demonstrated that
antibodies capable of binding to CA19-9 and blocking the downstream
biological pathways of pancreatitis have a positive effect on
ameliorating the disease. Combining the preclinical science
supporting the use of the CA19-9 blocking antibodies in the
treatment of pancreatitis with the clinically validated data and
supplies of MVT-5873 already available gives MabVax the
opportunity, assuming adequate funding, to move quickly into the
clinic in a mid-stage proof of concept clinical trial in the
near-term.
The
Company completed a preclinical asset sale and license agreement
with Boehringer Ingelheim International GmbH (“Boehringer
Ingelheim”) in July 2018, and a license agreement for a
cancer vaccine to Y-mAbs Therapeutics, Inc. in June 2018. The
Company received nearly $5 million in upfront payments from these
two transactions to begin the third quarter, with an additional
$7.6 million in downstream milestones the Company may receive based
either on reaching an anniversary date of entering the agreement,
provided the agreement is not canceled before a milestone has been
earned or due, or upon reaching a milestone.
We have
incurred net losses since inception and expect to incur substantial
losses for the foreseeable future as we continue our research,
development and clinical activities. To date, we have funded
operations primarily through revenues earned from asset sale and
license agreements, proceeds from the sale of common and preferred
stock, government grants, the issuance of debt, the issuance of
common stock in lieu of cash for services, payments from
collaborators, and interest income. The process of developing
products will require significant additional research and
development, preclinical testing and clinical trials, as well as
regulatory approvals. We expect these activities, together with
general and administrative expenses, to result in substantial
operating losses for the foreseeable future. We will not receive
substantial revenue unless we or our collaborative partners
complete clinical trials, obtain regulatory approvals and
successfully commercialize one or more product candidates; or we
license our technology after achieving one or more milestones of
interest to a potential partner.
Reverse Stock Splits
On
August 16, 2016, we filed a certificate of amendment to our Amended
and Restated Certificate of Incorporation with the Secretary of
State of the State of Delaware to effectuate a reverse stock split
of our issued and outstanding common stock on a 1-for-7.4 basis,
effective on August 16, 2016 (the “2016 Reverse Stock
Split”). On February 14, 2018, we filed a certificate of
amendment to our Amended and Restated Certificate of Incorporation
with the Secretary of State of the State of Delaware to effectuate
another reverse stock split of our issued and outstanding common
stock on a 1-for-3 basis, effective on February 16, 2018 (the
“2018 Reverse Stock Split”; collectively with the 2016
Reverse Stock Split, the “Reverse Stock Splits”). All
share and per share amounts, and number of shares of common stock
into which each share of preferred stock will convert, in the
financial statements and notes thereto have been retroactively
adjusted for all periods presented to give effect to the Reverse
Stock Splits, including rounding for fractional shares and
reclassifying any amount equal to the reduction in par value of
common stock to additional paid-in capital.
Delaware
Order Granting Petition for Relief
On
September 20, 2018, the Court of Chancery of the State of Delaware
(the “Court”) entered an order validating (i) issuances
of common stock upon conversions of the Company’s preferred
stock occurring between June 30, 2014 and February 12, 2018, and
(ii) stockholder approval of corporate actions presented to the
Company’s stockholders from June 30, 2014 to February 12,
2018. In so doing, the Court granted the Company’s Verified
Petition for Relief Under
8 Del.
C. § 205
(the “Delaware Petition”)
captioned
In re: MabVax
Therapeutics Holdings, Inc.
, filed on July 27, 2018, in
order to rectify the uncertainty regarding whether shares of our
common stock were validly issued upon conversion of our preferred
stock from June 30, 2014 to February 12, 2018. The Delaware
Petition and the Court’s order granting the Delaware Petition
are discussed further in the Section below titled, “Court
Validation of Previously Issued Shares of Common Stock upon
Conversion of Preferred Stock.”
Basis
of Presentation
The
balance sheet data at December 31, 2017, was derived from audited
financial statements at that date. It does not include, however,
all the information and notes required by accounting principles
generally accepted in the United States of America
(“GAAP”) for complete financial
statements.
The
accompanying unaudited condensed consolidated financial statements
were prepared using GAAP for interim financial information and the
instructions to Regulation S-X. While these statements reflect all
normal recurring adjustments, which are, in the opinion of
management, necessary for a fair presentation of the results of the
interim period, they do not include all information or notes
required by GAAP for annual financial statements and should be read
in conjunction with the audited financial statements of MabVax
Therapeutics Holdings, Inc. for the year ended December 31,
2017, included in our Annual Report on Form 10-K filed with
the SEC on April 2, 2018
and amended
on Form 10-K/A as filed with the SEC on October 15, 2018
.
These quarterly results are not necessarily indicative of future
results.
Use
of Estimates
The
preparation of condensed consolidated financial statements in
conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at
the date of the condensed consolidated financial statements and the
reported amounts of expenses during the reporting period.
Management believes that these estimates are reasonable; however,
actual results may differ from these estimates.
Fair
Value Measurements
The
Company had no assets or liabilities that were measured using
quoted prices for similar assets and liabilities or significant
unobservable inputs (Level 2 and Level 3 assets and liabilities,
respectively) as of September 30, 2018 and December 31, 2017. The
carrying value of cash held in money market funds of $864,110 and
$1,196 as of September 30, 2018 and December 31, 2017,
respectively, is included in cash and cash equivalents and
approximates market values based on quoted market prices (Level 1
inputs).
Concentration
of Credit Risk
Credit
risk represents the risk that the Company would incur a loss if
counterparties failed to perform pursuant to the terms of their
agreements. Financial instruments that potentially expose the
Company to concentrations of credit risk consist primarily of cash
and cash equivalents. Cash and cash equivalents consist of money
market funds with major financial institutions in the United
States. These funds may be redeemed upon demand and, therefore,
bear minimal risk. The Company does not anticipate any losses on
such balances.
Consideration
of Impairment of Goodwill
The
Company maintains a goodwill balance of $6,826,003 on its balance
sheet as of September 30, 3018 and December 31, 2017, and tests for
impairment at least annually and whenever there has been a material
change in the Company by applying GAAP principles related to ASC
350
Intangibles – Goodwill
and Other
(ASC 350). Based on a qualitative analysis of the
Company’s products in the pipeline as of September 30, 2018,
the $4.0 million in revenue earned during the quarter, and a
potential new indication for the Company’s lead antibody
program, MVT-5873, for the treatment of pancreatitis, the Company
concluded there was no goodwill impairment as of September 30,
2018. The goodwill was established in connection with the merger of
MabVax Therapeutics, Inc. a Delaware corporation, with a subsidiary
of the Company on July 8, 2014, pursuant to an Agreement and Plan
of Merger, dated May 12, 2014, by and among the Company, a
subsidiary of the Company and MabVax Therapeutics, Inc. as amended
June 30, 2014 and July 7, 2014 (the
“Merger”), whereby MabVax Therapeutics, Inc. is the
surviving company in the Merger, as a wholly-owned subsidiary of
the Company.
Revenue
Recognition
Effective January
1, 2018, the Company adopted Accounting Standards Codification, or
ASC, Topic 606,
Revenue from
Contracts with Customers
(Topic 606), using the full
retrospective transition method. Under this method, the Company
would have been required to revise its financial statements, if
applicable, for the years ended December 31, 2016 and 2017, and
applicable interim periods within those years, as if Topic 606 had
been effective for those periods. However, Topic 606 did not have
any impact on the Company’s revenue recognition upon
adoption. This standard applies to all contracts with customers,
except for contracts that are within the scope of other standards,
such as leases, insurance, collaboration arrangements and financial
instruments. Under Topic 606, an entity recognizes revenue when its
customer obtains control of promised goods or services in an amount
that reflects the consideration which the entity expects to receive
in exchange for those goods and services. To determine revenue
recognition for arrangements that an entity determines are within
the scope of Topic 606, the entity performs the following five
steps: (i) identify the contract(s) with the customer(s); (ii)
identify the performance obligations in the contract; (iii)
determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v)
recognize revenue when (or as) the entity satisfies a performance
obligation. The Company only applies the five-step model to
contracts when it is probable that the entity will collect the
consideration it is entitled to in exchange for the goods and
services it transfers to the customer. At contract inception, the
Company assesses the goods or services promised within each
contract that falls under the scope of Topic 606, determines those
that are performance obligations and assesses whether each promised
good or service is distinct. The Company then recognizes as revenue
the amount of the transaction price that is allocated to the
respective performance obligation when (or as) the performance
obligation is satisfied.
License and Other Revenues
The
Company enters into licensing agreements which are within the scope
of Topic 606, under which it licenses certain of its product
candidates’ rights to third parties. The terms of these
arrangements typically include payment of one or more of the
following: non-refundable, up-front license fees; development,
regulatory and commercial milestone payments; and royalties on
Gross Profit of the licensed product, which will be classified as
royalty revenues, if and when earned.
In
determining the appropriate amount of revenue to be recognized as
it fulfills its obligation under each of its agreements, the
Company performs the five steps described above. As part of the
accounting for these arrangements, the Company must develop
assumptions that require judgment to determine the stand-alone
selling price, which may include forecasted revenues, development
timelines, reimbursement of personnel costs, discount rates and
probabilities of technical and regulatory success.
Licensing of Intellectual
Property
–
If
the license to the Company’s intellectual property is
determined to be distinct from the other performance obligations
identified in the arrangement, the Company recognizes revenue from
non-refundable, up-front fees allocated to the license when the
license is transferred to the licensee and the licensee is able to
use and benefit from the license. For licenses that are bundled
with other performance obligations, the Company utilizes judgment
to assess the nature of the combined performance obligation to
determine whether the combined performance obligation is satisfied
over time or at a point in time and, if over time, the appropriate
method of measuring progress for purposes of recognizing revenue
from non-refundable, up-front fees. The Company evaluates the
measure of progress each reporting period, and, if necessary,
adjusts the measure of performance and related revenue
recognition.
Milestone Payments
–
At the inception of
each arrangement that includes development milestone payments, the
Company evaluates whether the milestones are considered probable of
being reached and estimates the amount to be included in the
transaction price using the most likely amount method. If it is
probable that a significant revenue reversal will not occur, the
associated milestone value is included in the transaction price.
Milestone payments that are not within the control of the Company
or the licensee, such as regulatory approvals, are not considered
probable of being achieved until those approvals are received. The
transaction price is then allocated to each performance obligation
on a relative stand-alone selling price basis, for which the
Company recognizes revenue as or when the performance obligations
under the contract are satisfied. At the end of each subsequent
reporting period, the Company re-evaluates the probability of
achievement of such development milestones and any related
constraint and, if necessary, adjusts its estimate of the overall
transaction price. Any such adjustments are recorded on a
cumulative catch-up basis, which would affect license,
collaboration and other revenues and earnings in their period of
adjustment. To date, the Company has not recognized any milestone
payments, because the milestones are not within the control of the
Company and the technology is at an early stage of development, or
the licensee has the ability to terminate the agreement before the
milestone payment is due.
Royalties –
For arrangements that include sales-based royalties, including
milestone payments based on the level of sales, and for which the
license is deemed to be the predominant item to which royalties
relate, the Company recognizes revenue at the later of (i) when the
related sales occur or (ii) when the performance obligation to
which some or all of the royalty has been allocated has been
satisfied (or partially satisfied). To date, the Company has not
recognized any royalty revenue from its license
agreements.
Accrued Liabilities
The
Company is required to estimate accrued liabilities as part of the
process of preparing its financial statements. The estimation of
accrued liabilities involves identifying services that have been
performed on the Company’s behalf, and then estimating the
level of service performed and the associated cost incurred for
such services as of each balance sheet date. Accrued liabilities
include professional service fees, such as for lawyers and
accountants, contract service fees, such as those under contracts
with clinical monitors, data management organizations and
investigators in conjunction with clinical trials, and fees to
contract manufacturers in conjunction with the production of
clinical materials. Pursuant to the Company’s assessment of
the services that have been performed, the Company recognizes these
expenses as the services are provided. Such assessments include:
(i) an evaluation by the project manager of the work that has been
completed during the period; (ii) measurement of progress prepared
internally and/or provided by the third-party service provider;
(iii) analyses of data that justify the progress; and (iv) the
Company’s judgment.
Research and Development Costs
Except
for payments made in advance of services, research and development
costs are expensed as incurred. For payments made in advance, the
Company recognizes research and development expense as the services
are rendered. Research and development costs primarily consist of
salaries and related expenses for personnel, laboratory supplies
and raw materials, and sponsored research, Other research and
development expenses include fees paid to consultants and outside
service providers including clinical research organizations and
clinical manufacturing organizations.
Recently Issued Accounting Standards
Adopted Accounting Standards
In May 2014, the FASB issued Topic 606 which
amends the guidance for accounting for revenue from contracts with
customers. This ASU supersedes the revenue recognition requirements
in ASC Topic 605,
Revenue Recognition,
and creates a new Topic 606,
Revenue from
Contracts with Customers
. The
Company did not have any revenue generating contracts in 2017,
therefore, the adoption of this standard had no effect on the
financial statement line items that could have been affected by the
transition. For further discussion on the adoption of this
standard, see “Revenue Recognition” above and Note 10,
“Contracts and Agreements.”
In
January 2017, the FASB issued ASU No. 2017-01,
Business Combinations (Topic 805), Clarifying
the Definition of a Business
. The guidance changes the
definition of a business to assist entities with evaluating when a
set of transferred assets and activities is a business. The new
guidance requires an entity to evaluate if substantially all of the
fair value of the gross assets acquired is concentrated in a single
identifiable asset or a group of similar identifiable assets; if
so, the set of transferred assets and activities is not a business.
The Company adopted this ASU as of January 1, 2018. The adoption of
this ASU had no impact on the Company’s financial statements
for the three and nine months ended September 30,
2018.
In May
2017, the FASB issued ASU No. 2017-09,
Compensation – Stock Compensation (Topic
718), Scope of Modification Accounting
, which clarifies when
a change to the terms or conditions of a share-based payment award
must be accounted for as a modification. The new guidance requires
modification accounting if the fair value, vesting conditions or
classification of the award is not the same immediately before and
after a change to the terms and conditions of the
award. The Company adopted this ASU on a prospective
basis as of January 1, 2018. The adoption of this ASU had no impact
on the Company’s financial statements for the three and nine
months ended September 30, 2018.
In
August 2016, the FASB issued ASU No. 2016-15 (“ASU
2016-15”), “
Statement
of Cash Flows (Topic 230): Classification of Certain Cash Receipts
and Cash Payments
.” The standard provides guidance on
eight (8) cash flow issues: (1) debt prepayment or debt
extinguishment costs; (2) settlement of zero-coupon bonds; (3)
contingent consideration payments after a business combination; (4)
proceeds from the settlement of insurance claims; (5) proceeds from
the settlement of corporate-owned life insurance policies; (6)
distributions received from equity method investees; (7) beneficial
interests in securitization transactions; and (8) separately
identifiable cash flows and application of the predominance
principle. ASU 2016-15 addresses how certain cash receipts and cash
payments are presented and classified in the statement of cash
flows. The Company adopted this ASU effective January 1, 2018. The
adoption of this new standard did not have a material impact on our
condensed consolidated financial statements.
Accounting Standards Not Yet Adopted
In
February 2016, the FASB issued ASU No. 2016-02,
Leases (Topic 842)
, which supersedes
existing guidance on accounting for leases in
Leases (Topic 840)
and generally
requires all leases, including operating leases, to be recognized
in the statement of financial position as right-of-use assets and
lease liabilities by lessees. The provisions of ASU 2016-02 are to
be applied using a modified retrospective approach and are
effective for reporting periods beginning after December 15, 2018;
early adoption is permitted. The Company plans to elect the
transition option provided under ASU 2018-11, which will not
require adjustments to comparative periods nor require modified
disclosures in those comparative periods. Upon adoption, the
Company expects to elect the transition package of practical
expedients permitted within the new standard, which among other
things, allows the carryforward of the historical lease
classification. Based on its anticipated election of practical
expedients, the Company anticipates the recognition of right of use
assets and related lease liabilities on its balance sheets related
to its leases. The Company intends on engaging a professional
services firm to assist in the implementation of ASC 842, and to
analyze the impact of adopting ASC 842 on the Company’s
statements of income and balance sheets.
In June
2018, the FASB issued ASU No. 2018-07,
Compensation – Stock Compensation (Topic
718):
Improvements to
Nonemployee Share-based Payment Accounting
, to simplify the
accounting for share-based payments to nonemployees by aligning it
with the accounting for share-based payments to employees, with
certain exceptions. The provisions of ASU 2018-07 are effective for
reporting periods beginning after December 15, 2018, including
interim periods within that fiscal year; early adoption is
permitted, but no earlier than a company’s adoption date of
Topic 606. Upon transition, the Company will be required to measure
these nonemployee awards at fair value as of the adoption
date. The Company had not early adopted this ASU as of
September 30, 2018, but plans on adopting this ASU for its
reporting period beginning January 1, 2019. The Company is
currently evaluating the effect that this ASU will have on its
financial statements.
In
June 2016, the FASB issued ASU No. 2016-13,
“
Financial
Instruments—Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments
.” This ASU requires
instruments measured at amortized cost to be presented at the net
amount expected to be collected. Entities are also required to
record allowances for available-for-sale debt securities rather
than reduce the carrying amount. This ASU is effective for fiscal
years beginning after December 15, 2019, including interim
periods within those fiscal years. We expect the adoption of this
new standard will not have a material impact on our condensed
consolidated financial statements.
In
January 2017, the FASB issued ASU
No. 2017-04, “
Intangibles—Goodwill and Other (Topic
350): Simplifying the Test for Goodwill
Impairment
.” This ASU eliminates Step 2 from the
goodwill impairment test. Instead, an entity should recognize an
impairment charge for the amount by which the carrying value
exceeds the reporting unit’s fair value, not to exceed the
total amount of goodwill allocated to that reporting unit. This ASU
is effective for annual or any interim goodwill impairment tests in
fiscal years beginning after December 15, 2019. We expect the
adoption of this new standard will not have a material impact on
our condensed consolidated financial statements.
With
the exception of the new standards discussed above, there have been
no new accounting pronouncements that have significance, or
potential significance, to the Company’s financial
statements.
2.
Liquidity and Going
Concern.
The
accompanying condensed consolidated financial statements have been
prepared on the going concern basis, which assumes that the Company
will continue to operate as a going concern and which contemplates
the realization of assets and the satisfaction of liabilities and
commitments in the normal course of business. As reflected in the
accompanying condensed consolidated financial statements, the
Company had a net loss of $5,908,068, net cash used in operating
activities of $2,620,437, net cash used in investing activities of
$0, and net cash provided by financing activities of $2,686,478 for
the nine months ended September 30, 2018. As of September 30, 2018,
the Company had $951,751 in cash and cash equivalents, a working
capital deficit of $6,334,244, an accumulated deficit of
$118,349,884, and stockholders’ equity of $42,558. The
Company also has significant debt payments due within the next
twelve months.
Overview
of 2018 Private Placements
Between
February 2 and February 10, 2018, the Company entered into separate
purchase agreements with investors pursuant to which the Company
sold (i) shares of its common stock, (ii) shares of its convertible
preferred stock
,
and
(iii) warrants to purchase shares of common (the “February
2018 Private Placements”). From April 30 to May 2, 2018, the
Company entered into separate purchase agreements with investors
pursuant to which we agreed to sell shares of its common stock and
convertible preferred stock
(the “May 2018 Private
Placements”)
. No financial advisor was used in
connection with the February 2018 Private Placements nor the May
2018 Private Placements.
The
securities issued in connection with the February 2018 Private
Placements and the May 2018 Private Placements were offered and
sold solely to accredited investors in reliance on the exemption
from registration afforded by Rule 506 of Regulation D and Section
4(a)(2) of the Securities Act. The Company entered into separate
registration rights agreements with each of the investors in the
February 2018 Private Placements and the May 2018 Private
Placements, pursuant to which the Company agreed to undertake to
file a registration statement to register the resale of the shares
of common stock and the shares of common stock underlying the
warrants and preferred stock. The Company also agreed to use
reasonable best efforts to cause such registration statement to be
declared effective and to maintain the effectiveness of the
registration statement until all of such shares of common stock
have been sold or are otherwise able to be sold pursuant to Rule
144 under the Securities Act, without any
restrictions.
February
2018 Private Placements
In
connection with the February 2018 Private Placements, the Company
sold (i) an aggregate of 555,557 shares of its common stock for an
aggregate purchase price of $1,250,000, or $2.25 per share, (ii)
5,000 shares of our newly designated 0%
Series M Convertible Preferred Stock
(the “Series M Preferred Stock”) for an aggregate
purchase price of $1,500,000, or $300.00 per share,
and
(iii) warrants to purchase up to an aggregate of 855,561 shares of
common stock each with an exercise price of $2.70 per share. The
net proceeds of the February 2018 Private Placements were
$2,700,000 after transaction costs of $50,000.
May
2018 Private Placements
In
connection with the May 2018 Private Placements, the Company agreed
to sell (i) 218,182 shares of common stock at an aggregate purchase
price of $240,000, or $1.10 per share, and (ii) 5,363.64 shares of
newly designated 0%
Series
N Convertible Preferred Stock (the “Series N Preferred
Stock”) at an aggregate purchase price of $590,000, or
$110.00 per share
. The following investors in the May 2018
Private Placements
also
invested in the February 2018 Private Placements (the “Prior
Investors”):
GRQ Consultants Inc., Roth 401K FBO
Renee Honig; GRQ Consultants Inc., Roth 401K FBO Barry Honig;
Melechdavid, Inc.; Grander Holdings Inc. 401K; Robert S. Colman
Trust UDT 3/13/85; Ben Brauser; Joshua A. Brauser; Daniel A.
Brauser; Gregory Aaron Brauser; Erick E. Richardson; and Ronald B.
Low.
Under
the terms of the May 2018 Private Placements, we were required to
offer an aggregate of 12,777.77 shares (the “May 2018
Inducement Shares”) of newly designated 0% Series O Preferred
Stock (the “Series O Preferred Stock”) to investors who
previously purchased securities in the February 2018 Private
Placements and who also purchased securities in the May 2018
Private Placements with an aggregate purchase price of at least 40%
of their investment amounts in the February 2018 Private
Placements. Based on the closing of the offering, and participation
of the Prior Investors who invested an aggregate of $830,000 (the
“May 2018 Inducement Investors”), the Company issued an
aggregate of 10,605.56 May 2018 Inducement Shares in the form of
Series O Preferred Stock convertible into an aggregate of 1,060,556
shares of common stock.
The
May 2018 Private Placements closed on May 15, 2018, with the
Company receiving gross proceeds totaling
$830,000
.
Plans
for Continuing to Fund the Company’s Losses from
Operations
We plan
to continue to fund the Company’s losses from operations and
capital funding needs through equity financings in the form of
common stock and preferred stock, licensing agreements, asset
sales, strategic collaborations, government grants, issuance of
common stock in lieu of cash for services, debt financings or other
arrangements. Further, to extend availability of existing cash
available for our programs for achieving milestones or a strategic
transaction, in mid-2017 we began reducing personnel from
twenty-five (25) full time employees to six (6) as of November 12,
2018, and reduced other operating expenses following the completion
of two (2) Phase 1a clinical trials of our lead antibody product
candidate, HuMab 5B1, which has enabled us to reduce our
expenditures on clinical trials. We plan to continue funding Phase
1 clinical trials of our product candidate MVT-5873 in cancer
patients, MVT-2163 as a diagnostic agent in pancreatic cancer
patients, and MVT-1075 as a radioimmunotherapy agent for the
treatment of various cancers, preclinical testing of follow-on
antibody candidates, investor and public relations, SEC compliance
efforts, and the general and administrative expenses associated
with each of these activities, and prepare for a mid-stage
proof-of-concept clinical trial of MVT-5873 as a treatment for
pancreatitis. We will also support research efforts and continued
Phase 1 clinical development by MSK of our Positron-emission
tomography (“PET”) imaging agent MVT-2163 under an R01
Research Grant provided by the National Institutes of Health
(“NIH”) to MSK in April 2018, with the bulk of the
costs of the research and clinical development being borne by the
NIH. Although we achieved two strategic transactions in late June
2018 and early July 2018, there can be no assurance that we will be
able to achieve additional license and or sales agreements and earn
revenues large enough to offset our operating expenses in the
future, as discussed further in Management’s Discussion and
Analysis of Financial Condition and Results of Operations of our
Quarterly Report. We cannot be sure that asset sales or licensing
agreements can be signed in a timely manner, if any, or that
capital funding will be available on reasonable terms, or at all.
If we are unable to secure significant asset sales or licensing
agreements and adequate additional funding, we may be forced to
make additional reductions in spending, incur further cutbacks in
personnel, extend payment terms with suppliers, liquidate assets
where possible, suspend or curtail planned programs and/or cease
our operations entirely. In addition, if the Company does not meet
its payment obligations to third parties as they come due, it may
be subject to litigation claims. Even if we are successful in
defending against these claims, litigation could result in
substantial costs and be a distraction to management.
We
anticipate the Company will continue to incur net losses into the
foreseeable future as we: (i) continue our clinical trial of
MVT-5873 in cancer patients, (ii) continue our clinical trial for
the development of MVT-1075 as a radioimmunotherapy, (iii) prepare
for a mid-stage proof-of-concept clinical trial of MVT-5873 as a
treatment for pancreatitis, to be initiated in early 2019, and (iv)
continue operations as a public company. Based on receipt of $2.7
million net of transaction costs in February 2018, an additional
$830,000 from a financing in May 2018, and receipt of $700,000 from
an upfront payment under a sublicense agreement with Y-mAbs
Therapeutics, Inc. (“Y-mAbs”) during the first nine
months of 2018; and receipt of $4.0 million in gross proceeds from
an asset purchase and license agreement with Boehringer Ingelheim
International GmbH (“Boehringer Ingelheim”) in July
2018, and without any other additional funding or receipt of
payments from potential asset sales or licensing agreements, we
expect we will have sufficient funds to meet our obligations until
December 2018. These conditions give rise to substantial doubt as
to the Company’s ability to continue as a going concern. Any
of these actions could materially harm the Company’s
business, results of operations, and prospects. The accompanying
consolidated financial statements do not include any adjustments
that might result from the outcome of this
uncertainty.
If the
Company raises additional funds by issuing equity securities,
substantial dilution to existing stockholders could result. If the
Company raises additional funds by incurring debt financing, the
terms of the debt may involve significant cash payment obligations
as well as covenants and specific financial ratios that may
restrict the Company’s ability to operate its
business.
3.
Cash and Cash
Equivalents.
We
consider all highly liquid investments purchased with original
maturities of three months or less to be cash equivalents. The
Company limits its exposure to credit loss by holding cash in U.S.
dollars or, from time to time, placing cash and investments in U.S.
government, agency and government-sponsored enterprise
obligations.
4.
Fair Value of Financial
Instruments.
Our
financial instruments consist of cash and cash equivalents and
accounts payable, all of which are generally considered to be
representative of their respective fair values because of the
short-term nature of those instruments.
5.
Convertible Preferred Stock, Common
Stock and Warrants.
Dividends
on Preferred Stock
We
immediately recognize the changes in the redemption value on
preferred stock as they occur and the carrying value of the
security is adjusted to equal what the redemption amount would be
as if redemption were to occur at the end of the reporting date
based on the conditions that exist as of that date.
No
dividends have ever been declared by the Board of Directors of the
Company (the “Board of Directors”) since our inception
on any series of convertible preferred stock.
Overview of Preferred Stock & Beneficial Ownership
Blockers
All
issued and outstanding shares of the Company’s preferred
stock have a par value of $0.01 per share and rank prior to any
class or series of the Company’s common stock as to the
distribution of assets upon liquidation, dissolution or winding up
of the Company or as to the payment of dividends. The Company must
obtain the consent of a majority of the holders of each series of
preferred stock before taking any action that materially and
adversely affects the rights, preferences, or privileges of the
applicable series of preferred stock. Also, the holders of each
series of preferred stock are entitled to vote on any matter on
which the holders of common stock are entitled to vote.
Additionally, the Company must obtain the consent of the holders of
the Series E Preferred Stock, Series J Preferred Stock, Series L
Preferred Stock, and Series N Preferred Stock (as each of those
terms are defined below) prior to increasing or decreasing (other
than by conversion) the authorized number of the applicable series
of preferred stock or issuing any additional shares of the
applicable series of preferred stock.
Generally, the same investors participated in each
of the Company’s preferred stock offerings such that the same
investors own most of the shares of each series of the
Company’s issued and outstanding preferred stock. Pursuant to
terms negotiated in connection with the Company’s sales of
preferred stock,
the certificates of
designation for the Company’s preferred stock each include a
4.99% and/or 9.99% beneficial ownership conversion blocker.
These conversion blockers
may be decreased or increased, at the option of each holder, to a
percentage not to exceed 9.99% upon written notice to the Company,
as further specified in the applicable certificate of
designation
. The certificate of
designation for our S
eries N
Preferred Stock
includes a 19.99%
blocker provision applicable until
stockholders approve issuances of common stock in
excess of such amount. The stated values, as applicable, and
conversion prices of our preferred stock are subject to adjustment
in the event of stock splits, stock dividends, combination of
shares and similar recapitalization transactions. The
Company’s ability to administer the blockers according to
their terms depends on group determinations and accurate reporting
by outside investors with respect to their own beneficial
ownership.
Series
D Preferred Stock
As of
September 30, 2018 and December 31, 2017, there were 44,104 shares
of Series D Convertible Preferred Stock (“Series D Preferred
Stock”) issued and outstanding, and convertible into an
aggregate of 198,667 shares of common stock.
As of September 30, 2018, each one share of Series
D Preferred Stock is convertible into
4.5045
shares of Common Stock.
Series
E Preferred Stock
As of
September 30, 2018 and December 31, 2017, there were 33,333 shares
of Series E Convertible Preferred Stock (“Series E Preferred
Stock”) issued and outstanding, and convertible into 173,249
shares of common stock.
The
shares of Series E Preferred Stock are
convertible into shares of common stock based on a conversion
calculation equal to the stated value of such preferred share ($75
per share), plus all accrued and unpaid dividends, if any, on such
share of Series E Preferred Stock, as of such date of
determination, divided by the conversion price $14.43 per
share.
Series
I Preferred Stock
As of
September 30, 2018 and December 31, 2017, there were 645,640 and
798,460 shares of our Series I Preferred Stock issued and
outstanding, and convertible into 215,214 and 266,154 shares of our
common stock, respectively. During the nine months ended September
30, 2018, 152,820 shares of Series I Preferred Stock were converted
by Grander Holdings, Inc. 401K into 50,940 shares of common
stock.
The Series I Preferred Stock has a stated value of
$0.01 per share. Each one share of Series I Preferred Stock is
convertible into
one-third share of common stock
.
Series
J Preferred Stock
As of
September 30, 2018 and December 31, 2017, there were 772.73 shares
of our Series J Convertible Preferred Stock (“Series J
Preferred Stock”) issued and outstanding and convertible into
386,365 shares of our common stock.
T
he shares of Series J Preferred Stock are
convertible into shares of common stock based on a conversion
calculation equal to the stated value of the Series J Preferred
Stock ($550), plus all accrued and unpaid dividends, if any, on
such Series J Preferred Stock, as of such date of determination,
divided by the conversion price ($1.10). If we issue or sell common
stock, or common equivalent shares, for consideration per share
that is less than the conversion price in effect immediately prior
to the issuance, then the conversion price in effect immediately
prior to such issuance will be adjusted to the lower issuance
price, but not be less than $0.10.
Series
K Preferred Stock
As of
September 30, 2018 and December 31, 2017, there were 63,150 shares
of our Series K convertible preferred stock (“Series K
Preferred Stock”) issued and outstanding, and convertible
into 2,105,000 of our common stock.
The
shares of Series K Preferred Stock are convertible into shares of
common stock based on a conversion calculation equal to the stated
value of the Series K Preferred Stock ($0.01) divided by the
conversion price ($0.0003).
Series
L Preferred Stock
As of
September 30, 2018, and December 31, 2017, there were 45,500 and
58,000 shares of our Series L Preferred Stock issued and
outstanding, and convertible into 2,527,778 and 3,222,223 shares of
our common stock, respectively. During the nine months ended
September 30, 2018, 12,500 shares of Series L Preferred Stock were
converted into 694,445 shares of common stock
by GRQ Consultants, Inc. Roth 401K FBO Renee Honig
Trustee, and HS Contrarian Investments, LLC.
The
shares of Series L Preferred Stock are convertible into shares of
common stock based on a conversion calculation equal to the stated
value of the Series L Preferred Stock ($100), plus all accrued and
unpaid dividends, if any, on such Series L Preferred Stock, as of
such date of determination, divided by the conversion price
($1.80).
Series
M Preferred Stock
As of
September 30, 2018 and December 31, 2017, there were 5,000 and no
shares of our Series M Preferred Stock issued and outstanding, and
convertible into 666,667 and no shares of our common stock,
respectively.
The
shares of Series M Preferred Stock are convertible into shares of
common stock based on a conversion calculation equal to the stated
value of the Series M Preferred Stock ($300), plus all accrued and
unpaid dividends, if any, on such Series M Preferred Stock, as of
such date of determination, divided by the conversion price
($2.25).
Series
N Preferred Stock
As of
September 30, 2018, and December 31, 2017, there were 5,363.64 and
no shares of our Series N Preferred Stock issued and outstanding,
and convertible into 536,364 and no shares of our common stock,
respectively.
The
shares of Series N Preferred Stock are convertible into shares of
common stock based on a conversion calculation equal to the stated
value of the Series N Preferred Stock ($110), plus all accrued and
unpaid dividends, if any, on such Series N Preferred Stock, as of
such date of determination, divided by the conversion price
($1.10). If we issue or sell common stock, or common equivalent
shares, for consideration per share that is less than the
conversion price in effect immediately prior to the issuance, then
the conversion price in effect immediately prior to such issuance
will be adjusted to the lower issuance price, but not be less than
$0.10.
Series
O Preferred Stock
As of
September 30, 2018, and December 31, 2017, there were 10,605.56 and
no shares of our Series O Preferred Stock issued and outstanding,
and convertible into 1,060,556 and no shares of our common stock,
respectively.
The
shares of Series O Preferred Stock are convertible into shares of
common stock based on a conversion calculation equal to the stated
value of the Series O Preferred Stock ($0.01), plus all accrued and
unpaid dividends, if any, on such Series O Preferred Stock, as of
such date of determination, divided by the conversion price
($0.0001). We are not permitted to issue any shares of common stock
upon conversion of the Series O Preferred Stock until our
stockholders approve, in accordance with the rules of the Nasdaq
Stock Market LLC, the conversion of Series N Preferred Stock
authorized on April 26, 2018, or the conversion of Series O
Preferred Stock.
Warrants
Issued in Connection with February 2018 Private
Placements
The warrants
issued in the February 2018 Private Placements (the “February
2018 Warrants”) are exercisable, at any time on or after the
sixth month anniversary of the closing date, at a price of $2.70
per share, subject to adjustment, and expire three years from the
initial exercise date. The holders of the February 2018 Warrants
may, subject to certain limitations, exercise the February 2018
Warrants on a cashless basis if the shares of common stock issuable
upon exercise of the February 2018 Warrants are not registered for
resale under the Securities Act within four (4) months of issuance,
or between June 2 and June 10, 2018. The Company is prohibited from
effecting an exercise of any February 2018 Warrants to the extent
that, as a result of any such exercise, the holder would
beneficially own more than 9.99% of the number of shares of common
stock outstanding immediately after giving effect to the issuance
of shares of common stock upon exercise of such February 2018
Warrants. The February 2018 Warrants are not listed or quoted on
any securities exchange or other trading market.
Warrants
Issued in Connection with October 2015 Public Offering
As of
September 30, 2018, and December 31, 2017, warrants to purchase
56,306 shares of common stock previously issued in connection with
our public offering closing on October 5, 2015 (the “October
2015 Warrants”) were outstanding. The October 2015 Warrants,
which had an exercise price of $29.31 per share, expired on
September 30, 2018
.
Consultant Grants
On
February 10, 2017, the Company entered into a consulting agreement
with MDM Worldwide, pursuant to which MDM Worldwide agreed to
provide investor relations services to the Company in consideration
for an immediate grant of 6,667 shares of the Company’s
common stock and a monthly cash retainer of $10,000 a month for
ongoing services for a period of one year. The shares granted were
fully vested upon grant and the Company recognized the grant date
fair value of the shares of $56,600 as investor relations expense
upon grant during the first quarter of 2017. The services with MDM
Worldwide, which the Company was required to purchase by some
investors in connection with prior financings of the Company, were
terminated effective June 1, 2018.
On
March 7, 2017, the Company entered into a consulting agreement with
Jenene Thomas Communications, pursuant to which Jenene Thomas
Communications agreed to provide investor relations services to the
Company. In consideration for these services, which began on April
1, 2017, we paid a monthly cash retainer of $12,500. Additionally,
we issued 6,667 restricted shares of common stock on April 1, 2017,
to be vested at 1,667 per quarter over the four quarters of
services under the agreement beginning April 1, 2017. The shares
granted were vested over a one-year period over which the services
were performed and, as such, were amortized over the same period
beginning in April 1, 2017. The services with Jenene Thomas
Communications terminated effective June 1, 2018.
6.
Notes Payable.
Loan
and Security Agreement with Oxford Finance, LLC
On
January 15, 2016, we entered into a loan and security agreement
with Oxford Finance, LLC (“Oxford Finance”) pursuant to
which we had the option to borrow $10,000,000 in two equal tranches
of $5,000,000 each (the “Loan Agreement”). The first
tranche of $5,000,000 was funded at close on January 15, 2016 (the
“Term A Loans”). The option to fund the second tranche
of $5,000,000 (the “Term B Loans”) was exercisable upon
the Company achieving positive interim data on the Phase 1
HuMab-5B1 antibody trial in pancreatic cancer and successfully
uplisting to either the Nasdaq Stock Market or NYSE MKT on or
before September 30, 2016. The option for the Term B Loans expired
unexercised on September 30, 2016. The interest rate for the Term A
Loans is set on a monthly basis at the index rate plus 11.29%,
where the index rate is the greater of the 30-day LIBOR rate or
0.21%. Interest is due on the first day of each month, in arrears,
calculated based on a 360-day year. The Term A Loans were interest
only for the first year after funding, and the principal amount of
the loan is amortized in equal principal payments, plus period
interest, over the next 36 months. A facility fee of 1.0% or
$100,000 was due at closing of the transaction and was earned and
paid by the Company on January 15, 2016. The Company is obligated
to pay a $150,000 final payment upon completion of the term of the
Term A Loans, and this amount is being accreted using the effective
interest rate method over the term of the loans. The Term A Loans
can be prepaid subject to a graduated prepayment fee, depending on
the timing of the prepayment.
Concurrent with the
execution of the Loan Agreement, the Company issued warrants to
purchase up to 75,075 shares of common stock to Oxford Finance with
an exercise price of $16.65 per share. The warrants were
immediately exercisable, may be exercised on a cashless basis and
expire on January 15, 2021. The Company recorded $607,338 for the
fair value of the warrants as a debt discount within notes payable
and an increase to additional paid-in capital on the
Company’s balance sheet. We used the Black-Scholes-Merton
valuation method to calculate the value of the warrants. The debt
discount is being amortized as interest expense over the term of
the loan using the effective interest method.
We
granted Oxford Finance a perfected first priority lien on all of
the Company’s assets with a negative pledge on IP. The
Company paid Oxford Finance a good faith deposit of $50,000, which
was applied towards the facility fee at closing. The Company agreed
to pay all costs, fees and expenses incurred by Oxford Finance in
the initiation and administration of the facilities including the
cost of loan documentation.
At the
initial funding on January 15, 2016, the Company received net
proceeds from the Term A Loans of approximately $4,610,000 after
fees and expenses. These fees and expenses are being accounted for
as a debt discount and classified within notes payable on the
Company’s condensed consolidated balance sheet. The Company's
transaction costs of approximately $390,000 are presented in the
condensed consolidated balance sheet as a direct deduction from the
carrying amount of the notes payable, consistent with debt
discounts. Debt discounts, issuance costs and the final payment are
being amortized or accreted as interest expense over the term of
the loan using the effective interest method.
The
Loan Agreement also contains customary indemnification obligations
and customary events of default, including, among other things, our
failure to fulfill certain of the Company's obligations under the
Loan Agreement, the occurrence of a material adverse change, which
is defined as a material adverse change in the Company's business,
operations, or condition (financial or otherwise), a material
impairment of the prospect of repayment of any portion of the loan,
or a material impairment in the perfection or priority of Oxford
Finance’s lien in the collateral or in the value of such
collateral. In the event of default by the Company under the
Loan Agreement, Oxford Finance would be entitled to exercise their
remedies thereunder, including the right to accelerate payment of
the debt, upon which we may be required to repay all amounts then
outstanding under the Loan Agreement, which could harm the
Company's financial condition.
First
Amendment to Loan and Security Agreement
On
March 31, 2017, we and Oxford Finance signed the First Amendment to
Loan and Security Agreement providing that the payment of principal
on the Term A Loans that otherwise would have been due on the March
1, 2017 will be due and payable on May 1, 2017 along with any other
payment of principal due on May 1, 2017. We were obligated to pay a
fully earned and non-refundable amendment fee of $15,000 to the
Collateral Agent (as defined in the Loan Agreement). On May 1,
2017, we paid the principal due on May 1, 2017, along with the
$15,000 amendment fee.
Second
Amendment to Loan and Security Agreement
On July
3, 2018, we and Oxford Finance signed the Second Amendment to Loan
and Security Agreement whereby Oxford Finance has (i) consented to
the Company’s license and sale to Boehringer Ingelheim of
certain preclinical assets (the “Acquired Assets”) and
release of any encumbrances under the Loan Agreement that relate to
the Acquired Assets, (ii) payments of advisory fees to Greenhill
& Company of $385,000 over the course of six months in equal
monthly payments, and (iii) deferred principal payments under the
Loan Agreement for six months starting with the July 2018 payment,
in exchange for the Company granting such additional collateral
that was not pledged previously or in which security interest was
not granted prior to the Second Amendment. We are obligated to pay
a fully earned and non-refundable amendment fee of $5,000 to Oxford
Finance, which shall become due and payable upon the earlier of:
(i) the maturity date of the term loans, (ii) the acceleration of
any term loan, or (iii) the prepayment of the term loans pursuant
to the Loan Agreement.
For the
three and nine months ended September 30, 2018, the Company
recorded interest expense related to the Loan Agreement of $94,755
and $308,271, respectively. For the three and nine months ended
September 30, 2017, the Company recorded $138,642 and $445,934 in
interest expense related to the term loan, respectively. The annual
effective interest rate on the note payable, including the
amortization of the debt discounts and accretion of the final
payment, but excluding the warrant amortization, was approximately
11.82% and 12.30% as of September 30, 2018 and 2017,
respectively.
The
future principal payments under notes payable for the Loan
Agreement and financed insurance as of September 30, 2018 are as
follows:
Years ending
December 31:
|
|
2018
(remaining)
|
$
36,348
|
2019
|
2,380,952
|
2020
|
396,826
|
Notes payable,
balance as of September 30, 2018
|
2,814,126
|
Unamortized
discount on notes payable
|
(179,025
)
|
Notes payable, net,
balance as of September 30, 2018
|
2,635,101
|
Current portion of
notes payable, net
|
(1,822,062
)
|
Non-current portion
of notes payable, net
|
$
813,039
|
Notice
of Events of Default under Loan and Security Agreement
The
Company believes it was in compliance with all applicable covenants
set forth in the Loan Agreement as of September 30, 2018.
However, on August 14, 2018, the Company received a letter from
Oxford Finance (the “Notice”) asserting certain events
of default under the Loan Agreement had occurred as a result of
certain events the Company reported as having occurred, including,
without limitation, (i) the resignation of the Company’s
external auditor, CohnReznick
LLP
(“CohnReznick”),
effective August 3, 2018, and its withdrawal of its audit reports
for the years 2014 through 2017, (ii) the resignation of four (4)
members of the Board of Directors, effective as of July 31, 2018,
and (iii) the delisting of the Company’s common stock from
The Nasdaq Stock Market LLC on July 11, 2018 (collectively, the
“Alleged Default Events”). The Company informed Oxford
Finance that it disputes the Alleged Default Events, individually
or collectively, constitute a “Material Adverse Change”
or other event of default under the Loan Agreement. In addition,
the Company already engaged a new auditor, Haskell & White LLP,
effective August 22, 2018, and on September 20, 2018, the Court
ratified the Delaware Petition. Also, on October 16, 2018, the
Company applied for listing on the OTCQB Venture Marketplace (the
“OTCQB Marketplace”) and believes it now meets the
requisite eligibility requirements; however, there can be no
assurance of being listed while the SEC Action is underway. As of
November 12, 2018, Company management has been meeting at least
weekly since September 30, 2018, to keep Oxford Finance informed on
potential fund-raising activities.
7.
Related Party
Transactions
On
April 1, 2016, the Company entered into a two-year consulting
agreement with Jeffrey Ravetch, M.D., Ph.D., a member of the Board
of Directors at that time, for work beginning January 1, 2016
through December 31, 2017, at a rate of $100,000 a year, in support
of scientific and technical advice on the discovery and development
of technology and products for the Company primarily related to
monoclonal antibodies, corporate development, and corporate
partnering efforts. In April 2016, the Company paid Dr. Ravetch
$100,000 for services to be performed in 2016, and made quarterly
payments thereafter beginning January 1, 2017. On February 16,
2018, the Company extended Dr. Ravetch’s consulting agreement
until February 16, 2019, with services to be provided, as may be
needed by the Company. During the three and nine months ended
September 30, 2018, Dr. Ravetch provided no consulting services
related to this agreement and no payments were made. During the
three and nine months ended September 30, 2017, the Company
recorded $25,000 and $50,000, respectively, in consulting expenses
as part of general and administration expenses related to this
agreement.
On
November 3, 2016, the Company granted 5,833 stock options to
Jeffrey Ravetch, M.D., Ph.D., for his ongoing consulting services
to the Company. The option award vests over a three-year period.
During the three and nine months ended September 30, 2018, the
Company recognized $0 and $6,584, respectively, of stock-based
compensation expense, as part of general and administration
expenses, related to this option grant. During the three and nine
months ended September 30, 2017, the Company recognized $3,826 and
$7,652, respectively, of stock-based compensation expense, as part
of general and administration expenses, related to this option
grant.
On May
19, 2017, the Company granted each director, other than J. David
Hansen, Jeffrey Ravetch (a member of the Board of Directors at the
time) and Philip Livingston, 16,667 options at a market price of
$5.40, with immediate vesting for their continuing service to the
Company, in exchange for giving up their director fees for the
remainder of the year. J. David Hansen and Jeffrey Ravetch were
each granted 166,667 options and Philip Livingston was granted
16,667 options each at an exercise price of $6.00 per share with
immediate vesting and no performance obligations. Options granted
to J. David Hansen and Philip Livingston were granted as a
condition of the May 2017 financing transaction. The 166,667
options granted to Dr. Ravetch in addition to the 16,667 options
granted to other non-employee members of the Company’s Board
of Directors were in recognition of the additional value provided
by Dr. Ravetch as a scientific expert. Because of the immediate
vesting and all of the expenses recorded in 2017, no expenses are
being recorded for these grants in 2018. During the three and nine
months ended September 30, 2017, the Company recorded $0 and
$1,480,089, respectively, in stock-based compensation expenses in
general and administration expenses, related to these
grants.
8.
Stock-based
Activity
Stock-based
Compensation
We
measure stock-based compensation expense for equity-classified
awards, principally related to stock options and restricted stock
units (“RSUs”), based on the estimated fair value of
the award on the date of grant. We recognize the value of the
portion of the award that we ultimately expect to vest as
stock-based compensation expense over the requisite service period
in our condensed consolidated statements of
operations.
We use
the Black-Scholes model to estimate the fair value of stock options
granted. The expected term of stock options granted represents the
period of time that we expect them to be outstanding. For the three
and nine months ended September 30, 2018 and 2017, the following
valuation assumptions were used:
|
Three
Months Ended
September
30,
|
Nine
Months Ended
September
30,
|
|
|
|
|
|
Risk-free interest
rate
|
-
|
-
|
2.4
%
|
1.5 to
2.0%
|
Dividend
yield
|
-
|
-
|
0
%
|
0
%
|
Expected
volatility
|
-
|
-
|
87
%
|
73 to
85%
|
Expected life of
options, in years
|
-
|
-
|
5.5 yrs.
|
1.4 to 6.0
yrs.
|
Weighted-average
grant date fair value
|
-
|
-
|
$
1.42
|
$
1.53
|
Total
estimated stock-based compensation expense, related to all the
Company’s stock-based payment awards recognized under ASC
718,
“Compensation—Stock
Compensation”
was comprised of the
following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
$
96,157
|
$
292,523
|
$
340,979
|
$
989,884
|
General and
administrative
|
172,458
|
721,213
|
966,183
|
3,526,488
|
Total stock-based
compensation expense
|
$
268,615
|
$
1,013,736
|
$
1,307,162
|
$
4,516,372
|
Stock-based
Award Activity
The
following table summarizes the Company’s stock option
activity during the nine months ended September 30,
2018:
|
|
Weighted-Average
Exercise
Price
|
Outstanding at
December 31, 2017
|
953,937
|
$
13.97
|
Granted
|
1,186,000
|
1.99
|
Exercised
|
—
|
—
|
Forfeited/cancelled/expired
|
(319,348
)
|
6.71
|
Outstanding and
expected to vest at September 30, 2018
|
1,820,589
|
$
7.44
|
Vested and
exercisable at September 30, 2018
|
1,060,093
|
$
10.24
|
The
total unrecognized compensation cost related to unvested stock
option grants as of September 30, 2018, was $1,549,114 and the
weighted average period over which these grants are expected to
vest is 1.3 years. The weighted average remaining contractual life
of stock options outstanding at September 30, 2018 and 2017 is 9.2
and 9.1 years, respectively.
During
the first nine months of 2018, the Company granted 1,186,000
options to officers and employees with a weighted average exercise
price of $1.99 and vesting over a three-year period with a vesting
starting at the one-year anniversary date of the grant date. During
the first nine months of 2017, the Company granted 682,230 options
to officers and employees with a weighted average exercise price of
$7.11 and vesting over a three-year period with vesting starting at
the one-year anniversary of the grant date.
Stock
options granted to employees generally vest over a three-year
period with one third of the grants vesting at each one-year
anniversary of the grant date.
Because
the Company had a net operating loss carryforward as of September
30, 2018, no tax benefits for the tax deductions related to
stock-based compensation expense were recognized in the
Company’s condensed consolidated statements of operations.
Additionally, no stock options were exercised in the three and nine
months ended September 30, 2018 and 2017.
A
summary of activity related to restricted stock grants under the
Fifth Amended and Restated MabVax Therapeutics Holdings, Inc. 2014
Employee, Director and Consultant Equity Incentive Plan for the
nine months ended September 30, 2018 is presented
below:
|
|
Weighted
Average
Grant-Date
Fair
Value
|
Non-vested at
December 31, 2017
|
832,226
|
$
3.88
|
Granted
|
—
|
—
|
Vested
|
(832,226
)
|
50.26
|
Forfeited
|
—
|
—
|
Non-vested at
September 30, 2018
|
—
|
$
—
|
As of
September 30, 2018, there were no non-vested RSUs remaining
outstanding.
Management
Bonus Plan
On
February 21, 2018, the compensation committee of the Board of
Directors reviewed 2017 results and concluded that the year’s
performance, relative to the objectives set at the beginning of the
year, did not merit any bonus payment. The compensation committee
also determined that management base salaries would currently
remain unchanged from 2017 levels.
Common
stock reserved for future issuance
Common
stock reserved for future issuance consists of the following at
September 30, 2018:
Common stock
reserved for conversion of preferred stock
|
7,869,862
|
Warrants to
purchase common stock
|
1,221,935
|
Common stock
options outstanding
|
1,820,589
|
Authorized for
future grant or issuance under the Stock Plan
|
646,059
|
Total
|
11,558,445
|
9.
Net Income (Loss) per
Share
The
Company calculates basic and diluted net income (loss) per share
using the weighted-average number of shares of common stock
outstanding during the period.
When
the Company is in a net loss position, it excludes from the
calculation of diluted net loss per share all potentially dilutive
stock options, preferred stock and warrants, and the diluted net
loss per share is the same as the basic net loss per share for such
periods. If the Company was to be in a net income position, the
weighted average number of shares used to calculate the diluted net
income per share would include the potential dilutive effect of
in-the-money securities, as determined using the treasury stock
method.
Basic
and diluted net loss per share is computed as follows:
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|
|
|
|
|
Net
income (loss) allocable to common stockholders
|
$
340,681
|
$
(6,200,161
)
|
$
(7,296,247
)
|
$
(22,784,296
)
|
Basic
net income (loss) per common share
|
$
0.04
|
$
(1.62
)
|
$
(0.81
)
|
$
(8.04
)
|
Diluted
net income (loss) per share
|
$
0.02
|
$
(1.62
)
|
$
(0.81
)
|
$
(8.04
)
|
Weighted
average common shares outstanding
|
9,253,880
|
3,830,280
|
8,983,980
|
2,834,692
|
Diluted
weighted average shares outstanding
|
17,123,742
|
3,830,280
|
8,983,980
|
2,834,692
|
Diluted
weighted average shares outstanding for the three months ended
September 30, 2018, includes only the common stock reserved for
conversion of preferred stock, as the exercise price for the
warrants to purchase common stock and the exercise price for common
stock options outstanding are substantially above the weighted
average price per share during the period. The table below presents
the potentially dilutive securities that would have been included
in the calculation of diluted net loss per share for the three
months ended September 30, 2017, and for the Nine Months ended
September 30, 2018 and 2017, respectively, if they were not
antidilutive for those periods presented.
|
Nine
Months Ended September 30,
|
|
|
|
Common stock
reserved for conversion of preferred stock
|
7,869,862
|
3,877,796
|
Warrants to
purchase common stock
|
1,221,935
|
691,139
|
Common stock
options outstanding
|
1,820,589
|
938,413
|
Unvested restricted
stock
|
—
|
317,902
|
Total
|
10,912,386
|
5,825,250
|
10.
Contracts and
Agreements
Asset
Purchase and License Agreement with Boehringer
Ingelheim
On July
4, 2018, the Company entered into an
Asset Purchase Agreement and License
Agreement
with Boehringer Ingelheim International GmbH
(hereafter, “BII” and the
“Asset Purchase Agreement”)
centered on MabVax's program targeting a glycan commonly
overexpressed on multiple solid tumor cancers. BII has acquired all
rights in and to the program. MabVax received a non-refundable $4
million payment upon signing the agreement and expects to receive
an additional $7 million in connection with BII reaching certain
near-term milestones and downstream regulatory milestones plus
further earn-out payments.
The
Company recognized the initial $4 million non-refundable upfront
payment as revenue, as BII obtained the exclusive rights to use the
intellectual property and there were no continuing obligations
other than to deliver materials and documents of an administrative
nature that were completed within 15 days of entering into the
agreement. As of September 30, 2018, the Company had not recognized
as revenue any of the future milestones given the high risk and
uncertainty of continuing development by BII given such
risks.
In
connection with the Asset Purchase Agreement, the Company incurred
cost of sales totaling $785,000, including 10% of the $4 million
payment or $400,000 to MSK to obtain MSK’s consent to enter
into the Asset Purchase Agreement, and $385,000 in a fixed fee to
investment banker Greenhill & Co. MabVax agreed to share with
MSK 20% or $1.4 million of the $7.0 million in near-term milestones
if achieved by BII.
The
asset acquisition is separate and distinct from other programs
under development at MabVax, enabling MabVax to retain all rights
to its lead HuMab-5B1 antibody program which is in Phase 1 clinical
trials as a therapeutic product candidate and as a diagnostic
product candidate, as well as other antibody discovery programs
from the Company's antibody discovery portfolio targeting other
cancer antigens.
Cold
Spring Harbor Laboratory License Agreement
On
September 8, 2018, the Company entered into an agreement with Cold
Spring Harbor Laboratory (“CSHL”), a nonprofit New York
State education corporation, whereby the Company licensed the
exclusive worldwide rights to certain discoveries and technology
including exclusive interest in certain patent applications filed
by the Company on behalf of CSHL for use of MVT-5873 as a treatment
for pancreatitis. The Company paid $20,000 as an upfront license
fee and will pay to CSHL a nonrefundable annual license maintenance
fee of the same amount beginning on January 1, 2020 and continuing
each year thereafter during the term of the agreement and will
increase to $50,000 a year upon issuance of the first patent in
connection with the technology. The annual license fee will be
reduced for any patent prosecution and maintenance costs and will
be fully creditable against any royalties or milestone payments
earned during the year. Future milestone payments are in the
aggregate less than $2.5 million, with royalties that range from
0.25% if no valid claim to patents, to 2.5% if there is a valid
claim of the patent in the territory of sales.
Sublicense Grant to Y-mAbs Therapeutics, Inc.
On June 27, 2018, we granted an exclusive
sublicense to Y-mAbs, a privately held clinical stage
biopharmaceutical company, for a bi-valent ganglioside-based
vaccine intended to treat neuroblastoma, a rare pediatric cancer
(the “Y-mAbs Sublicense”). Total value of the
transaction to MabVax is $1.3 million plus a share of a Priority
Review Voucher (as defined in the sublicense agreement) if granted
by the FDA to Y-mAbs on approval of the vaccine and the Priority
Review Voucher is subsequently sold. Additionally, Y-mAbs will be
responsible for all further development of the product as well as
any downstream payment obligations related to this specific vaccine
to MSK that were specified in the original MabVax-MSK license
agreement dated April 30, 2008. If Y-mAbs successfully develops and
receives FDA approval for the neuroblastoma vaccine, it is
obligated to file with the FDA for a Priority Review Voucher. If
the voucher is granted to Y-mAbs and subsequently sold, then MabVax
will receive a percentage of the proceeds from the sale of the
voucher by Y-mAbs. Upon entering the Y-mAbs Sublicense, the Company
received a non-refundable upfront payment of $700,000 and will
receive an additional $600,000 upon the one-year anniversary of
entering into the agreement, provided Y-mAbs has not terminated the
agreement prior to the one-year anniversary.
The Sublicense
Agreement contains termination provisions allowing for the
termination of the agreement (i) upon material breach if the
breaching party fails to cure the breach within 60 days of notice
by the non-breaching party, (ii) by Y-mAbs at any time upon 90
days’ advance notice to MabVax, or (iii) the expiration or
termination of the underlying license from MSK to MabVax, provided
that MSK will assume the agreement if Y-mAbs is in material
compliance with the agreement upon the termination of the
MSK-MabVax license
. There were no
continuing obligations on the part of the Company in connection
with the agreement other than one-time administrative matters that
were completed within thirty (30) days of signing the agreement.
Therefore, the Company recognized $700,000 as revenue upon signing
the agreement and receiving the funds. Because Y-mAbs has the right
to terminate the Y-mAbs Sublicense before the one-year anniversary
and the uncertainty of continuing clinical development by Y-mAbs,
the Company will not recognize additional revenue until it is
likely the termination provisions are no longer
applicable.
Letter Agreement with MSK
On
June 27, 2018, we entered into a letter agreement with MSK (the
“MSK Letter”) in connection with obtaining the consent
from MSK for the Company to enter into the Y-mAbs Sublicense and
allow Y-mAbs to “step into the shoes” of the
obligations that the Company would have had to pay MSK if the
Company had continued development of the neuroblastoma vaccine,
including future payment obligations of the Company regarding
future milestones. As part of the agreement, the Company and MSK
agreed that MabVax would receive 100% of both the $700,000 upfront
payment and $600,000 upon the one-year anniversary of the Y-mAbs
Sublicense. All of the obligations to MSK in the MSK Letter were
fully expensed as of June 30, 2018.
May
2017 Letter Agreement
On May
15, 2017, as a condition to the participation of HS Contrarian
Investments, LLC (“HS Contrarian”) in the public
offering of the Company’s common stock and Series G Preferred
Stock in May 2017 (the “May 2017 Public Offering”), the
Company entered into a Letter Agreement with HS Contrarian (the
“May 2017 Letter Agreement”) where the Company agreed
to offer incentive shares (the “May 2017 Inducement
Shares”) to investors who (i) participated in both the
Company’s August 2016 public offering and the Company’s
April 2015 private offering, (ii) purchased securities in the May
2017 Public Offering equal to at least 50% of their original
investment in the August 2016 public offering or 25% of their
original investment in the April 2015 private offering, and (iii)
still hold 100% of their common stock or preferred stock purchased
in those investments.
Further, the
Company agreed to the following in the May 2017 Letter
Agreement:
Board
Nomination:
|
|
To
nominate one (1) candidate to the Board of Directors acceptable to
the holder of a majority of the Series G Preferred Stock by
December 31, 2017, and that (2) two current Board members would
resign.
|
Executive
Hire:
|
|
To hire
a new C-level executive in a leadership role by July 15,
2017.
|
Board
Compensation:
|
|
To
issue an aggregate of 350,000 options to certain employees and
members of the Board of Directors, at a price not less than $6.00
per share, and 16,667 options to each other member of the Board of
Directors at the current market price in connection with this
offering. The options were issued pursuant to the Company’s
option plan, subject to the requisite approvals and availability
under the plan. The company was responsible for obtaining the
approval of the Board of Directors and stockholders of the Company
to the extent the company needed their approval to increase the
number of shares available under the plan. All Board of Director
fees were waived for 2017.
|
Funds
Held in Escrow:
|
|
$500,000
of the funds from the May 2017 Public Offering were to be held in
escrow and released to one or more investor relations services
acceptable to the Company following the closing of this
offering.
|
Additionally, we
granted HS Contrarian consent rights: the right to approve future
(i) issuances of our securities, (ii) equity or debt financings and
(iii) sales of any development product assets currently held by us,
subject to certain exceptions, if such securities are sold at a
price below $7.50 per share and for as long as HS Contrarian in the
offering holds 50% or more of the shares of Series G Preferred
Stock purchased by HS Contrarian in the May 2017 Public Offering
(the “Consent Rights”). All other prior consent rights
of HS Contrarian were superseded by these consent rights. As of
September 30, 2018, none of the shares of Series G Preferred Stock
is outstanding. Thus, HS Contrarian no longer holds the Consent
Rights.
For the
period from the May 2017 Public Offering to December 31, 2017, the
Company exceeded the minimum $500,000 in expenses related to
outside investor relations services fulfilling the Company’s
obligation for spending on investor relations. HS Contrarian
elected not to hold the funds in escrow. Further, the Company
issued the May 2017 Inducement Shares and adjusted the Board of
Directors compensation per the May 2017 Letter Agreement. Also, two
members of the Board of Directors resigned during 2017, achieving
one of the conditions of HS Contrarian. The Company did not
nominate a new member to the Board of Directors, nor did it hire a
new C-level executive in light of limited amount of cash available
to the Company.
Letter
Agreement Regarding Future Financing Transactions
On
August 9, 2017, in connection with an offering in the aggregate
amount of $1,312,500 in which the Company sold shares of its Series
J Preferred Stock (the “August 2017 Offering”), we
entered into a Letter Agreement with HS Contrarian (the
“August 2017 Letter Agreement”), whereby HS Contrarian
consented to and agreed that, the Company may sell securities to
the investors set forth below, of an aggregate amount of up to
$2,350,000, and the Company would issue incentive shares in the
form of newly designated shares of Series K Preferred Stock
convertible into an aggregate of 2,166,667 shares of common stock
to be distributed to the following individuals or entities, as
directed by HS Contrarian, as an incentive (the “Inducement
Shares”) for HS Contrarian and these entities and individuals
to invest in the August 2017 Offering.
HS
Contrarian Investments, LLC
|
GRQ
Consultants, Inc. Roth 401K FBO Barry Honig Trustee
|
GRQ
Consultants, Inc. Roth 401K FBO Renee Honig Trustee
|
Grander
Holdings, Inc. 401K
|
Robert
B. Prag
|
David
Moss
|
Paradox
Capital Partners, LLC
|
Melechdavid,
Inc.
|
Melechdavid, Inc.
Retirement Plan
|
Robert
S. Colman Trust UDT 3/13/85
|
Sargeant Capital
Ventures, LLC
|
Edward
W. Easton TTEE The Easton Group ORP PSP U/A DTD
02/09/2000
|
Donald
E. Garlikov
|
Airy
Properties
|
Ryan
O'Rourke
|
Corey
Patrick O'Rourke
|
In addition, the Company agreed to the following in the August 2017
Letter Agreement:
●
|
To file a proxy statement for a special meeting of stockholders
within 10 days of closing the
August 2017 Offering.
Proposals were to include (i) an amendment to the Company’s
Certificate of Incorporation to effect a reverse stock split of its
issued and outstanding common stock by a ratio of not less than
one-for-two and not more than one-for-twenty at any time prior to
one year from the date of the special meeting, with the exact ratio
to be set at a whole number within this range as determined by the
Board of Directors, (ii) the issuance of securities in one or more
non-public offerings where the maximum discount at which securities
will be offered will be equivalent to a discount of 30% below the
market price of the common stock, as required by and in accordance
with Nasdaq Marketplace Rule 5635(d), (iii) the issuance of
securities in one or more non-public offerings where the maximum
discount at which securities will be offered will be equivalent to
a discount of 20% below the market price of the Common Stock, as
required by and in accordance with Nasdaq Marketplace Rule 5635(d),
(iv) the issuance of common stock upon the conversion of Series J
Preferred Stock and (v) the issuance of
incentive shares in the form of shares of Series K
Preferred Stock convertible into an aggregate of 2,166,667 shares
of common stock
.
|
●
|
Subject
to agreement on terms and conditions of the investment, HS
Contrarian committed to a $1,000,000 lead order in an offering
amount of $8,000,000 (the “$8,000,000 Financing”). The
$8,000,000 Financing was subject to the Company obtaining approval
of a reverse stock split, issuance of the Series J Preferred Stock,
and filing a proxy statement for stockholder approval of the
Inducement Shares as identified in the August 2017 Letter
Agreement.
|
●
|
That
the
employment terms of all
management be reduced to two years from three years and that
management defer portions of their salary for the remainder of the
year, which would be paid upon the earlier of completion of the
$8,000,000 Financing or a business transaction that represents, or
transactions in the aggregate that represent, in excess of
$10,000,000.
|
In
connection with HS Contrarian’s and the Company’s
obligations under the August 2017 Letter Agreement, neither the
$8,000,000 Financing nor the change in employment terms from three
years to two years were completed as of November 19,
2018.
Memorial
Sloan Kettering Cancer Center
Since
2008, the Company has engaged in various research agreements and
collaborations with MSK including licensed rights to cancer
vaccines and the blood samples from patients who have been
vaccinated with MSK’s cancer vaccines. Total sponsored
research contracts outstanding in 2016 amounting to approximately
$800,000 in 2016 were 100% complete as of the year ended December
31, 2016. Such sponsored research agreements provide support for
preclinical work on the Company’s product development
programs. The work includes preparing radioimmunoconjugates of the
Company’s antibodies and performing
in vitro
and
in vivo
pharmacology studies for our
therapeutic antibody product candidate, imaging agent product
candidate, and radioimmunotherapy product candidate programs. For
the three months ended September 30, 2018, there were no expenses
incurred related to these contracts.
Patheon
Biologics LLC Agreement
On
April 14, 2014, the Company entered into a development and
manufacturing services agreement with Patheon Biologics LLC (f.k.a.
Gallus Biopharmaceuticals) to provide a full range of manufacturing
and bioprocessing services, including cell line development,
process development, protein production, cell culture, protein
purification, bio-analytical chemistry and QC testing. Total amount
of the contract is estimated at approximately $3.0
million. For the three months ended September 30, 2018 and
2017, the Company recorded no expenses associated with the
agreement, as no manufacturing was completed during either
period.
11.
Commitments and
Contingencies
Capital
Leases
O
n March 21, 2016, the Company entered into
a lease agreement with ThermoFisher Scientific
(“Lessor”). Under the terms of the agreement, the
Company agreed to lease two pieces of equipment from the Lessor, a
liquid chromatography system and an incubator, totaling in cost of
$95,656. The term of the lease is five years (60 months), and
the monthly lease payment is $1,942. In addition, there is a $1.00
buyout option at the end of the lease term.
Minimum
future annual capital lease obligations are as follows as of
September 30, 2018:
2018
(remaining)
|
$
5,601
|
2019
|
22,402
|
2020
|
22,402
|
2021
|
7,468
|
Less
interest
|
(7,426
)
|
Principal
|
50,447
|
Less current
portion
|
(18,943
)
|
Noncurrent
portion
|
$
31,504
|
Operating
Leases
In
2015, the Company recorded a $590,504 contingent lease termination
fee of the master lease and sublease of 3165 Porter Drive in Palo
Alto, California, which was payable to ARE-San Francisco No. 24
(“ARE”), if the Company received $15 million or more in
additional financing in the aggregate. The additional financing was
achieved in 2015 and the termination fee is reflected on the
condensed consolidated balance sheet as an accrued lease
contingency fee.
On
September 2, 2015,
the
Company
entered a lease (the “Lease”) with AGP
Sorrento Business Complex, L.P., for certain premises of office and
laboratory space in buildings located at 11535 Sorrento Valley Rd.,
San Diego, California, to serve as the Company’s corporate
offices and laboratories (the “New
Premises”). Because certain tenant improvements needed
to be made to the New Premises before the Company could take
occupancy, the term of the Lease did not commence until the New
Premises were ready for occupancy, which was on February 4,
2016. The Lease terminates on February 28, 2022, unless
earlier terminated in accordance with the Lease. Pursuant to the
terms of the Lease, the monthly base rent is $35,631, subject to
annual increases as set forth in the Lease.
The
Company has an option to extend the Lease term for a single,
five-year period. If the Lease term is extended for the optional
five-year period, the monthly base rent will be adjusted based on
fair market rental value. In addition to rent, the Company agreed
to pay a portion of the taxes and utility, maintenance and other
operating costs paid or accrued in connection with the ownership
and operation of the property.
The
Company recognized rent expense on a straight-line basis over the
term of the lease.
During
the three and nine months ended September 30, 2018, the Company
recorded rent expense of $115,238 and $345,714,
respectively.
Minimum
future annual operating lease obligations are as follows as of
September 30, 2018:
2018
(remaining)
|
$
151,204
|
2019
|
466,085
|
2020
|
480,068
|
2021
|
494,470
|
2022
|
41,306
|
Total
|
$
1,633,133
|
Legal
Proceedings
See
Item 1 of Part II “Other Information” and Note 12
“Subsequent Events” for a discussion of legal
proceedings.
12.
Subsequent
Events
Legal
Proceedings
Jackson v. Hansen et
al.
, Case No.
18-cv-2302-BEN-BGS
.
On October 4,
2018, a shareholder derivative complaint was filed in the United
States District Court for the Southern District of
California. The complaint arises from similar allegations as
In re MabVax Therapeutics
Securities Litigation
and
Liesman v. Hansen et al.,
filed on
September 26, 2018 (See Part II. Item 1. “Legal
Proceedings”) but, in addition to a breach of fiduciary duty
claim, also includes causes of action for unjust enrichment, abuse
of control, gross mismanagement and waste of corporate
assets. Plaintiff seeks, on behalf of the Company, damages,
fees, costs, and equitable relief.
R
EPORT OF INDEP
E
NDENT REGISTERED PUBLIC
ACCOUNTING FIRM
To the Stockholders
and Board of Directors
MabVax Therapeutics
Holdings, Inc.
Opinion on the Financial Statements
We have audited the
accompanying consolidated balance sheets of MabVax Therapeutics
Holdings, Inc. (the “Company”) as of December 31,
2017 and 2016, and the related consolidated statements of
operations, stockholders’ equity, and cash flows, for the
years then ended, and the related notes (collectively referred to
as the “consolidated financial statements”). In our
opinion, the consolidated financial statements present fairly, in
all material respects, the financial position of the Company as of
December 31, 2017 and 2016, and the results of its operations and
its cash flows for the years then ended, in conformity with
accounting principles generally accepted in the United States of
America.
Substantial Doubt about the Company’s Ability to Continue as
a Going Concern
The accompanying
consolidated financial statements have been prepared assuming that
the Company will continue as a going concern. As discussed in Note
2 to the consolidated financial statements, the Company has
incurred recurring operating losses and is dependent on additional
financing to fund operations. These conditions raise substantial
doubt about the Company’s ability to continue as a going
concern. Management’s plans in regard to these matters are
described in Note 2 to the consolidated financial statements. The
consolidated financial statements do not include any adjustments
that might result from the outcome of this
uncertainty.
Basis for Opinion
These consolidated financial statements are the
responsibility of the Company’s management. Our
responsibility is to express an opinion on the Company’s
consolidated financial statements based on our audits. We are a
public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (“PCAOB”)
and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and
the PCAOB.
We conducted our
audits in accordance with the standards of the PCAOB. Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial
statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an
understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of
the Company’s internal control over financial reporting.
Accordingly, we express no such opinion.
Our audits included
performing procedures to assess the risks of material misstatement
of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such
procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits
also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the
overall presentation of the consolidated financial statements. We
believe that our audits provide a reasonable basis for our
opinion.
/s/ CohnReznick
LLP
We have served as
the Company’s auditor from 2014 to 2018.
San Diego,
California
October 12,
2018
MABVAX T
H
ERAPEUTICS HOLDINGS,
INC.
Consolidated
B
alance
Sheets
|
|
|
|
|
Assets
|
|
|
Current
assets:
|
|
|
Cash
and cash equivalents
|
$
885,710
|
$
3,979,290
|
Prepaid
expenses
|
150,462
|
281,858
|
Other
current assets
|
171,346
|
32,830
|
Total
current assets
|
1,207,518
|
4,293,978
|
Property
and equipment, net
|
578,206
|
731,712
|
Goodwill
|
6,826,003
|
6,826,003
|
Other
long-term assets
|
178,597
|
168,597
|
Total
assets
|
$
8,790,324
|
$
12,020,290
|
|
|
|
Liabilities and Stockholders’ Equity
|
|
|
Current
liabilities:
|
|
|
Accounts
payable
|
$
1,090,904
|
$
1,137,903
|
Accrued
compensation
|
311,675
|
770,592
|
Accrued
clinical operations and site costs
|
1,669,201
|
1,218,641
|
Accrued
lease termination fee
|
590,504
|
590,504
|
Other
accrued expenses
|
404,923
|
315,034
|
Interest
payable
|
39,373
|
51,295
|
Current
portion of notes payable
|
1,681,876
|
1,589,661
|
Current
portion of capital lease payable
|
17,810
|
17,004
|
Total
current liabilities
|
5,806,266
|
5,690,634
|
Long-term
liabilities:
|
|
|
Long-term
portion of notes payable, net
|
1,621,483
|
2,774,627
|
Long-term
portion of capital lease payable
|
45,857
|
68,113
|
Other
long-term liabilities
|
186,278
|
144,394
|
Total
long-term liabilities
|
1,853,618
|
2,987,134
|
Total
liabilities
|
7,659,884
|
8,677,768
|
Commitments
and contingencies
|
|
|
Stockholders’
equity:
|
|
|
Series
D convertible preferred stock, $0.01 par value, 1,000,000 shares
authorized, 44,104 and 132,489 shares issued and outstanding as of
December 31, 2017 and 2016, respectively, with liquidation
preference of $441 and $1,325 as of December 31, 2017 and 2016,
respectively
|
441
|
1,325
|
Series
E convertible preferred stock, $0.01 par value, 100,000 shares
authorized, 33,333 shares issued and outstanding as of
December 31, 2017 and 2016, with a liquidation preference of
$333 as of December 31, 2017 and 2016
|
333
|
333
|
Series
F convertible preferred stock, $0.01 par value, 1,559,252 shares
authorized, no shares and 665,281 shares issued and
outstanding as of December 31, 2017 and 2016, respectively, with a
liquidation preference of $0 and $
6,653
as of December 31, 2017 and 2016, respectively
|
—
|
6,653
|
Series
I convertible preferred stock, $0.01 par value, 1,968,664 shares
authorized,
798,460
and no shares issued and outstanding as of December 31, 2017 and
2016, respectively, with a liquidation preference of $7,984 and $0
as of December 31, 2017 and 2016, respectively
|
7,984
|
—
|
Series
J convertible preferred stock, $0.01 par value, 3,400 shares
authorized,
773
and no shares issued and outstanding as of December 31, 2017 and
2016, respectively, with a liquidation preference of $531,252 and
$0 as of December 31, 2017 and 2016, respectively
|
8
|
—
|
Series
K convertible preferred stock, $0.01 par value, 65,000 shares
authorized,
63,150
and no shares issued and outstanding as of December 31, 2017 and
2016, respectively, with a liquidation preference of $632 and $0 as
of December 31, 2017 and 2016, respectively
|
632
|
—
|
Series
L convertible preferred stock, $0.01 par value, 58,000 shares
authorized,
58,000
and 0 shares issued and outstanding as of December 31, 2017 and
2016, respectively, with a liquidation preference of $5,800,000 and
$0 as of December 31, 2017 and 2016, respectively
|
580
|
—
|
Common
stock, $0.01 par value, 150,000,000 shares authorized, 6,862,928
and 2,098,705 shares issued and outstanding as of December 31,
2017 and 2016, respectively
|
68,629
|
20,987
|
Additional
paid-in capital
|
112,105,470
|
81,575,485
|
Accumulated
deficit
|
(111,053,637
)
|
(78,262,261
)
|
Total
stockholders’ equity
|
1,130,440
|
3,342,522
|
Total
liabilities and stockholders’ equity
|
$
8,790,324
|
$
12,020,290
|
See
Accompanying Notes to Consolidated Financial
Statements.
MABVAX THERAPEU
T
ICS HOLDINGS,
INC.
Consolidated Statements of
O
perations
|
For the Years Ended
December 31,
|
|
|
|
Revenues:
|
|
|
Grants
|
$
—
|
$
148,054
|
Total
revenues
|
—
|
148,054
|
|
|
|
Operating
costs and expenses:
|
|
|
Research
and development
|
7,544,122
|
7,800,723
|
General
and administrative
|
10,526,340
|
9,010,450
|
Total
operating costs and expenses
|
18,070,462
|
16,811,173
|
Loss
from operations
|
(18,070,462
)
|
(16,663,119
)
|
Interest
and other expenses, net of income
|
(950,217
)
|
(997,364
)
|
Net
loss
|
(19,020,679
)
|
(17,660,483
)
|
Deemed
dividend on May 2017 inducement shares
|
(5,220,000
)
|
—
|
Deemed
dividend on August 2017 inducement shares
|
(3,120,000
)
|
—
|
Deemed
dividend on warrant repricing
|
(19,413
)
|
—
|
Deemed
dividend on preferred stock exchange
|
(5,411,284
)
|
—
|
Net
loss allocable to common stockholders
|
$
(32,791,376
)
|
$
(17,660,483
)
|
Basic
and diluted net loss per share
|
$
(8.56
)
|
$
(10.91
)
|
Shares
used to calculate basic and diluted net loss per share
|
3,830,162
|
1,619,251
|
See
Accompanying Notes to Consolidated Financial
Statements.
MABVAX THER
A
PEUTICS HOLDINGS,
INC.
Consolidated Statements of Stockholders’
E
quity
|
Series D through
L Convertible
Preferred
Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2015
|
224,823
|
$
2,248
|
1,278,877
|
$
12,788
|
$
68,025,506
|
$
(60,601,778
)
|
$
7,438,764
|
Issuance
of warrants in connection with notes payable transaction in January
2016
|
—
|
—
|
—
|
—
|
607,338
|
—
|
607,338
|
Issuance
of whole in lieu of fractional shares resulting from reverse split
in August 2016
|
—
|
—
|
809
|
8
|
(8
)
|
—
|
—
|
Issuance
of Series F Preferred Stock, common stock and warrants in August
public offering, net of costs
|
665,281
|
6,653
|
432,346
|
4,323
|
8,556,472
|
—
|
8,567,448
|
Issuance
of additional common stock related to April 2015
financing
|
—
|
—
|
85,153
|
852
|
(852
)
|
—
|
—
|
Common
stock issued for services
|
—
|
—
|
11,882
|
119
|
163,881
|
—
|
164,000
|
Conversion
of Series D Preferred Stock to common stock
|
(59,001
)
|
(590
)
|
265,771
|
2,658
|
(2,068
)
|
—
|
—
|
Common
stock issued upon vesting of restricted stock units in April, July
and August of 2016, net of payroll taxes
|
—
|
—
|
23,867
|
239
|
(178,062
)
|
—
|
(177,823
)
|
Stock-based
compensation
|
—
|
—
|
—
|
—
|
4,403,278
|
—
|
4,403,278
|
Net
loss
|
—
|
—
|
—
|
—
|
—
|
(17,660,483
)
|
(17,660,483
)
|
Balance at
December 31, 2016
|
831,103
|
8,311
|
2,098,705
|
20,987
|
81,575,485
|
(78,262,261
)
|
3,342,522
|
Issuance
of Series H Preferred Stock, net of costs, May 2017
|
850
|
9
|
—
|
—
|
820,562
|
—
|
820,571
|
Issuance
of Series G Preferred Stock and common stock, net of costs, May
2017
|
1,000,000
|
10,000
|
447,620
|
4,476
|
3,669,307
|
—
|
3,683,783
|
Issuance
of common stock, net of costs, August 2017
|
—
|
—
|
50,715
|
507
|
124,493
|
—
|
125,000
|
Issuance
of Series J Preferred stock, net of costs, August 2017
|
2,386
|
24
|
—
|
—
|
1,189,393
|
—
|
1,189,417
|
Issuance
of common stock, net of costs, September 2017
|
—
|
—
|
1,333,334
|
13,333
|
1,844,028
|
—
|
1,857,361
|
Issuance
of common stock, net of costs, September 2017
|
—
|
—
|
672,043
|
6,720
|
1,229,280
|
—
|
1,236,000
|
Issuance
of common stock, net of costs, October 2017
|
—
|
—
|
256,410
|
2,564
|
493,686
|
—
|
496,250
|
Issuance
of inducement shares of common stock and Series I Preferred Stock,
May 2017
|
1,968,664
|
19,687
|
310,446
|
3,105
|
(22,792
)
|
—
|
—
|
Deemed
dividends on inducement shares, May 2017
|
—
|
—
|
—
|
—
|
5,220,000
|
(5,220,000
)
|
—
|
Deemed
dividends on incentive shares of Series K Preferred Stock, August
2017
|
65,000
|
650
|
—
|
—
|
3,119,350
|
(3,120,000
)
|
—
|
Deemed
dividends on preferred stock exchange, October 2017
|
—
|
—
|
—
|
—
|
5,411,284
|
(5,411,284
)
|
—
|
Repricing
of warrants
|
—
|
—
|
—
|
—
|
19,413
|
(19,413
)
|
—
|
Issuance
of common stock for services
|
—
|
—
|
271,667
|
2,717
|
550,567
|
—
|
553,284
|
Issuance
of common stock upon conversion of Series D Preferred
Stock
|
(88,384
)
|
(884
)
|
398,131
|
3,981
|
(3,097
)
|
—
|
—
|
Issuance
of common stock upon conversion of Series I Preferred
Stock
|
(1,170,204
)
|
(11,702
)
|
390,068
|
3,901
|
7,801
|
—
|
—
|
Issuance
of common stock upon conversion of Series J Preferred
Stock
|
(1,614
)
|
(16
)
|
537,874
|
5,379
|
(5,363
)
|
—
|
—
|
Issuance
of common stock upon conversion of Series K Preferred
Stock
|
(1,850
)
|
(19
)
|
61,667
|
617
|
(598
)
|
—
|
—
|
Preferred
Stock exchange – Series F
|
(665,281
)
|
(6,653
)
|
—
|
—
|
—
|
—
|
(6,653
)
|
Preferred
Stock exchange – Series G
|
(1,000,000
)
|
(10,000
)
|
—
|
—
|
—
|
—
|
(10,000
)
|
Preferred
Stock exchange – Series H
|
(850
)
|
(9
)
|
—
|
—
|
—
|
—
|
(9
)
|
Preferred
Stock exchange – Series L
|
58,000
|
580
|
—
|
—
|
16,082
|
—
|
16,662
|
Common
stock issued upon vesting of RSUs
|
—
|
—
|
34,248
|
342
|
(342
)
|
—
|
—
|
Stock-based
compensation
|
—
|
—
|
—
|
—
|
6,846,931
|
—
|
6,846,931
|
Net
loss
|
—
|
—
|
—
|
—
|
—
|
(19,020,679
)
|
(19,020,679
)
|
Balance at December 31, 2017
|
997,820
|
$
9,978
|
6,862,928
|
$
68,629
|
$
112,105,470
|
$
(111,053,637
)
|
$
1,130,440
|
See
Accompanying Notes to Consolidated Financial
Statements.
MABVAX THERAPEUTI
C
S
HOLDINGS, INC.
Consolidated Statements of Cash
F
lows
|
For the Years Ended
December 31,
|
|
|
|
Operating activities
|
|
|
Net
loss
|
$
(19,020,679
)
|
$
(17,660,483
)
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|
|
Depreciation
and amortization
|
159,842
|
96,553
|
Stock-based
compensation
|
6,846,931
|
4,403,278
|
Issuance
of restricted common stock for services
|
553,284
|
164,000
|
Amortization
and accretion related to notes payable
|
393,829
|
413,676
|
Increase
(decrease) in operating assets and liabilities:
|
|
|
Grants
receivable
|
—
|
757,562
|
Prepaid
expenses and other
|
25,980
|
340,187
|
Accounts
payable
|
(46,999
)
|
(1,898,520
)
|
Accrued
clinical operations and site costs
|
450,560
|
827,600
|
Accrued
compensation
|
(458,917
)
|
207,837
|
Other
accrued expenses
|
100,658
|
(15,101
)
|
Net
cash used in operating activities
|
(10,995,511
)
|
(12,363,411
)
|
Investing activities
|
|
|
Purchases
of property and equipment
|
(21,072
)
|
(563,196
)
|
Net
cash used in investing activities
|
(21,072
)
|
(563,196
)
|
Financing activities
|
|
|
Principal
payments on financed insurance policies
|
(80,087
)
|
(167,597
)
|
Principal
payments on capital lease
|
(16,403
)
|
(10,540
)
|
Principal
payments on bank loan
|
(1,388,889
)
|
—
|
Purchase
of vested employee stock in connection with tax withholding
obligation
|
—
|
(177,823
)
|
Cash
receipts from bank loan, net of financing costs
|
—
|
4,610,324
|
Proceeds
from issuance of common stock and Series F Preferred Stock, net of
costs, August 2016
|
|
8,567,448
|
Proceeds
from issuance of Series H Preferred Stock, net of costs, May
2017
|
820,571
|
—
|
Proceeds
from issuance of common stock and Series G Preferred Stock, net of
costs, May 2017
|
3,683,783
|
—
|
Proceeds
from issuance of common stock, net of costs, August
2017
|
125,000
|
—
|
Proceeds
from issuance of Series J Preferred Stock, net of costs, August
2017
|
1,189,417
|
—
|
Proceeds
from issuance of common stock, net of costs, September
2017
|
1,857,361
|
—
|
Proceeds
from issuance of common stock, net of costs, September
2017
|
1,236,000
|
—
|
Proceeds
from issuance of common stock, net of costs, October
2017
|
496,250
|
—
|
Net
cash provided by financing activities
|
7,923,003
|
12,821,812
|
Net
change in cash and cash equivalents
|
(3,093,580
)
|
(104,795
)
|
Cash
and cash equivalents at beginning of year
|
3,979,290
|
4,084,085
|
Cash
and cash equivalents at end of year
|
$
885,710
|
$
3,979,290
|
Supplemental disclosures of cash flow information:
|
|
|
Cash
paid during the year for income taxes
|
$
1,600
|
$
1,600
|
Cash
Paid during the year for interest on term note
|
$
568,852
|
$
532,436
|
Supplemental disclosures of non-cash investing and financing
information:
|
|
|
Purchase
of equipment accrued in accounts payable
|
$
—
|
$
33,934
|
Fair
value of warrants issued
|
$
—
|
$
607,338
|
Fair
value of repricing of warrants issued in previous
financing
|
$
19,413
|
$
—
|
Conversion
of Series D preferred stock to common stock
|
$
3,981
|
$
2,658
|
Conversion
of Series I preferred stock to common stock
|
$
3,901
|
$
—
|
Conversion
of Series J preferred stock to common stock
|
$
5,379
|
$
—
|
Conversion
of Series K preferred stock to common stock
|
$
617
|
$
—
|
Exchange
preferred stock Series F for Series L
|
$
6,653
|
$
—
|
Exchange
preferred stock Series G for Series L
|
$
10,000
|
$
—
|
Exchange
preferred stock Series H for Series L
|
$
9
|
$
—
|
Exchange
preferred stock Series L for Series F, Series G and Series
H
|
$
580
|
$
—
|
Deemed
dividends on May 2017 inducement shares
|
$
5,220,000
|
$
—
|
Deemed
dividends on August 2017 inducement shares
|
$
3,120,000
|
$
—
|
Deemed
dividends on preferred stock exchange
|
$
5,411,284
|
$
—
|
Capital
lease in connection with purchase of equipment
|
$
—
|
$
95,657
|
See
Accompanying Notes to Consolidated Financial
Statements.
MABVAX THERA
P
EUTICS HOLDINGS,
INC.
N
otes to Consolidated Financial
Statements
1. Nature of Operations and Basis of Presentation
MabVax Therapeutics Holdings, Inc. (f.k.a. Telik,
Inc. and referred to herein as “MabVax Therapeutics
Holdings” or the “Company”) was
originally
incorporated in 1988 under the name “Terrapin Diagnostics,
Inc.” in the State of Delaware. In 1998, we changed our
corporate name to “Telik, Inc.” and changed our name
again to “MabVax Therapeutics Holdings, Inc.” in
2014
. Unless the context otherwise
requires, references to “we,” “our,”
“us,” “MabVax,” or the
“Company” in this Annual Report mean MabVax
Therapeutics Holdings, Inc. on a consolidated financial statement
basis with our wholly owned subsidiary, MabVax Therapeutics, Inc.,
as applicable.
Nature
of Business
MabVax is a clinical stage biopharmaceutical company engaged in the
discovery, development and commercialization of proprietary human
monoclonal antibody products for the treatment of a variety of
cancers and other disease states. We have discovered a pipeline of
human monoclonal antibody product candidates based on the
protective immune responses generated by patients who have been
immunized against targeted cancers with our proprietary
vaccines.
We have the exclusive license to these vaccines
and blood samples from vaccinated patients as antibody discovery
materials from
Memorial Sloan
Kettering Cancer Center (“MSK”). We operate in only one
business segment.
We have incurred net losses since inception and expect to incur
substantial losses for the foreseeable future as we continue our
research, development and clinical activities. To date, we have
funded operations primarily through
revenues earned from
asset sale and license agreements, proceeds from the sale of common
and preferred stock, government grants, the issuance of debt, the
issuance of common stock in lieu of cash for services, payments
from collaborators, and interest income. The process of developing
products will require significant additional research and
development, preclinical testing and clinical trials, as well as
regulatory approvals. We expect these activities, together with
general and administrative expenses, to result in substantial
operating losses for the foreseeable future. We will not receive
substantial revenue unless we or our collaborative partners
complete clinical trials, obtain regulatory approvals and
successfully commercialize one or more product candidates; or we
license our technology after achieving one or more milestones of
interest to a potential partner.
Reverse
Stock Splits
On August 16,
2016, we filed a certificate of amendment to our Amended and
Restated Certificate of Incorporation with the Secretary of State
of the State of Delaware to effectuate a reverse stock split of our
issued and outstanding common stock on a 1 for 7.4 basis, effective
on August 16, 2016 (the “2016 Reverse Stock Split”). On
February 14, 2018, we filed a certificate of amendment to our
Amended and Restated Certificate of Incorporation with the
Secretary of State of the State of Delaware to effectuate another
reverse stock split of our issued and outstanding common stock on a
1-for-3 basis, effective on February 16, 2018, (the “2018
Reverse Stock Split”; collectively with the 2016 Reverse
Stock Split, the “Reverse Stock Splits”). All share and
per share amounts, and number of shares of common stock into which
each share of preferred stock will convert, in the financial
statements and notes thereto have been retroactively adjusted for
all periods presented to give effect to the Reverse Stock Splits,
including rounding for fractional shares and reclassifying any
amount equal to the reduction in par value of common stock to
additional paid-in capital.
Delaware
Order Granting Petition for Relief
On September 20,
2018, the Court of Chancery of the State of Delaware (the
“Court”) entered an order validating (i) issuances of
common stock upon conversions of the Company’s preferred
stock occurring between June 30, 2014 and February 12, 2018, and
(ii) stockholder approval of corporate actions presented to the
Company’s stockholders from June 30, 2014 to February 12,
2018. In so doing, the Court granted the Company’s Verified
Petition for Relief Under
8 Del.
C. § 205
(the “Delaware Petition”)
captioned
In re: MabVax
Therapeutics Holdings, Inc.
, filed on July 27, 2018, in
order to rectify the uncertainty regarding whether shares of our
common stock were validly issued upon conversion of our preferred
stock from June 30, 2014 to February 12, 2018.
Basis
of Presentation
The preparation of consolidated financial
statements in conformity with accounting principles generally
accepted in the United States of America ("GAAP") requires
management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during
the reporting period. Management believes that these estimates are
reasonable; however, actual results may differ from these
estimates.
2. Liquidity and Going Concern
The
accompanying consolidated financial statements have been prepared
on the going concern basis, which assumes that the Company will
continue to operate as a going concern and which contemplates the
realization of assets and the satisfaction of liabilities and
commitments in the normal course of business. As reflected in the
accompanying consolidated financial statements, the Company had a
net loss of $19,020,679, net cash used in operating activities of
$10,995,511 and net cash used in investing activities of $21,072
for the year ended December 31, 2017. As of December 31,
2017, the Company had $885,710 in cash and cash equivalents and an
accumulated deficit of $111,053,637.
The
Company
has been able to achieve several financing transactions that in the
aggregate have been able to sustain the Company’s operations
for periods not exceeding one year for any one financing during the
last few years, resulting in the consolidated financial statements
being prepared on the going concern basis. Terms of financing from
investors have caused substantial dilution in the Company, which
could continue to be dilutive in the future without other forms of
non-dilutive financing transactions such as through licensing our
technology and other strategic transactions. Since July 8, 2014, we
have been subject to restrictions on financing and other material
transactions of the Company that require the consent of either a
holder of preferred stock or HS Contrarian
Investments, LLC
(“HS Contrarian”)
.
Additionally, we granted HS Contrarian in the May 2017 Public
Offering (defined below) the right to approve future (i) issuances
of our securities, (ii) equity or debt financings and (iii) sales
of any development product assets currently held by us, subject to
certain exceptions, if such securities are sold at a price below
$7.50 per share and for as long as HS Contrarian in the offering
holds 50% or more of the shares of Series G Preferred Stock
purchased by HS Contrarian in the May 2017 Public Offering (the
“May 2017 Consent Right”). On October 18, 2017, HS
Contrarian exchanged the Series G Preferred Stock for Series L
Preferred Stock. As of December 31, 2017, none of the shares of
Series G Preferred Stock is outstanding. Thus, HS Contrarian no
longer holds the May 2017 Consent Rights. All other prior consent
rights of HS Contrarian were superseded by the May 2017 Consent
Right. The financings in 2016 and 2017 are summarized below and
described in more detail along with details of letter agreements
with HS Contrarian in Note 8, “Convertible Preferred Stock,
Common Stock and Warrants.”
On January 15, 2016, the Company and Oxford
Finance LLC (“Oxford Finance”), as collateral agent and
lender, entered into a loan and security agreement (the “Loan
Agreement”) providing for senior secured term loans to the
Company in an aggregate principal amount of up to $10,000,000,
subject to the terms and conditions set forth in the Loan
Agreement. On January 15, 2016, the Company received an
initial loan of $5,000,000 under the Loan Agreement, before fees
and issuance costs of approximately $390,000. On March 31, 2017, we
and Oxford Finance signed a First Amendment to the Loan Agreement,
providing that the payment of principal of $138,889 that otherwise
would have been due on the Amortization Date of April 1, 2017, will
be due and payable on May 1, 2017 along with any other payment of
principal due on May 1, 2017. We were obligated to pay a fully
earned and non-refundable amendment fee of $15,000 to Oxford
Finance. On May 1, 2017, we paid the principal that was due on May
1, 2017, along with the $15,000 amendment
fee.
On
August 22, 2016, we closed a public offering of 432,346 shares of
common stock and 665,281 shares of Series F Preferred Stock, and
warrants to purchase 654,107 shares of common stock at $16.65 per
share and warrants to purchase 654,107 shares of common stock at
$18.87 per share, at an offering price of $14.43 per share (the
“August 2016 Public Offering”). For every
one-third share of common stock or Series F Preferred Stock sold,
we issued one warrant to purchase one share of common stock at
$16.65 per share and one warrant to purchase one share of common
stock at $18.87 per share. We received $9,438,753 in gross
proceeds, before underwriting discounts and commissions and
offering expenses totaling $871,305. The gross proceeds include the
underwriters’ over-allotment option, which they exercised on
the closing date.
On May 3, 2017, we
sold 850 shares of
Series H Preferred
Stock,
at a stated value of $1,000 per share, representing
an aggregate of $850,000 before offering costs of $29,429 in a
private placement (the “May 2017 Private Placement”),
to certain existing investors
.
The shares of Series H Preferred Stock are
convertible into shares of common stock based on a conversion
calculation equal to the stated value of the Series H Preferred
Stock, plus all accrued and unpaid dividends, if any, on such
Series H Preferred Stock, as of such date of determination, divided
by the conversion price. The stated value of each share of Series H
Preferred Stock is $1,000 and the conversion price is $5.25 per
share, after adjusting for the 2018 Reverse Stock Split, and
subject to further adjustment for stock splits, stock dividends,
recapitalizations, combinations, subdivisions or other similar
events.
On
May 19, 2017, we closed a public offering of 447,620 shares of
common stock and 1,000,000 shares of newly designated Series G
Preferred Stock, at $5.25 per share of common stock and $1.75 per
share of Series G Preferred Stock (the “May 2017 Public
Offering”). The Series G Preferred Stock is initially
convertible into 333,334 shares of common stock, subject to
adjustment for stock splits, stock dividends, recapitalizations,
combinations, subdivisions or other similar events, to certain
existing investors in the offering who, as a result of their
purchases of common stock, would hold in excess of 4.99% of our
issued and outstanding common stock, and elect to receive shares of
our Series G Preferred Stock. We received $4,100,000 in gross
proceeds, before underwriting discounts and commissions and
offering expenses of $416,217. This Offering is described in more
detail in Note 8, Convertible Preferred Stock, Common Stock and
Warrants of the Notes to Consolidated Financial
Statements.
On
July 27, 2017, we entered into a subscription agreement with an
accredited investor pursuant to which we agreed to sell 50,715
restricted shares of common stock for $125,000 (the “July
2017 Private Placement”). As part of the July 2017 Private
Placement, the Company agreed to reprice the investor’s
warrant to purchase 75,075 shares of common stock from $33.30 to
$6.00 per warrant share and remove the cashless exercise feature.
The transaction closed on August 2, 2017. The impact of
repricing the warrants to $6.00 a share, which took effect on
August 2, 2017, was immaterial, as the stock price on the date of
the closing of the transaction was $2.10 and the warrants at $6.00
a share, and expired on October 10, 2017, unexercised.
On August 11, 2017, we entered into securities
purchase agreements to sell 2,386.36 shares of Series J Preferred
Stock with a stated value of $550 per share. The Series J
Preferred Stock is convertible into common stock at $1.65 per
share, subject to adjustment for stock splits, stock dividends,
recapitalizations, combinations, subdivisions or other similar
events. The total amount of the securities purchase agreements
amounted to approximately $1,312,500, before offering expenses
of
$123,083
. The Certificate of
Designation for the Series J Preferred Stock includes a 4.99%
beneficial ownership conversion blocker, a 19.99% blocker provision
to comply with The Nasdaq Capital Market rules until stockholders
have approved any or all shares of common stock issuable upon
conversion of the Series J Preferred Stock, which was approved at
the October 2017 Special Meeting, and a 125% liquidation
preference. All shares of the Company’s capital stock will be
junior in rank to the Series J Preferred Stock at the time of
creation, with respect to the preferences as to dividends,
distributions and payments upon the liquidation, dissolution and
winding-up of the Company, except for the Company’s Series D
Preferred Stock, Series E Preferred Stock, Series F Preferred
Stock, Series G Preferred Stock, Series H Preferred Stock, and
Series I Preferred Stock.
On September 11,
2017,
we entered into
an agreement to sell 1,333,334 shares of common stock at $1.50 a
share for gross proceeds of approximately $2.0 million, before
offering expenses of $142,639. The shares were offered and sold to
certain accredited investors in a registered direct offering.
Laidlaw & Company (UK) Ltd.
(“Laidlaw”)
acted as placement agent for the
offering.
On September 22,
2017, we entered into a subscription agreement with select
accredited investors relating to the Company’s registered
direct offering, issuance and sale of 672,043 shares of the
Company’s common stock, $0.01 par value per share. The
purchase price per share was $1.86. The total amount of the
subscription agreements amounted to $1,250,000, before estimated
expenses of $14,000.
On
October 10, 2017, the Company entered into additional subscription
agreements with select accredited investors relating to the
Company’s registered direct offering, issuance and sale of
256,410 shares of the Company’s common stock. The purchase
price per share was $1.95. We received $500,000 in gross proceeds,
before offering expenses totaling approximately $3,750. The
offering closed on October 11, 2017.
We
plan to continue to fund the Company’s losses from operations
and capital funding needs through equity or debt financings,
strategic collaborations, licensing arrangements, government grants
or other arrangements. Further, to extend availability of existing
cash available for our programs for achieving milestones or a
strategic transaction, in mid-2017 we cut personnel from 25 full
time people to 11, and reduced other operating expenses following
the completion of two Phase Ia clinical trials of our lead antibody
HuMab 5B1, which has enabled us to reduce our expenditures on
clinical trials. We plan to continue spending on Phase I clinical
trials of MVT-5873 in combination with a chemotherapy agent and
MVT-1075 as a radioimmunotherapy agent for the treatment of various
cancers, preclinical testing of follow-on antibody candidates,
investor and public relations, SEC compliance efforts, and the
general and administrative expenses associated with each of these
activities. There can be no assurance that we will be able to
achieve a license and earn revenues large enough to offset our
operating expenses, as discussed further in Management’s
Discussion and Analysis of Financial Condition and Results of
Operations. We cannot be sure that licensing agreements can be
signed in a timely manner, if any, or that capital funding will be
available on reasonable terms, or at all. If we are unable to
secure significant licensing agreements and adequate additional
funding, we may be forced to make additional reductions in
spending, incur further cutbacks in personnel, extend payment terms
with suppliers, liquidate assets where possible, and/or suspend or
curtail planned programs. In addition, if the Company does not meet
its payment obligations to third parties as they come due, it may
be subject to litigation claims. Even if we are successful in
defending against these claims, litigation could result in
substantial costs and be a distraction to management.
We
anticipate that the Company will continue to incur net losses into
the foreseeable future as we: (i) continue our clinical trial for
the development of MVT1075 as a radioimmunotherapy, (ii) continue
our clinical trial of MVT-5873 in combination with gemcitabine
and nab-paclitaxal in first line therapy for the treatment of
patients newly diagnosed with pancreatic cancer, and (iii) continue
operations as a public company. Based on receipt of $9.4 million
net of transaction costs in 2017, $2.7 million net of transaction
costs in February 2018, and including other transactions as
disclosed in Note 16, and without any other additional funding or
receipt of payments from potential licensing agreements, we expect
we will have sufficient funds to meet our obligations through
December 2018. These conditions give rise to substantial doubt as
to the Company’s ability to continue as a going concern. Any
of these actions could materially harm the Company’s
business, results of operations, and prospects. These conditions
give rise to substantial doubt as to the Company’s ability to
continue as a going concern. The accompanying consolidated
financial statements do not include any adjustments that might
result from the outcome of this uncertainty.
If
the Company raises additional funds by issuing equity securities,
substantial dilution to existing stockholders would result. If the
Company raises additional funds by incurring debt financing, the
terms of the debt may involve significant cash payment obligations
as well as covenants and specific financial ratios that may
restrict the Company’s ability to operate its
business.
3. Summary of Significant Accounting Policies
Basis of Presentation
The
accompanying consolidated financial statements reflect all of our
activities, including those of our wholly owned subsidiaries. All
material intercompany accounts and transactions have been
eliminated in consolidation.
Use of Estimates
The
preparation of financial statements in conformity with GAAP,
requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of expenses during
the reporting period. Management believes that these estimates are
reasonable; however, actual results may differ from these
estimates.
Cash and Cash Equivalents
We
consider all highly liquid investments purchased with original
maturities of three months or less to be cash equivalents. The
Company minimizes its credit risk associated with cash and cash
equivalents by periodically evaluating the credit quality of its
primary financial institution. The balance at times may exceed
federally insured limits. As of December 31, 2017, cash and cash
equivalents exceeded federally insured limits by approximately $0.6
million. The Company has not experienced any losses on such
accounts.
Fair Value of Financial Instruments
The
Company’s financial instruments consist of cash and cash
equivalents, grants receivable, other receivable, accounts payable,
all of which are generally considered to be representative of their
respective fair values because of the short-term nature of those
instruments.
Property
and Equipment
Property
and equipment are carried at cost less accumulated depreciation.
Depreciation of property and equipment is computed using the
straight-line method over the estimated useful lives of the assets,
which are generally three to seven years. Leasehold improvements
are amortized over the lesser of the life of the lease or the life
of the asset.
Impairment of Long-lived Assets
We
evaluate the Company’s long-lived assets with definite lives,
such as property and equipment, for impairment. We record
impairment losses on long-lived assets used for operations when
indicators of impairment are present and the undiscounted cash
flows estimated to be generated by those assets are less than the
carrying value of the assets. There have not been any impairment
losses of long-lived assets for the years ended December 31,
2017 and 2016.
Impairment of Goodwill
The Company applies
the GAAP principles related to Intangibles – Goodwill and
Other
related to
performing a test for goodwill impairment annually. For the years
ended December 31, 2017 and 2016, the Company performed a step 1
analysis and assessed the market value of the Company to determine
whether an impairment had taken place. Based upon the analysis
performed, no impairment was noted; therefore, performing step 2
was not required. The Company has concluded that no impairment of
goodwill has taken place for the years ended December 31, 2017 and
2016. Further, in performing a qualitative assessment, the Company
concluded no events and circumstances have taken place that would
have indicated that an impairment had taken place.
Revenue Recognition
Revenue
from grants is based upon internal and subcontractor costs incurred
that are specifically covered by the grant, including a facilities
and administrative rate that provides funding for overhead
expenses. National Institute of Health (“NIH”) Grants
are recognized when the Company incurs internal expenses that are
specifically related to each grant, in clinical trials at the
clinical trial sites, by subcontractors who manage the clinical
trials, and provided the grant has been approved for payment. The
Company records revenue associated with the NIH Grants as the
related costs and expenses are incurred. Any amounts received by
the Company pursuant to the NIH Grants prior to satisfying the
Company’s revenue recognition criteria are recorded as
deferred revenue.
Research and Development Costs
Research
and development expenses, which consist primarily of salaries and
other personnel costs, clinical trial costs and preclinical study
fees, manufacturing costs for non-commercial products, and the
development of earlier-stage programs and technologies, are
expensed as incurred when these expenditures have no alternative
future uses. A significant portion of the development activities
are outsourced to third parties, including contract research
organizations. In such cases, the Company may be required to
estimate related service fees incurred.
Stock-based Compensation
The
Company’s stock-based compensation programs include grants of
common stock and stock options to employees, non-employee directors
and non-employee consultants. Stock-based compensation cost is
measured at the grant date, based on the calculated fair value of
the award, and is recognized as an expense, under the straight-line
method, over the employee’s requisite service period
(generally the vesting period of the equity grant).
The
Company accounts for equity instruments, including common stock and
stock options, issued to non-employees in accordance with
authoritative guidance for equity based payments to non-employees.
Stock options issued to non-employees are accounted for at their
estimated fair value determined using the Black-Scholes-Merton
option-pricing model. The fair value of options granted to
non-employees is re-measured as they vest, and the resulting
increase in value, if any, is recognized as expense during the
period the related services are rendered.
Income Taxes
The
Company uses the asset and liability method of accounting for
income taxes. Deferred tax assets and liabilities are recognized
for the estimated future tax consequences attributable to basis
differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases.
Deferred tax assets and liabilities are measured using enacted tax
rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or
settled. Valuation allowances are established when necessary to
reduce deferred tax assets to the amount expected to be realized.
As of December 31, 2017, and 2016, all deferred tax assets
were fully offset by a valuation allowance.
The
Company accrues interest and penalties, if any, on underpayment of
income taxes related to unrecognized tax benefits as a component of
income tax expense in its consolidated statements of
operations.
Fair Value Measurements
Level
1 fair value inputs are quoted prices for identical items in
active, liquid and visible markets such as stock exchanges.
Level 2 fair value inputs are observable information for
similar items in active or inactive markets, and appropriately
consider counterparty creditworthiness in the valuations. Level 3
fair value inputs reflect our best estimate of inputs and
assumptions market participants would use in pricing an asset or
liability at the measurement date. The inputs are unobservable in
the market and significant to the valuation estimate.
4. Recent Accounting Pronouncements
In May 2014, the
Financial Accounting Standards Board
(“FASB”)
issued
ASU 2014-09,
“
Revenue
from Contracts with Customers (Topic 606)
”,
which
contains new accounting literature relating to how and when a
company recognizes revenue. Under ASU 2014-09, a company will
recognize revenue when it transfers promised goods or services to
customers in an amount that reflects the consideration to which the
company expects to be entitled in exchange for those goods and
services. ASU 2014-09 is effective for the
Company’s fiscal year beginning January 1, 2018, which
reflects a one-year deferral approved by the FASB in July 2015, and
will be adopted by the Company beginning January 1, 2018.
The adoption of this new standard did not have a material impact on
our consolidated financial statements.
In February 2016, the FASB issued ASU
2016-2,
“Leases (Topic
842).” This update will increase transparency and
comparability by recognizing lease assets and lease liabilities on
the balance sheet and disclosing key information about leasing
arrangements. Under the new guidance, lessees will be
required to recognize the following for all leases (with the
exception of short-term leases) at the commencement date: (i) a
lease liability, which is a lessee’s obligation to make lease
payments arising from a lease, measured on a discounted basis, and
(ii) a right-of-use asset, which is an asset that represents the
lessee’s right to use, or control the use of, a specified
asset for the lease term. Under the new guidance, lessor accounting
is largely unchanged, and it simplified the accounting for sale and
leaseback transactions. Lessees will no longer be provided with a
source of off-balance sheet financing. Lessees (for capital and
operating leases) and lessors (for sales-type, direct financing,
and operating leases) must apply a modified retrospective
transition approach for leases existing at, or entered into after,
the beginning of the earliest comparative period presented in the
financial statements. The modified retrospective approach would not
require any transition accounting for leases that expired before
the earliest comparative period presented. Lessees and lessors may
not apply a full retrospective transition approach. The standard is
effective for fiscal years beginning after December 15, 2018,
including interim periods within those fiscal years. We are
currently in the process of assessing what impact this new standard
may have on our consolidated financial
statements.
In March 2016, the FASB issued ASU 2016-09,
“Compensation—Stock Compensation (Topic 718):
Improvements to Employee Share-Based Payment Accounting.”
This update includes multiple provisions intended to simplify
various aspects of the accounting for share-based payment
transactions including accounting for excess tax benefits and tax
deficiencies, classification of excess tax benefits in the
statement of cash flows and accounting for award forfeitures. This
update is effective for annual and interim reporting periods of
public entities beginning after December 15, 2016, with early
adoption permitted.
The adoption of this new standard did
not have a material impact on our consolidated financial
statements.
In June 2016, the FASB issued ASU
No. 2016-13,
“
Financial Instruments—Credit Losses
(Topic326): Measurement of Credit Losses on Financial
Instruments.
”
This ASU requires instruments measured
at amortized cost to be presented at the net amount expected to be
collected. Entities are also required to record allowances for
available-for-sale debt securities rather than reduce the carrying
amount. This ASU is effective for fiscal years beginning after
December 15, 2019, including interim periods within those
fiscal years.
We expect the adoption of this new standard
will not have a material impact on our consolidated financial
statements.
In August 2016, the
FASB issued ASU No. 2016-15 (“ASU 2016-15”),
“Statement of Cash Flows (Topic 230): Classification of
Certain Cash Receipts and Cash Payments.” The standard
provides guidance on eight (8) cash flow issues: (1) debt
prepayment or debt extinguishment costs; (2) settlement of
zero-coupon bonds; (3) contingent consideration payments after a
business combination; (4) proceeds from the settlement of insurance
claims; (5) proceeds from the settlement of corporate-owned life
insurance policies; (6) distributions received from equity method
investees; (7) beneficial interests in securitization transactions;
and (8) separately identifiable cash flows and application of the
predominance principle. ASU 2016-15 addresses how certain cash
receipts and cash payments are presented and classified in the
statement of cash flows. ASU 2016-15 is effective for fiscal years,
and interim periods within those years, beginning after December
15, 2017 with early adoption permitted. We expect the adoption of
this new standard will not have a material impact on our
consolidated financial statements.
In August 2016, the FASB issued ASU
No. 2016-16, “Income Taxes (Topic 740):
Intra-Entity Transfers of Assets Other Than
Inventory
.
” This ASU requires the recognition of
the income tax consequences of an intra-entity transfer of an asset
other than inventory when the transfer occurs. The amendments in
this ASU should be applied on a modified retrospective basis
through a cumulative-effect adjustment directly to retained
earnings as of the beginning of the period of adoption.
The
adoption of this new standard did have a material impact on our
consolidated financial statements.
In January 2017, the FASB issued ASU
No. 2017-03,
“Accounting Changes and Error Corrections
(Topic 250) and Investments—Equity Method and Joint Ventures
(Topic 323).” This ASU amends the disclosure requirements for
ASU No. 2014-09, Revenue from Contracts with Customers
(Topic 606); ASU No. 2016-02, Leases (Topic
842); and ASU No. 2016-13, Financial
Instruments—Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments. This ASU states that if a
registrant does not know or cannot reasonably estimate the impact
that the adoption of the above ASUs is expected to have on the
financial statements, then in addition to making a statement to
that effect, the registrant should consider additional qualitative
financial statement disclosures to assist the reader in assessing
the significance of the impact that the standard will have on the
financial statements of the registrant when adopted. This ASU was
effective upon issuance.
The adoption of this new standard
did not have a material impact on our consolidated financial
statements.
In January 2017, the FASB issued ASU
No. 2017-04, “Intangibles—Goodwill and Other
(Topic 350): Simplifying the Test for Goodwill
Impairment.” This ASU eliminates Step 2 from the
goodwill impairment test. Instead, an entity should recognize an
impairment charge for the amount by which the carrying value
exceeds the reporting unit’s fair value, not to exceed the
total amount of goodwill allocated to that reporting unit. This ASU
is effective for annual or any interim goodwill impairment tests in
fiscal years beginning after December 15, 2019.
We
expect the adoption of this new standard will not have a material
impact on our consolidated financial statements.
In January 2017, the FASB issued ASU
No. 2017-01, “Business Combinations (Topic 805):
Clarifying the Definition of a Business.” This ASU
clarifies the definition of a business with the objective of adding
guidance to assist entities with evaluating whether transactions
should be accounted for as acquisitions (or disposals) of assets or
businesses. This ASU is effective for annual periods beginning
after December 15, 2017, including interim periods within
those periods.
We expect the adoption of this new standard
will not have a material impact on our consolidated financial
statements.
Management
believes that any other recently issued, but not yet effective,
accounting standards if currently adopted would not have a material
effect on the accompanying consolidated financial
statements.
5. Property and Equipment, Net
Property
and equipment consisted of the following as of December 31,
2017 and 2016:
|
|
|
|
|
Furniture
and fixtures
|
$
51,909
|
$
51,909
|
Office
equipment
|
52,547
|
52,547
|
Lab
equipment
|
909,589
|
894,942
|
Capital
lease equipment
|
90,952
|
95,657
|
Leasehold
improvement
|
55,949
|
59,555
|
|
1,160,946
|
1,154,610
|
Less
accumulated depreciation and amortization
|
(582,740
)
|
(422,898
)
|
Totals
|
$
578,206
|
$
731,712
|
Depreciation
expense for the years ended December 31, 2017 and 2016 was
$159,842 and $96,553, respectively.
6. Reverse Stock Splits
On August 16, 2016,
we filed a certificate of amendment to our Amended and Restated
Certificate of Incorporation with the Secretary of State of the
State of Delaware to effectuate the 2016 Reverse Stock Split, which
was on a 1-for-7.4 basis, effective on August 16, 2016. On February
14, 2018, we filed a certificate of amendment to our Amended and
Restated Certificate of Incorporation with the Secretary of State
of the State of Delaware to effectuate the 2018 Reverse Stock
Split, which was on a 1-for-3 basis, effective on February 16,
2018. All share and per share amounts, and number of shares of
common stock into which each share of preferred stock will convert,
in the financial statements and notes thereto have been
retroactively adjusted for all periods presented to give effect to
the Reverse Stock Splits, including rounding for fractional shares
and reclassifying any amount equal to the reduction in par value of
common stock to additional paid-in capital.
7. Notes Payable, Net
On
January 15, 2016, we entered into the Loan Agreement with Oxford
Finance pursuant to which we had the option to borrow $10,000,000
in two equal tranches of $5,000,000 each. The first
tranche of $5,000,000 was funded at close on January 15, 2016 (the
“Term A Loan”). The option to fund the second tranche
of $5,000,000 (the “Term B Loan”) was upon the Company
achieving positive interim data on the Phase 1 HuMab-5B1 antibody
trial in pancreatic cancer and successfully uplisting to either The
Nasdaq Capital Market or NYSE MKT on or before September 30,
2016. The option for the Term B Loan expired on
September 30, 2016. The Company is not pursuing completion of any
additional debt financing with Oxford Finance at the present time.
The interest rate for the Term A Loan is set on a monthly basis at
a rate equal to the greater of the index rate plus 11.29%, where
the index rate is the 30-day LIBOR rate, or 11.5%. Interest is due
on the first day of each month, in arrears, calculated based on a
360-day year. The loan is interest only for the first
year after funding, and the principal amount of the loan is
amortized in equal principal payments, plus period interest, over
the next 36 months. A facility fee of 1.0% or $100,000
was due at closing of the transaction, and was incurred and paid by
the Company on January 15, 2016. The Company is
obligated to pay a $150,000 final payment upon completion of the
term of the loan, and this amount is being accreted using the
effective interest rate method over the term of the loan. The
amount being accreted is included in the long-term portion of notes
payable, net, on the balance sheet. Each of the term loans can be
prepaid subject to a graduated prepayment fee, depending on the
timing of the prepayment.
Concurrent
with the closing of the transaction, the Company issued a warrant
to purchase 75,076 shares of common stock to Oxford Finance with an
exercise price of $16.65 per share. The warrants are
exercisable for five years and may be exercised on a cashless
basis, and expire on January 15, 2021. The Company recorded
$607,338 for the fair value of the warrants as a debt discount
within notes payable and an increase to additional paid-in capital
on the Company’s balance sheet. We used the
Black-Scholes-Merton valuation method to calculate the value of the
warrants. The debt discount is being amortized as interest expense
over the term of the loan using the effective interest
method.
We
granted Oxford Finance a perfected first priority lien on all of
the Company’s assets with a negative pledge on intellectual
property. The Company paid Oxford Finance a good faith deposit of
$50,000, which was applied towards the facility fee at
closing. The Company agreed to pay all costs, fees and
expenses incurred by Oxford Finance in the initiation and
administration of the facilities including the cost of loan
documentation.
At
the initial funding, the Company received net proceeds of
approximately $4,610,000 after fees and expenses. These fees and
expenses are being accounted for as a debt discount and classified
within notes payable on the Company’s consolidated balance
sheet as a direct deduction from the carrying amount of the notes
payable, consistent with debt discounts. Debt discounts, issuance
costs and the final payment are being amortized or accreted as
interest expense over the term of the loan using the effective
interest method.
The
Loan Agreement also contains customary indemnification obligations
and customary events of default, including, among other things, our
failure to fulfill certain of the Company's obligations under the
Loan Agreement, the occurrence of a material adverse change, which
is defined as a material adverse change in the Company's business,
operations, or condition (financial or otherwise), a material
impairment of the prospect of repayment of any portion of the loan,
or a material impairment in the perfection or priority of the
Lenders’ lien in the collateral or in the value of such
collateral. In the event of default by the Company under the
Loan Agreement, the Lenders would be entitled to exercise their
remedies thereunder, including the right to accelerate payment of
the debt, upon which we may be required to repay all amounts then
outstanding under the Loan Agreement, which could harm the
Company's financial condition.
The
Company was in compliance with all applicable covenants set forth
in the Loan Agreement as of December 31, 2017.
The
Company recorded interest expense related to the term loan of
$929,106 for the year ended December 31, 2017. The annual effective
interest rate on the note payable, including the amortization of
the debt discounts and accretion of the final payment, but
excluding the warrant amortization, is approximately
12.8%.
As
of December 31, 2017, the Company had one insurance premium
note outstanding with a balance totaling $15,210, which
matured in April 2018. This note bears interest at a
rate of 6.7% per annum, and the monthly payments are
$3,855.
Future
principal payments under the Loan Agreement and insurance premium
note as of December 31, 2017 are as follows:
Years
ending December 31:
|
|
2018
|
$
1,681,888
|
2019
|
1,666,667
|
2020
|
277,778
|
Notes
payable, balance as of December 31, 2017
|
3,626,333
|
Unamortized
discount on notes payable
|
(322,974
)
|
Notes
payable, net, balance as of December 31, 2017
|
3,303,359
|
Current
portion of notes payable, net
|
(1,681,876
)
|
Long-term
portion of notes payable, net
|
$
1,621,483
|
8. Convertible Preferred Stock, Common Stock and
Warrants
At
December 31, 2017 and 2016, there were no financial instruments
requiring fair value measurement.
Dividends on Preferred Stock
Since
the Company’s inception, no dividends were ever declared or
paid by the Company’s Board of Directors.
Conversion of Preferred Stock into Common Stock
During
2017 holders of Series D Preferred Stock converted 88,384 shares
into 398,131 shares of common stock, holders of Series I Preferred
Stock converted 1,170,204 shares into 390,068 shares of common
stock, holders of Series J Preferred Stock converted 1,614 shares
into 537,874 shares of common stock and holders of Series K
Preferred Stock converted 1,850 shares into 61,667 shares of common
stock.
Exchange of Series F Preferred Stock, Series G Preferred Stock and
Series H Preferred Stock into Series L Preferred Stock
On
October 18, 2017, we entered into exchange agreements (each, an
“Exchange Agreement” and collectively, the
“Exchange Agreements”) with the holders of all of the
Company’s outstanding shares of Series F Preferred Stock,
Series G Preferred Stock and Series H Preferred Stock, pursuant to
which 665,281 shares of Series F Preferred Stock, 1,000,000 shares
of Series G Preferred Stock and 850 shares of Series H Preferred
Stock were exchanged for 58,000 newly authorized shares of Series L
Preferred Stock convertible into 3,222,223 shares of common
stock.
In connection with the Exchange Agreement the Company
became obligated to schedule and hold a special meeting of the
stockholders of the Company within 60 days of the date of signing
the Exchange Agreement, at which time the Company shall present to
its stockholders a proposal for approval of the potential issuance
of up to an aggregate of 3,222,223 shares of common stock, in
excess of 19.99% of the number of shares of common stock that were
issued and outstanding on October 17, 2017, upon the conversion of
58,000 shares of the Series L Preferred Stock issued to the holders
pursuant to the Exchange Agreements. On December 1, 2017, the
stockholders approved the number of shares underlying the Series L
Preferred Stock upon conversion.
On
December 21, 2017, following the completion of the exchange of
Series L Preferred Stock for all outstanding Series F Preferred
Stock, Series G Preferred Stock and Series H Preferred Stock and
related documentation, the Company filed with the Secretary of
State of the State of Delaware a Certificate of Elimination
eliminating from its Amended and Restated Certificate of
Incorporation the designation of shares of its preferred stock as
Series F Preferred Stock, Series G Preferred Stock and Series H
Preferred Stock. As a result, all shares of preferred stock
previously designated as Series F, Series G and Series H Preferred
Stock were eliminated and returned to the status of authorized but
unissued shares of preferred stock, without
designation.
Series D Preferred Stock
As
of December 31, 2017 and 2016, there were 44,104 and 132,489 shares
of Series D Preferred Stock issued and outstanding, respectively.
Shares outstanding as of December 31, 2017 and 2016 were
convertible into 198,667 and 596,798 shares of common stock,
respectively.
As
contemplated by the exchange agreements and as approved by the
Company’s Board of Directors, the Company filed with the
Secretary of State of the State of Delaware a Certificate of
Designation of Preferences, Rights and Limitations of Series D
Convertible Preferred Stock (the “Series D Certificate of
Designations”), on March 25, 2015. Pursuant to the
Series D Certificate of Designations, the Company designated
1,000,000 shares of its blank check preferred stock as Series D
Preferred Stock. Each share of Series D Preferred Stock has a
stated value of $0.01 per share. In the event of a
liquidation, dissolution or winding up of the Company, each share
of Series D Preferred Stock will be entitled to a per share
preferential payment equal to the par value. Each share of Series D
Preferred Stock is convertible into 4.5045 shares of common
stock. The conversion ratio is subject to adjustment in the
event of stock splits, stock dividends, combination of shares and
similar recapitalization transactions. The Company is
prohibited from effecting the conversion of the Series D Preferred
Stock to the extent that, as a result of such conversion, the
holder beneficially would own more than 4.99% (provided that
certain investors elected to block their beneficial ownership
initially at 2.49% in the exchange agreements), in the aggregate,
of the issued and outstanding shares of the Company’s common
stock calculated immediately after giving effect to the issuance of
shares of common stock upon the conversion of the Series D
Preferred Stock. Each share of Series D Preferred Stock
entitles the holder to vote on all matters voted on by holders of
common stock. With respect to any such vote, each share of Series D
Preferred Stock entitles the holder to cast such number of votes
equal to the number of shares of common stock such shares of Series
D Preferred Stock are convertible into at such time, but not in
excess of the beneficial ownership limitations.
Series E Preferred Stock
As
of December 31, 2017, and 2016, there were 33,333 shares of Series
E Preferred Stock issued and outstanding, convertible into 173,251
shares of common stock.
On
March 30, 2015, the Company filed with the Secretary of State of
the State of Delaware a Certificate of Designation of Preferences,
Rights and Limitations of Series E Convertible Preferred Stock (the
“Series E Certificate of Designations”) to designate
100,000 shares of its blank check preferred stock as Series E
Preferred Stock.
The
shares of Series E Preferred Stock are convertible into shares of
common stock based on a conversion calculation equal to the stated
value of such preferred share, plus all accrued and unpaid
dividends, if any, on such share of Series E Preferred Stock, as of
such date of determination, divided by the conversion price. The
stated value of each share of Series E Preferred Stock is $75 and
the initial conversion price is $16.65 per share, each subject to
adjustment for stock splits, stock dividends, recapitalizations,
combinations, subdivisions or other similar events. In addition,
during the period proscribed for in the Series E Certificate of
Designations, in the event the Company issues or sells, or is
deemed to issue or sell, shares of common stock at a per share
price that is less than the conversion price then in effect, the
conversion price shall be reduced to such lower price, subject to
certain exceptions. The Company is prohibited from effecting a
conversion of the share of Series E Preferred Stock to the extent
that, as a result of such conversion, such holder would
beneficially own more than 4.99% of the number of shares of common
stock outstanding immediately after giving effect to the issuance
of shares of common stock upon conversion of the Series E Preferred
Stock, which beneficial ownership limitation may be increased by
the holder up to, but not exceeding, 9.99%. Each holder is entitled
to vote on all matters submitted to stockholders of the Company and
shall have the number of votes equal to the number of shares of
common stock issuable upon conversion of such holder’s share
of Series E Preferred Stock, but not in excess of beneficial
ownership limitations. The shares of Series E Preferred Stock bear
no interest.
On August 22, 2016, when the
Company closed on the August 2016 Public Offering, the current
Series E Preferred Stock conversion price of $16.65 per share was
reduced to $14.43 per share under the terms of the Series E
Certificate of Designations, resulting in an increase in the number
of shares of common stock to 173,251 that the Series E Preferred
Stock may be converted into. In the event of a liquidation,
dissolution or winding up of the Company, each share of Series E
preferred stock will be entitled to a per share preferential
payment equal to the stated value. There is no further adjustment
required by the Series E Certificate of Designations in the event
of an offering of shares below $14.43 per share by the
Company.
Series F Preferred Stock
As
of December 31, 2017, and 2016, there were no shares and 665,281
shares, respectively, of Series F Preferred Stock issued and
outstanding. Shares outstanding as of December 31, 2016 were
convertible into 221,761 shares of common stock. These shares were
exchanged for Series L Preferred Stock in connection with the
Exchange Agreement.
On August 16, 2016,
we filed a Certificate of Designations, Preferences and Rights of
the 0% Series F Convertible Preferred Stock with the Delaware
Secretary of State, designating 1,559,252 shares of preferred stock
as 0% Series F
Preferred Stock
.
The shares of Series F
Preferred
Stock
were convertible into shares of common stock based on
a conversion calculation equal to the stated value of such Series F
Preferred Stock
, plus all
accrued and unpaid dividends, if any, on such Series F
Preferred Stock
, as of such date of
determination, divided by the conversion price. The stated value of
each share of Series F
Preferred
Stock
is $4.81 and the initial conversion price is $14.43
per share, each subject to adjustment for stock splits, stock
dividends, recapitalizations, combinations, subdivisions or other
similar events. In the event of a liquidation, dissolution or
winding up of the Company, each share of Series F
Preferred Stock
was entitled to a per share
preferential payment equal to the par value. All shares of the
Company’s capital stock were junior in rank to Series F
Preferred Stock
with respect to
the preferences as to dividends, distributions and payments upon
the liquidation, dissolution and winding-up of the Company, except
for the Company’s Series D
Preferred Stock
and Series E
Preferred Stock
.
The holders of
Series F
Preferred Stock
were
entitled to receive dividends if and when declared by our Board of
Directors. The Series F
Preferred
Stock
had the ability to participate on an “as
converted” basis, with all dividends declared on the
Company’s common stock. In addition, if we had granted,
issued or sold any rights to purchase our securities pro rata to
all our record holders of our common stock, each holder was
entitled to acquire such securities applicable to the granted
purchase rights as if the holder had held the number of shares of
common stock acquirable upon complete conversion of all Series F
Preferred Stock
then
held.
We were prohibited
from effecting a conversion of the Series F
Preferred Stock
to the extent that, as a
result of such conversion, the holder would beneficially own more
than 4.99% of the number of shares of common stock outstanding
immediately after giving effect to the issuance of shares of common
stock upon conversion of the Series F
Preferred Stock
, which beneficial ownership
limitation may be increased by the holder up to, but not exceeding,
9.99%. Each holder was entitled to vote on all matters submitted to
stockholders of the Company and would have had the number of votes
equal to the number of shares of common stock issuable upon
conversion of such holder’s Series F
Preferred Stock
, but not in excess of the
beneficial ownership limitations.
Series G Preferred Stock
As of December 31,
2017, and 2016, there were no shares of our Series G Preferred
Stock issued and outstanding. On May 19, 2017, we closed a public
offering of 1,000,000 shares of newly designated 0% Series G
Convertible Preferred stock; however, on October 17, 2017, these
shares were exchanged for our Series L Preferred Stock in
connection with the Exchange Agreement.
Pursuant to a
Series G Preferred Stock Certificate of Designations, on May 15,
2017, we designated 5,000,000 shares of our blank check preferred
stock as Series G Preferred Stock, par value of $0.01 per share.
The shares of Series G Preferred Stock were convertible into shares
of common stock based on a conversion calculation equal to the
stated value of the of such Series G Preferred Stock, plus all
accrued and unpaid dividends, if any, on such Series G Preferred
Stock, as of such date of determination, divided by the conversion
price. The stated value of each share of Series G Preferred Stock
is $1.75 and the initial conversion price is $5.25 per share, each
subject to adjustment for stock splits, stock dividends,
recapitalizations, combinations, subdivisions or other similar
events. The holder of a majority of the Series G
Preferred Stock had the right to nominate a candidate for the
Company’s Board of Directors, such right to expire on
December 31, 2017.
In the event of a
liquidation, dissolution or winding up of the Company, each share
of Series G Preferred Stock was entitled to a per share
preferential payment equal to the par value. All shares of our
capital stock were junior in rank to Series G Preferred Stock with
respect to the preferences as to dividends, distributions and
payments upon the liquidation, dissolution and winding-up of the
Company, except for the Company’s Series D Preferred Stock,
Series E Preferred Stock and Series F Preferred Stock. The
holders of Series G Preferred Stock were entitled to receive
dividends if and when declared by our Board of Directors. The
Series G Preferred Stock were entitled to participate on an
“as converted” basis, with all dividends declared on
our common stock. In addition, if we had granted, issued
or sold any rights to purchase our securities pro rata to all our
record holders of our common stock, each holder was entitled to
acquire such securities applicable to the granted purchase rights
as if the holder had held the number of shares of common stock
acquirable upon complete conversion of all Series G Preferred Stock
then held.
We were prohibited
from effecting a conversion of the Series G Preferred Stock to the
extent that, as a result of such conversion, the holder would
beneficially own more than 4.99% of the number of shares of common
stock outstanding immediately after giving effect to the issuance
of shares of common stock upon conversion of the Series G Preferred
Stock, which beneficial ownership limitation may be increased by
the holder up to, but not exceeding, 9.99%. Each holder was
entitled to vote on all matters submitted to stockholders of the
Company and would have had the number of votes equal to the number
of shares of common stock issuable upon conversion of such
holder’s Series G Preferred Stock, but not in excess of the
beneficial ownership limitations.
Series
H Preferred Stock
As of December 31,
2017 and 2016, there were no shares of our Series H Preferred Stock
issued and outstanding. On May 3, 2017 we closed a private
placement of 850 shares; however, these shares were exchanged for
our Series L Preferred Stock in connection with the Exchange
Agreement.
Pursuant to a
Series H Preferred Stock Certificate of Designations, on May 3,
2017, we designated 2,000 shares of our blank check preferred stock
as Series H Preferred Stock, par value of $0.01 per share. The
shares of Series H Preferred Stock were convertible into shares of
common stock based on a conversion calculation equal to the stated
value of the Series H Preferred Stock, plus the base amount, if
any, on such Series H Preferred Stock, as of such date of
determination, divided by the conversion price. The stated value of
each share of Series H Preferred Stock was $1,000 and the initial
conversion price was $5.25 per share, each subject to adjustment
for stock splits, stock dividends, recapitalizations, combinations,
subdivisions or other similar events.
In the event of a
liquidation, dissolution or winding up of the Company, each share
of Series H Preferred Stock was entitled to a per share
preferential payment equal to the base amount. All shares of
our capital stock were junior in rank to Series H Preferred Stock
with respect to the preferences as to dividends, distributions and
payments upon the liquidation, dissolution and winding-up of the
Company other than Series A through G Preferred Stock. The
holders of Series H Preferred Stock were entitled to receive
dividends if and when declared by our Board of Directors. The
Series H Preferred Stock holders were entitled to participate on an
“as converted” basis, with all dividends declared on
our common stock. In addition, if we granted, issued or
sold any rights to purchase our securities pro rata to all our
record holders of our common stock, each holder was entitled to
acquire such securities applicable to the granted purchase rights
as if the holder had held the number of shares of common stock
acquirable upon complete conversion of all Series H Preferred Stock
then held.
We were prohibited
from effecting a conversion of the Series H Preferred Stock to the
extent that, as a result of such conversion, the holder would
beneficially own more than 4.99% of the number of shares of common
stock outstanding immediately after giving effect to the issuance
of shares of common stock upon conversion of the Series H Preferred
Stock, which beneficial ownership limitation may be increased by
the holder up to, but not exceeding, 9.99%. Each holder was
entitled to vote on all matters submitted to stockholders of the
Company, and would have had the number of votes equal to the number
of shares of common stock issuable upon conversion of such
holder’s Series H Preferred Stock, but not in excess of the
beneficial ownership limitations.
Series
I Preferred Stock
As of December 31,
2017 and 2016, there were 798,460 and no shares of our Series I
convertible preferred stock (the “Series I Preferred
Stock”) issued and outstanding and convertible into 266,154
and no shares of our common stock, respectively.
Pursuant to a
Series I Preferred Stock Certificate of Designations, on May 26,
2017, we designated 1,968,664 shares of our blank check preferred
stock as Series I Preferred Stock, par value of $0.01 per
share.
Each share of
Series I Preferred Stock has a stated value of $0.01 per
share. In the event of a liquidation, dissolution or winding
up of the Company, each share of Series I Preferred Stock will be
entitled to a per share preferential payment equal to the stated
value. Each share of Series I Preferred Stock is convertible into
one-third share of common stock. The conversion ratio is
subject to adjustment in the event of stock splits, stock
dividends, combination of shares and similar recapitalization
transactions. The Company is prohibited from effecting the
conversion of the Series I Preferred Stock to the extent that, as a
result of such conversion, the holder beneficially owns more than
4.99%, in the aggregate, of the issued and outstanding shares of
the Company’s common stock calculated immediately after
giving effect to the issuance of shares of common stock upon the
conversion of the Series I Preferred Stock, which beneficial
ownership limitation may be increased by the holder up to, but not
exceeding, 9.99%. Each share of Series I Preferred Stock
entitles the holder to vote on all matters voted on by holders of
common stock. With respect to any such vote, each share of Series I
Preferred Stock entitles the holder to cast such number of votes
equal to the number of shares of common stock such shares of Series
I Preferred Stock are convertible into at such time, but not in
excess of the above beneficial ownership
limitation.
Series
J Preferred Stock
As of December 31,
2017, and December 31, 2016, there were 773 and no shares of our
Series J Preferred Stock issued and outstanding and convertible
into 257,577 and no shares of our common stock,
respectively.
On August 14, 2017,
the Company filed a Certificate of Designations, Preferences and
Rights of the 0% Series J Convertible Preferred Stock with the
Delaware Secretary of State, designating 3,400 shares of preferred
stock as Series J Preferred Stock. The shares of Series J Preferred
Stock are convertible into shares of common stock based on a
conversion calculation equal to the stated value of the Series J
Preferred Stock, plus all accrued and unpaid dividends, if any, on
such Series J Preferred Stock, as of such date of determination,
divided by the conversion price. The stated value of each share of
Series J Preferred Stock is $550 and the initial conversion price
is $1.65 per share, each subject to adjustment for stock splits,
stock dividends, recapitalizations, combinations, subdivisions or
other similar events.
For so long as the
holder has Series J Preferred Stock, if the Company sells, or is
deemed to have sold, common stock, or common equivalent shares, for
consideration per share less than the conversion price in effect
immediately prior to the issuance (the “Lower Issuance
Price”), then the conversion price in effect immediately
prior to such issuance will be adjusted to the Lower Issuance
Price, provided however the Lower Issuance Price shall not be less
than $0.03.
The holders of
Series J Preferred Stock will be entitled to receive dividends if
and when declared by our Board of Directors. The Series J Preferred
Stock shall participate on an “as converted” basis,
with all dividends declared on our common stock. In
addition, if we grant, issue or sell any rights to purchase our
securities pro rata to all our record holders of our common stock,
each holder will be entitled to acquire such securities applicable
to the granted purchase rights as if the holder had held the number
of shares of common stock acquirable upon complete conversion of
all Series J Preferred Stock then held.
We are prohibited
from effecting a conversion of the Series J Preferred Stock to the
extent that, as a result of such conversion, the holder would
beneficially own more than 4.99% of the number of shares of common
stock outstanding immediately after giving effect to the issuance
of shares of common stock upon conversion of the Series J Preferred
Stock, which beneficial ownership limitation may be increased by
the holder up to, but not exceeding, 9.99%. Each holder is entitled
to vote on all matters submitted to stockholders of the Company,
and shall have the number of votes equal to the number of shares of
common stock issuable upon conversion of such holder’s Series
J Preferred Stock, substituting the consolidated closing bid
price of the common stock on August 10, 2017 for the
then-applicable conversion price, and not in excess of the
beneficial ownership limitations.
The Company shall
not be obligated to issue any shares of common stock upon
conversion of the Series J Preferred Stock, and the holder of any
shares of Series J Preferred Stock shall not have the right to
receive upon conversion of any shares of the Series J Preferred
Stock if the issuance of such shares of common stock would exceed
the aggregate number of shares of common stock which the Company
may issue upon conversion of the Series J Preferred Stock without
breaching the Company's obligations under the rules or regulations
of The Nasdaq Capital Market, which aggregate number equals 19.99%
of the number of shares outstanding on the closing date, except
that such limitation shall not apply in the event that the Company
obtains the approval of its stockholders as required by the
applicable rules of The Nasdaq Capital Market for issuances of
common stock in excess of such amount. Such approval was obtained
in October 2017.
Holders of Series J
Preferred Stock will be entitled to a preferential payment of cash
per share equal to the greater of 125% of the base amount on the
date of payment or the amount per share had the holders converted
such preferred shares immediately prior to the date of payment upon
the liquidation, dissolution or winding up of the affairs of the
Company, or a consolidation or merger of the Company with or into
any other corporation or corporations, or a sale of all or
substantially all of the assets of the Company, or the effectuation
by the Company of a transaction or series of transactions in which
more than 50% of the voting shares of the Company is disposed of or
conveyed.
Series
K Preferred Stock
As of December 31,
2017 and 2016, there were 63,150 and no shares, respectively, of
our Series K convertible preferred stock (“Series K Preferred
Stock”) issued and outstanding and convertible into 2,105,000
and no shares of our common stock, respectively.
On August 14, 2017,
the Company filed a Certificate of Designations, Preferences and
Rights of the Series K Convertible Preferred Stock with the
Delaware Secretary of State, designating 65,000 shares of preferred
stock as Series K Preferred Stock. The shares of Series K Preferred
Stock are convertible into shares of common stock based on a
conversion calculation equal to the stated value of the Series K
Preferred Stock divided by the conversion price. The stated value
of each share of Series K Preferred Stock is $0.01 and the initial
conversion price is $0.0003 per share, each subject to adjustment
for stock splits, stock dividends, recapitalizations, combinations,
subdivisions or other similar events.
The holders of
Series K Preferred Stock will be entitled to receive dividends if
and when declared by our Board of Directors. The Series K Preferred
Stock shall participate on an “as converted” basis,
with all dividends declared on our common stock. In
addition, if we grant, issue or sell any rights to purchase our
securities pro rata to all our record holders of our common stock,
each holder will be entitled to acquire such securities applicable
to the granted purchase rights as if the holder had held the number
of shares of common stock acquirable upon complete conversion of
all Series K Preferred Stock then held.
We are prohibited
from effecting any conversion of the Series K Preferred Stock if
the Company has not obtained shareholder approval for the full
conversion of the Series J Preferred Stock and Series K Preferred
Stock in accordance with the rules of The Nasdaq Capital Market or
to the extent that, as a result of such conversion, the holder
would beneficially own more than 4.99% of the number of shares of
common stock outstanding immediately after giving effect to the
issuance of shares of common stock upon conversion of the Series K
Preferred Stock, which beneficial ownership limitation may be
increased by the holder up to, but not exceeding, 9.99%. Each
holder is entitled to vote on all matters submitted to stockholders
of the Company, and shall have the number of votes equal to the
number of shares of common stock issuable upon conversion of such
holder’s Series K Preferred Stock, substituting the
consolidated closing bid price of the common stock on August 10,
2017 for the then-applicable conversion price, and not in excess of
the beneficial ownership limitations. Such approval was obtained in
October 2017.
Series
L Preferred Stock
As of December 31,
2017 and 2016, there were 58,000 and no shares of our Series L
Preferred Stock issued and outstanding and convertible into
3,222,223 and no shares of our common stock,
respectively.
On October 16,
2017, we filed a Certificate of Designations, Preferences and
Rights of the 0% Series L Convertible Preferred Stock (the
"Series L Certificate of Designation") with the Delaware
Secretary of State, designating 58,000 shares of preferred stock as
Series L Preferred Stock. On October 18, 2017, we filed a
Certificate of Correction to the Series L Certificate of
Designation to include a sentence that was inadvertently
omitted.
The shares of
Series L Preferred Stock are convertible into shares of common
stock based on a conversion calculation equal to the stated value
of the Series L Preferred Stock, plus all accrued and unpaid
dividends, if any, on such Series L Preferred Stock, as of such
date of determination, divided by the conversion price. The stated
value of each share of Series L Preferred Stock is $100 and the
initial conversion price is $1.80 per share, each subject to
adjustment for stock splits, stock dividends, recapitalizations,
combinations, subdivisions or other similar events.
The holders of
Series L Preferred Stock will be entitled to receive dividends if
and when declared by our Board of Directors. The Series L Preferred
Stock shall participate on an “as converted” basis,
with all dividends declared on our common stock. In
addition, if the Company grants, issues or sells any rights to
purchase its securities pro rata to all record holders of common
stock, each holder will be entitled to acquire such securities
applicable to the granted purchase rights as if the holder had held
the number of shares of common stock acquirable upon complete
conversion of all Series L Preferred Stock then held.
We are prohibited
from effecting a conversion of the Series L Preferred Stock if
the Company has not obtained stockholder approval for the full
conversion of the Series L Preferred Stock in accordance with the
rules of The Nasdaq Capital Market or to the extent that, as a
result of such conversion, the holder would beneficially own more
than 4.99% of the number of shares of common stock outstanding
immediately after giving effect to the issuance of shares of common
stock upon conversion of the Series L Preferred Stock, which
beneficial ownership limitation may be increased by the holder up
to, but not exceeding, 9.99%. Each holder is entitled to vote on
all matters submitted to stockholders of the Company, and shall
have the number of votes equal to the number of shares of common
stock issuable upon conversion of such holder’s Series L
Preferred Stock, substituting the consolidated closing bid
price of the common stock on October 13, 2017, for the
then-applicable conversion price, and not in excess of the
beneficial ownership limitations or limitations required by the
rules and regulations of The Nasdaq Capital
Market.
Holders of Series L
Preferred Stock will be entitled to a preferential payment of cash
per share equal to the greater of 100% of the base amount
representing the sum of the stated value and any unpaid dividends
(the “Base Amount”) on the date of payment or the
amount per share had the holders converted such preferred shares
immediately prior to the date of payment upon the liquidation,
dissolution or winding up of the affairs of the Company, or a
consolidation or merger of the Company with or into any other
corporation or corporations, or a sale of all or substantially all
of the assets of the Company, or the effectuation by the Company of
a transaction or series of transactions in which more than 50% of
the voting shares of the Company is disposed of or
conveyed.
Warrants
Issued in Connection with April 2015 Private Placement
As of December 31,
2017, there were no warrants outstanding in connection with the
April 2015 Private Placement as all of the warrants expired on
October 10, 2017. As of December 31, 2016, there were warrants
outstanding to purchase 268,454 shares of common stock at $33.30
per share.
The warrants priced
at $33.30 and $6.00 per share were remaining from our private
offering in March and April 2015 (the “April 2015 Private
Placement”) in which we sold $8,546,348 worth of units (the
“Units”), net of $668,150 in issuance costs, of which
$2,500,000 of the Units consisted of Series E Preferred Stock and
the balance consisted of 553,424 shares of common stock, together
with warrants to all investors to purchase 351,787 shares of common
stock at $33.30 per share. Each Unit was sold at a
purchase price of $16.65 per Unit. OPKO Health, Inc., the lead
investor in the April 2015 Private Placement, purchased $2,500,000
worth of Units consisting all the shares of the Series E Preferred
Stock.
In connection
with the May 2017 Public Offering, the Company had agreed to amend
the terms of a portion of the outstanding warrants, or warrants to
purchase 108,108 shares of common stock that had an exercise price
of $33.30 per share, such that the amended warrants shall have an
exercise price of $6.00 per share and no cashless exercise feature,
for those investors who made a certain minimum required investment
to qualify for repricing. After the repricing, the stock price
never reached above $6.00 in order for the warrants to be exercised
prior to the expiration date of October 10, 2017.
Warrants
Issued in Connection with October 2015 Public Offering
As of December 31,
2017 and 2016, there were warrants outstanding to purchase 56,307
shares of common stock at $29.31 per share in connection with a
public offering on October 5, 2015.
The warrants were
issued in connection with our public offering on October 5, 2015,
which consisted of the sale of 112,613 shares of common stock at a
price of $24.42 per share and warrants to purchase 56,307 shares of
common stock at an exercise price of $29.31 per share. For
every two shares of common stock sold, the Company issued one
warrant to purchase one share of common stock. We received
$2,750,000 in gross proceeds, before underwriting discounts and
commissions and offering expenses totaling approximately $586,608.
The shares and warrants were separately issued and sold in equal
proportions. The warrants expired unexercised on September 30,
2018.
Warrants
Issued in Connection with August 2016 Public Offering
As of December 31,
2017, there were warrants outstanding to purchase 145,444 shares of
common stock at $16.65 per share and 145,444 shares of common stock
at $18.87 per share. As of December 31, 2016, there were warrants
outstanding to purchase 654,107 shares of common stock at $16.65
per share and 654,107 shares of common stock at $18.87 per
share.
The warrants were
issued on August 22, 2016, in connection with a public offering of
432,346 shares of common stock and 665,281 shares of Series F
preferred stock, and warrants to purchase 654,107 shares of common
stock at $16.65 per share and warrants to purchase 654,107 shares
of common stock at $18.87 per share, at an offering price of $14.43
per share. For every share of common stock or Series F
preferred stock sold, we issued one warrant to purchase one-third
share of common stock at $16.65 per share and one warrant to
purchase one-third share of common stock at $18.87 per share.
We received $9,438,753 in gross proceeds, before underwriting
discounts and commissions and offering expenses totaling $871,305.
The gross proceeds include the underwriter’s over-allotment
option, which it exercised on the closing date.
August 22, 2016 Public Offering
On
August 22, 2016, we closed a public offering of 432,346 shares of
common stock and 665,281 shares of Series F Preferred Stock
convertible into 221,761 shares of common stock, and warrants to
purchase 654,107 shares of common stock at $16.65 per share and
warrants to purchase 654,107 shares of common stock at $18.87 per
share, at an offering price of $14.43 per share. For every
one-third share of common stock or Series F Preferred Stock sold,
we issued one warrant to purchase one-third share of common stock
at $16.65 per share and one warrant to purchase one-third share of
common stock at $18.87 per share. We received $9,438,753 in
gross proceeds, before underwriting discounts and commissions and
offering expenses totaling $871,305. The gross proceeds include the
underwriter’s over-allotment option, which they exercised on
the closing date.
May 3, 2017 Private Placement
On
May 3, 2017, we entered into separate subscription agreements with
accredited investors pursuant to which we sold an aggregate of
$850,000, or 850 shares, of Series H Preferred Stock, at a stated
value of $1,000 per share, before offering costs of $29,429, in the
May 2017 Private Placement. The shares of Series H Preferred Stock
are convertible into shares of common stock based on a conversion
calculation equal to the stated value of the Series H Preferred
Stock, plus the base amount, if any, on such Series H Preferred
Stock, as of such date of determination, divided by the conversion
price. The conversion price is $5.25 per share, after adjusting for
the 2018 Reverse Stock Split, and subject to further adjustment for
stock splits, stock dividends, recapitalizations, combinations,
subdivisions or other similar events.
In
the event of a liquidation, dissolution or winding up of the
Company, each share of Series H Preferred Stock will be entitled to
a per share preferential payment equal to the base amount. All
shares of our capital stock will be junior in rank to Series H
Preferred Stock with respect to the preferences as to dividends,
distributions and payments upon the liquidation, dissolution and
winding-up of the Company other than Series A through G Preferred
Stock. The holders of Series H Preferred Stock will be entitled to
receive dividends if and when declared by our Board of Directors.
The Series H Preferred Stock shall participate on an “as
converted” basis, with all dividends declared on our common
stock. In addition, if we grant, issue or sell any
rights to purchase our securities pro rata to all our record
holders of our common stock, each holder will be entitled to
acquire such securities applicable to the granted purchase rights
as if the holder had held the number of shares of common stock
acquirable upon complete conversion of all Series H Preferred Stock
then held.
We
are prohibited from effecting a conversion of the Series H
Preferred Stock to the extent that, as a result of such conversion,
the holder would beneficially own more than 4.99% of the number of
shares of common stock outstanding immediately after giving effect
to the issuance of shares of common stock upon conversion of the
Series H Preferred Stock, which beneficial ownership limitation may
be increased by the holder up to, but not exceeding, 9.99%. Each
holder is entitled to vote on all matters submitted to stockholders
of the Company, and shall have the number of votes equal to the
number of shares of common stock issuable upon conversion of such
holder’s Series H Preferred Stock, but not in excess of the
beneficial ownership limitations.
The
shares were offered and sold solely to “accredited
investors” in reliance on the exemption from registration
afforded by Rule 506 of Regulation D and Section 4(a)(2) of the
Securities Act. On the closing date, we entered into registration
rights agreements with each of the investors, pursuant to which we
agreed to undertake to file a registration statement to register
the resale of the shares within thirty (30) days following the
closing date, to cause such registration statement to be declared
effective by the Securities and Exchange Commission
(“SEC”) within sixty (60) days of the closing date and
to maintain the effectiveness of the registration statement until
all of such shares have been sold or are otherwise able to be sold
pursuant to Rule 144 under the Securities Act, without any
restrictions.
On
May 10, 2017, we entered into exchange agreements with each of the
holders of our Series H Preferred Stock representing an aggregate
of $850,000 of our Series H Preferred Stock with such exchange to
be effective on the closing of our May 2017 Public Offering. Prior
to the closing of the May 2017 Public Offering, we and the holders
rescinded and cancelled the exchange agreements and they have no
force and effect and no transaction contemplated by the Exchange
Agreements was consummated.
May 19, 2017 Public Offering
On
May 19, 2017, we closed the May 2017 Public Offering. The
Series G Preferred Stock is initially convertible into 333,334
shares of common stock, subject to adjustment for stock splits,
stock dividends, recapitalizations, combinations, subdivisions or
other similar events and was purchased by certain existing
investors of the Company who, as a result of their purchases of
common stock, would hold in excess of 4.99% of our issued and
outstanding common stock. We received $4,100,000 in gross proceeds,
before estimated underwriting discounts, commissions and offering
expenses of $416,217.
The
May 2017 Public Offering was consummated pursuant to an
underwriting agreement that we signed on May 15, 2017, with
Laidlaw, as underwriter (the “Underwriter”) pursuant to
which, among other things, we agreed to issue and sell to the
Underwriter, and the Underwriter agreed to purchase from us, in an
underwritten public offering, an aggregate of 447,620 shares of
common stock and 1,000,000 shares of Series G Preferred Stock. We
granted the Underwriters an option for a period of up to 45 days
from the date of our prospectus to purchase up to an aggregate of
67,143 additional shares of our common stock at the public offering
price of $5.25 per share, less the underwriting discount, solely to
cover overallotments, which was not exercised.
In connection with the May 2017 Public Offering, we agreed
with
HS Contrarian,
the lead
investor of the August 2016 Public Offering pursuant to a Letter
Agreement, dated May 18, 2017, to issue inducement shares (the
“May 2017 Inducement Shares”) to the investors in the
August 2016 Public Offering (the “August 2016
Investors”), as incentive shares to those investors to make a
minimum required investment in this public offering of at least 50%
of their investment in the $9,400,000 August 2016 Public Offering
(the “Minimum Required Investment”), and who still hold
100% of the shares of common stock previously acquired. Such August
2016 Investors shall be entitled to receive their pro rata share of
966,667 shares, after HS Contrarian in this offering receives the
first 10%. For the August 2016 Investors who purchased Series F
Preferred Stock and made the Minimum Required Investment and who
still held 100% of the shares of Series F Preferred Stock at the
closing of the May 2017 Public Offering, they may, instead of
receiving a pro rata share of the 870,000 shares remaining after HS
Contrarian receives the first 96,667 shares, elect to receive their
May 2017 Inducement Shares in the form of a new Series I Preferred
Stock to be created with similar rights as currently exist in the
Series G Preferred Stock. The stated value of each share of Series
I Preferred Stock will be $0.01 and the conversion rate shall be
one-third share of common stock for one share of Series I Preferred
Stock, each subject to adjustment for stock splits, stock
dividends, recapitalizations, combinations, subdivisions or other
similar events. In the event of a liquidation, dissolution or
winding up of the Company, each share of Series I Preferred Stock
will be entitled to a per share preferential payment equal to the
par value, or $0.01 per share. All shares of the Company’s
capital stock will be junior in rank to the Series I Preferred
Stock at the time of creation, with respect to the preferences as
to dividends, distributions and payments upon the liquidation,
dissolution and winding-up of the Company, except for the
Company’s Series D Preferred Stock, Series E Preferred Stock,
Series F Preferred Stock, Series G Preferred Stock, and Series H
Preferred Stock.
Also
in connection with the May 2017 Public Offering, for these August
2016 Investors to receive the May 2017 Inducement Shares, each of
them must also agree to the cancellation of the warrants issued to
them in the August 2016 Public Offering. Investors in the
Company’s 2015 private offering that invest at least 25% of
their original investment from such private financing in the May
2017 Public Offering and still hold 100% of their common stock or
Series E preferred stock from the private 2015 financing also must
agree to amend the terms of their outstanding warrants that
currently have an exercise price of $33.30 per share, such that the
amended warrants shall have an exercise price of $6.00 per share
and no cashless exercise feature (as amended, the “Inducement
Amended Warrants”). The Company agreed with HS Contrarian to
register for resale on a registration statement all the May 2017
Inducement Shares and shares of common stock underlying the
Inducement Amended Warrants, and to issue the May 2017 Inducement
Shares to each investor meeting the investment and ownership terms
described above.
Based
on the closing of the May 2017 Public Offering, and election of
certain prior investors who made the Minimum Required Investment
and elected to take Series I Preferred Stock upon its creation,
310,446 May 2017 Inducement Shares of common stock were issued and
1,968,664 May 2017 Inducement Shares were issued in the form of
Series I Preferred Stock convertible into 656,222 shares of common
stock that was created following the closing of the May 2017 Public
Offering and issued following verification with each investors that
the terms of the May 2017 Inducement Shares have been met. The
Company recorded a deemed dividend of $5,220,000 in June 2017 in
connection with issuing the May 2017 Inducement
Shares.
Additionally,
in connection with participation by the April 2015 investors in the
May 2017 Public Offering, the Company revised the exercise price
for warrants to purchase 30,033 shares of common stock from $33.30
to $6.00 per warrant share and recorded a deemed dividend of
$19,413 also in June 2017. In August 2017, the Company revised the
exercise price for warrants to purchase an additional 75,075
warrants from $33.30 to $6.00 per warrant share for the July 2017
Private Placement. The impact of the repricing of the additional
warrants was immaterial as the stock price on the date of repricing
was $2.10, with a volatility index in the neighborhood of 85%, and
were expiring in 69 days. The warrants expired on October 10, 2017,
unexercised.
May 2017 Letter Agreement
On May 15, 2017, as a condition to the participation of HS
Contrarian in the May 2017 Public Offering, the Company entered
into a Letter Agreement with HS Contrarian (the “May 2017
Letter Agreement”) where the Company agreed to offer
incentive shares (the “May 2017 Inducement Shares”) to
investors who (i) participated in both the Company’s August
2016 public offering and the Company’s April 2015 private
offering, (ii) purchased securities in the May 2017 Public Offering
equal to at least 50% of their original investment in the August
2016 public offering or 25% of their original investment in the
April 2015 private offering, and (iii) still hold 100% of their
common stock or preferred stock purchased in those
investments.
Further, the
Company agreed to the following in the May 2017 Letter
Agreement:
Board
Nomination:
|
|
To nominate one (1)
candidate to the Board of Directors acceptable to the holder of a
majority of the Series G Preferred Stock by December 31, 2017, and
that (2) two current members of the Board of Directors would
resign.
|
Executive
Hire:
|
|
To hire a new
C-level executive in a leadership role by July 15,
2017.
|
Board
Compensation:
|
|
To issue an
aggregate of 350,000 options to certain employees and members of
the Board of Directors, at a price not less than $6.00 per share,
and 16,667 options to each other member of the Board of Directors
at the current market price in connection with this offering. The
options were issued pursuant to the Company’s option plan,
subject to the requisite approvals and availability under the plan.
The company was responsible for obtaining the approval of the Board
of Directors and stockholders of the Company to the extent the
company needed their approval to increase the number of shares
available under the plan. All Board of Director fees were waived
for 2017.
|
Funds Held in
Escrow:
|
|
$500,000 of the
funds from the May 2017 Public Offering were to be held in escrow
and released to one or more investor relations services acceptable
to the Company following the closing of this offering.
|
Additionally, we
granted HS Contrarian consent rights: the right to approve future
(i) issuances of our securities, (ii) equity or debt financings and
(iii) sales of any development product assets currently held by us,
subject to certain exceptions, if such securities are sold at a
price below $7.50 per share and for as long as HS Contrarian in the
offering holds 50% or more of the shares of Series G Preferred
Stock purchased by HS Contrarian in the May 2017 Public Offering
(the “Consent Rights”). All other prior consent rights
of HS Contrarian were superseded by these consent rights. As of
March 31, 2018, none of the shares of Series G Preferred Stock is
outstanding. Thus, HS Contrarian no longer holds the Consent
Rights.
For the period from
the May 2017 Public Offering to December 31, 2017, the Company
exceeded the minimum $500,000 in expenses related to outside
investor relations services fulfilling the Company’s
obligation for spending on investor relations. HS Contrarian
elected not to hold the funds in escrow. Further, the Company
issued the May 2017 Inducement Shares and adjusted the Board of
Directors compensation per the May 2017 Letter Agreement. Also, two
members of the Board of Directors resigned during 2017, achieving
one of the conditions of HS Contrarian . The Company did not
nominate a new member to the Board of Directors, nor did it hire a
new C-level executive in light of limited amount of cash available
to the Company.
July 27, 2017 Private Placement
On
July 27, 2017, we entered into a subscription agreement with an
accredited investor pursuant to which we agreed to sell 50,715
restricted shares of common stock for $125,000 (the “July
2017 Private Placement”). As part of the transaction, the
Company agreed to reprice the investor’s warrant to purchase
75,075 shares of common stock from $33.30 to $6.00 per warrant
share and remove the cashless exercise feature. The transaction
closed on August 2, 2017. The impact of repricing the
warrants to $6.00 a share, which took effect on August 2, 2017, was
immaterial, as the stock price on the date of the closing of the
transaction was $2.10 and the warrants at $6.00 a share, and
expired on October 10, 2017, unexercised.
Letter
Agreement Regarding Future Financing Transactions
In
connection with an offering of the Company’s Series J.
Preferred Stock that took place in August 2017 (the “August
2017 Offering”), we agreed with HS Contrarian pursuant to a
letter agreement dated August 9, 2017 (the “August 2017
Letter Agreement”), whereby HS Contrarian together with
certain other investors would invest an aggregate of $2,350,000 in
a financing, and the Company would issue incentive shares in the
form of newly designated shares of Series K Preferred Stock
convertible into an aggregate of 2,166,667 shares of common stock
(the “August 2017 Inducement Shares”) to be distributed
to certain existing investors of the Company as directed by HS
Contrarian, as an incentive to invest in the August 2017
Offering.
In addition, the Company agreed to the following in the August 2017
Letter Agreement:
●
|
To file a proxy statement for a special
meeting of stockholders within 10 days of closing the
August
2017 Offering. Proposals were to include (i) an amendment to the
Company’s Certificate of Incorporation to effect a reverse
stock split of its issued and outstanding common stock by a ratio
of not less than one-for-two and not more than one-for-twenty at
any time prior to one year from the date of the special meeting,
with the exact ratio to be set at a whole number within this range
as determined by the Board of Directors, (ii) the issuance of
securities in one or more non-public offerings where the maximum
discount at which securities will be offered will be equivalent to
a discount of 30% below the market price of the common stock, as
required by and in accordance with Nasdaq Marketplace Rule 5635(d),
(iii) the issuance of securities in one or more non-public
offerings where the maximum discount at which securities will be
offered will be equivalent to a discount of 20% below the market
price of the common stock, as required by and in accordance with
Nasdaq Marketplace Rule 5635(d), (iv) the issuance of common stock
upon the conversion of Series J Preferred Stock and (v) the
issuance of
incentive shares in the
form of shares of Series K Preferred Stock convertible into an
aggregate of 2,166,667 shares of common stock
.
|
●
|
Subject to
agreement on terms and conditions of the investment, HS Contrarian
committed to a $1,000,000 lead order in an offering amount of
$8,000,000 (the “$8,000,000 Financing”). The $8,000,000
Financing was subject to the Company obtaining approval of a
reverse stock split, issuance of the Series J Preferred Stock, and
filing a proxy statement for stockholder approval of the Inducement
Shares as identified in the August 2017 Letter
Agreement.
|
●
|
That the
employment terms of all
management be reduced to two years from three years and that
management defer portions of their salary for the remainder of the
year, which would be paid upon the earlier of completion of the
$8,000,000 Financing or a business transaction that represents, or
transactions in the aggregate that represent, in excess of
$10,000,000.
|
In connection with
HS Contrarian’s and the Company’s obligations under the
August 2017 Letter Agreement, neither the $8,000,000 Financing nor
the change in employment terms from three years to two years were
completed as of October 15, 2018.
In
order to meet The Nasdaq Capital Market rules in the August 2017
Offering, we were not obligated to issue any shares of common stock
upon conversion of the Series J Preferred Stock which would cause
the Company to breach our obligations under the rules and
regulations of The Nasdaq Capital Market, which limit the aggregate
number of shares issued at a discount to market at 19.99% of the
number of shares outstanding on the closing date of the August 2017
Offering, except that such limitation shall not apply in the event
that we obtain the approval of our stockholders as required by the
applicable rules of The Nasdaq Capital Market for issuances of
common stock in excess of such amount. Similarly, none of the
Series K Preferred Stock could be converted into common stock until
we obtain the approval of our stockholders. At the October 2017
Special Meeting, we obtained approval to issue shares of common
stock underlying all of the Series J Preferred Stock and the Series
K Preferred Stock upon conversion.
September 11, 2017 Registered Direct Offerings
On
September 11, 2017, we entered into an agreement to sell
1,333,334 shares of common stock at $1.50 a share for gross
proceeds of approximately $2.0 million, before offering
expenses of $142,639. The shares were offered and sold to certain
accredited investors in a registered direct offering. Laidlaw acted
as placement agent for the offering.
On
September 22, 2017, we entered into a subscription agreement with
select accredited investors relating to the Company’s
registered direct offering, issuance and sale of 672,043 shares of
the Company’s common stock, $0.01 par value per share. The
purchase price per share was $1.86. The total amount of the
subscription agreements amounted to $1,250,000, before expenses of
$14,000.
October 10, 2017 Registered Direct Offering
On
October 10, 2017, we entered into a subscription agreement with
select accredited investors relating to the Company’s
registered direct offering, issuance and sale of 256,410 shares of
the Company’s common stock, $0.01 par value per share. The
purchase price per share was $1.95. The total amount of the
subscription agreements amounted to $500,000, before expenses of
$3,750.
Grant of Restricted Shares
Ravetch Grant
On
April 4, 2015, the Board of Directors approved the issuance of an
additional restricted stock award of 5,924 shares to Jeffrey
Ravetch, M.D., Ph. D, who is one of the members of the
Company’s Board of Directors. This award is for
future services covering at least a one-year period. The award was
granted in addition to the prior award to Dr. Ravetch on April 2,
2015 of (i) 1,543 restricted shares and (ii) options to purchase
1,543 shares of common stock with an exercise price of $51.06 per
share, for a total grant of 9,010 restricted shares and options. As
the 5,924 shares granted were fully vested upon grant and the
Company has no legal recourse to recover the shares in the event of
nonperformance, the Company recognized the grant date fair value of
the shares as consulting expense upon grant during the second
quarter of 2015.
Consultant Grants
On
April 5, 2015, the Company entered into consulting agreements with
two investor relations consultants to provide relations services to
the Company in consideration for an immediate grant of 13,514
shares of the Company’s restricted common stock and a monthly
cash retainer of $12,000 a month for ongoing services for a period
of one year. The consultants also received an additional 9,009
shares of the Company’s restricted common stock upon the
Company’s achieving a milestone based on its fully-diluted
market capitalization. As the shares granted were fully vested upon
grant and the Company has no legal recourse to recover the shares
in the event of nonperformance, the Company recognized the grant
date fair value of the 13,514 shares or $690,000, as investor
relations expense upon grant during the second quarter of 2015. The
performance condition for the 9,009 shares became probable and the
market capitalization metric was met during the second quarter;
therefore, the Company recognized an additional $460,000 of expense
during the second quarter of 2015.
Also
during 2015, the Board of Directors approved the issuance of
restricted stock awards to two other consultants totaling 5,406
shares with vesting terms ranging from one to three years, valued
from $39.30 to $47.28 per share. The Company is
expensing each of the grant date fair value of the awards over the
performance period for the award, which will be re-measured at the
end of each quarter until the performance is complete. As of
December 31, 2016, the Company expensed $32,569 related to these
grants. As of December 31, 2016, the expected future compensation
expense related to these grants is $24,571 based upon the
Company’s stock price on December 31, 2016.
On
January 13, 2016, the Board of Directors approved the issuance of
4,505 shares of restricted stock valued at $64,000 to a consultant
for advisory services to the Company that was fully recognized upon
issuance.
On
September 1, 2016, the Board of Directors approved the issuance of
7,377 shares of common stock with a date of issuance fair value of
$100,000 to an investor relations consulting firm. In exchange for
the shares granted and a monthly retainer, the consulting firm will
perform investor relations services on behalf of the Company. As
the shares granted were fully vested upon grant and the Company has
no legal recourse to recover the shares in the event of
nonperformance, the Company recognized the grant date fair value of
the 7,377 shares of $100,000 as investor relations expense upon
grant during the third quarter of 2016.
On
February 10, 2017, we entered into a consulting agreement with MDM
Worldwide, pursuant to which MDM Worldwide began providing investor
relations services to the Company in consideration for an immediate
grant of 6,667 shares of the Company’s common stock and a
monthly cash retainer of $10,000 a month for ongoing services for a
period of one year. As the shares granted were fully vested upon
grant and the Company has no legal recourse to recover the shares
in the event of nonperformance, the Company recognized the grant
date fair value of the 6,667 shares, or $56,600, as investor
relations expense upon grant during the first quarter of 2017. The
consulting agreement with MDM Worldwide was amended on October 15,
2017 to increase their monthly retainer to $12,500 a month for
ongoing services payable immediately upon signing the agreement and
an immediate grant of 13,334 shares. As the shares granted were
fully vested upon grant and the Company has no legal recourse to
recover the shares in the event of nonperformance, the Company
recognized the grant date fair value of the 13,334 shares, or
$30,400, as investor relations expense upon grant during the last
quarter of 2017.
On
March 7, 2017, we entered into a consulting agreement with Jenene
Thomas Communications, pursuant to which Jenene Thomas
Communications began providing investor relations services to the
Company on April 1, 2017. In consideration for the services, we
began paying a monthly cash retainer of $12,500. Additionally, we
issued 6,667 restricted shares of common stock on April 1, 2017, to
be vested at 1,667 per quarter over the four quarters of services
under the agreement beginning April 1, 2017. The shares granted
vest over a one-year period over which the services are performed
and, as such, will be amortized over the same period beginning in
April 1, 2017. For the year ended December 31, 2017, we have
recognized $13,700, in general and administrative expenses related
to this arrangement in common stock for services.
On
May 24, 2017, we issued 15,525 restricted shares of common stock
for legal services in connection with the May 2017 Private
Offering, on August 21, 2017 we issued 32,961 restricted shares of
common stock for legal services in connection with the May 2017
Public Offering, on September 14, 2017, we issued 33,334 restricted
shares of common stock for legal services and 33,334 restricted
shares of common stock for due diligence services in connection
with the September 11, 2017 registered direct offering and also on
September 22, 2017 we issued 4,849 restricted shares of common
stock for legal services in connection with the September 22, 2017
Registered Direct Offering. The total common stock value for these
shares issued were $201,470.
During
the month of October 2017, we issued an aggregate of 138,334 shares
of restricted common stock valued at $306,650 based on the closing
market prices ranging from $1.89 to $2.34, depending on the date of
issuance, to different investor relations services firms or
individuals in connection with providing investor relations
services to the Company. All of the shares were fully vested on the
date of issuance.
9. Related Party Transactions
On
April 1, 2016, the Company entered into a two-year consulting
agreement with Jeffrey Ravetch, M.D., Ph.D., a member of the
Company’s Board of Directors at the time, for work beginning
January 1, 2016 through December 31, 2017, at a rate of $100,000 a
year, in support of scientific and technical advice on the
discovery and development of technology and products for the
Company primarily related to monoclonal antibodies, corporate
development, and corporate partnering efforts. In April
2016, the Company paid Dr. Ravetch $100,000 for services to be
performed in 2016, and paid quarterly thereafter beginning January
1, 2017. On November 3, 2016, the Company granted 5,834 stock
options at an exercise price of $11.25 to Jeffrey Ravetch, M.D.,
Ph.D., a member of the Company’s Board of Directors, for his
ongoing consulting services to the Company. The option award vests
over a three-year period. Dr. Ravetch resigned from the
Company’s Board of Directors on August 3, 2017, although he
continued under the consulting agreement subsequent to his
resignation.
On
May 19, 2017, the Company granted each director, other than J.
David Hansen, Jeffrey Ravetch, a member of the Company’s
Board of Directors at the time, and Philip Livingston, 16,667
options at market price, $5.40 on May 19, 2017, with immediate
vesting for their continuing service to the Company, in exchange
for giving up their Board of Director fees for the remainder of the
year. J. David Hansen and Jeffrey Ravetch were each granted 166,667
options and Philip Livingston was granted 16,667 options each at
$6.00 exercise price per share with immediate vesting and no
performance obligations. Options granted to J. David Hansen, CEO
and Philip Livingston were granted as a condition of the May 2017
financing transaction. The 150,000 options granted to Dr. Ravetch
in addition to the 16,667 options granted to other non-employee
members of the Company’s Board of Directors were in
recognition of the additional value provided by Dr. Ravetch as a
scientific expert. During the year ended December 31, 2017, the
Company recorded $1,480,089 in stock-based compensation expense in
general and administration expenses, related to these
grants.
10. Stock-based Compensation
Stock Incentive Plan
In
September 2008, the Company’s stockholders approved the 2008
Stock Incentive Plan (the “2008 Plan”) which became
effective in September 2008 and under which 2,951 shares of the
Company’s common stock were initially reserved for issuance
to employees, non-employee directors and consultants of the
Company. In November 2012, the Company increased the authorized
shares under the plan to 7,023. On February 14, 2013, the 2008
Plan terminated and no further grants of equity may be made
thereunder.
In
June 2014, MabVax Therapeutics Inc.’s stockholders approved
the amended 2014 Stock Incentive Plan (the “2014 Plan”)
which became effective and was adopted by the Company in the Merger
in July 2014. The 2014 Plan authorized the issuance of up to 15,831
shares, 6,847 of which are contingent upon the forfeiture,
expiration or cancellation of the 2008 Reserved
Shares.
The
2014 Plan provided for the grant of incentive stock options,
non-incentive stock options, stock appreciation rights, restricted
stock awards, and restricted stock unit awards to eligible
recipients. The maximum term of options granted under the Stock
Plan is ten years.
Employee option grants generally
vest 25% on the first anniversary of the original vesting date, and
the balance vests monthly over the following three years. The
vesting schedules for grants to non-employee directors and
consultants is determined by the Company’s Compensation
Committee. Stock options are generally not exercisable prior to the
applicable vesting date, unless otherwise accelerated under the
terms of the applicable stock plan agreement.
Amendment of Equity Incentive Plan
On
March 31, 2015, the Company approved a Second Amended and
Restated 2014 Employee, Director and Consultant Equity Incentive
Plan (the “Plan”), effective as of and contingent upon
the consummation of the initial closing of the April Private
Placement, to increase the number of shares reserved for issuance
under the Plan from 7,121 to 376,613 shares of common stock.
Additional changes to the Plan include:
●
An
“evergreen” provision to reserve additional shares for
issuance under the Plan on an annual basis commencing on the first
day of fiscal 2016 and ending on the second day of fiscal 2024,
such that the number of shares that may be issued under the Plan
shall be increased by an amount equal to the lesser of: (i) 360,361
or the equivalent of such number of shares after the administrator,
in its sole discretion, has interpreted the effect of any stock
split, stock dividend, combination, recapitalization or similar
transaction in accordance with the Plan; (ii) the number of shares
necessary such that the total shares reserved under the Plan equals
(x) 15% of the number of outstanding shares of common stock on
such date (assuming the conversion of all outstanding shares of
Preferred Stock (as defined in the Plan) and other outstanding
convertible securities and exercise of all outstanding warrants to
purchase common stock) plus (y) 10,316; and (iii) an
amount determined by the Board.
●
Provision
that no more than 135,136 shares may be granted to any participant
in any fiscal year.
●
Provisions
to allow for performance based equity awards to be issued by the
Company in accordance with Section 162(m) of the Internal Revenue
Code.
●
On
September 22, 2016, the Board of Directors ratified an automatic
increase in the number of shares reserved for issuance under the
Plan, increasing the total shares reserved from 376,613 to 402,769
shares of common stock, under the annual evergreen provision for
the Plan
.
On
January 1, 2017, the Board of Directors ratified an automatic
increase in the number of shares reserved for issuance under the
Plan, effective January 1, 2017, increasing the total shares
reserved from 402,769 to 719,784 shares of common stock, under the
annual evergreen provision for the Plan, plus a fixed amount of
10,315.
On
June 12, 2017, the Company’s stockholders at its annual
meeting approved a proposal to increase the number of shares
reserved for issuance under the Plan, increasing the total shares
reserved under the Plan from 709,469 (including the fixed amount of
10,315) to 1,376,136, and increasing the number of shares that may
be granted to any participant in any fiscal year to 300,000, from
135,136.
On
October 2, 2017, in a special meeting of stockholders, the Company
received approval of the Fifth Amended and Restated MabVax
Therapeutics Holdings, Inc. 2014 Employee, Director and Consultant
Equity Incentive Plan (the “Plan”), including an
increase in the shares of common stock reserved for issuance under
the Plan from 1,376,136 to 2,042,802 shares.
On
December 1, 2017, in a special meeting of stockholders, the Company
received approval to increase the number of shares reserved for
issuance under the Plan, increasing the total shares reserved under
the Plan from 2,042,802 to 3,376,136.
Stock-based Compensation
Total estimated stock-based compensation expense,
related the Company’s stock-based payment awards recognized
under ASC 718, “Compensation—Stock
Compensation” and ASC 505,
“Equity,”
was comprised of the
following:
|
|
|
|
|
Research
and development
|
$
1,570,809
|
$
1,192,126
|
General
and administrative
|
5,276,122
|
3,211,152
|
Total
stock-based compensation expense
|
$
6,846,931
|
$
4,403,278
|
Stock-based Award Activity
The
following table summarizes the Company’s stock option
activity for the years ended December 31, 2017 and
2016:
|
|
Weighted
Average
Exercise Price
|
Outstanding
at December 31, 2015
|
141,910
|
$
51.90
|
Granted
|
149,871
|
15.39
|
Exercised
|
—
|
—
|
Forfeited/cancelled/expired
|
(7,936
)
|
44.15
|
Outstanding
and expected to vest at December 31, 2016
|
283,845
|
$
32.84
|
Granted
|
715,588
|
7.00
|
Exercised
|
—
|
—
|
Forfeited/cancelled/expired
|
(45,496
)
|
22.02
|
Outstanding
and expected to vest at December 31, 2017
|
953,937
|
$
13.97
|
Vested
and exercisable at December 31, 2017
|
605,822
|
$
13.37
|
Stock
options granted to employees generally vest over a three-year
period with one third of the grants vesting at each one-year
anniversary of the grant date. During 2016, the Company granted
149,871 options to its directors, officers, employees with a
weighted average exercise price of $15.39 and vesting over a
three-year period with vesting starting at the one-year anniversary
of the grant date. During 2017, the Company granted 715,588 options
to its directors, officers, employees with a weighted average
exercise price of $7.00 and vesting over a three-year period with
vesting starting at the one-year anniversary of the grant date
except for the 433,334 options issued to the Company’s
directors and officers in May 2017 which were fully vested upon
issuance.
The
total unrecognized compensation cost related to unvested stock
option grants as of December 31, 2017 was $1,932,026 and the
weighted average period over which these grants are expected to
vest is 1.6 years. The Company has elected to account for
forfeitures as they occur and reverse compensation cost as
forfeitures occur. The weighted average remaining contractual life
of stock options outstanding at December 31, 2017 and 2016 is
8.90 years and 8.82 years, respectively.
A
summary of activity related to restricted stock grants under the
Plan for the years December 31, 2017 and 2016 is presented
below:
|
|
Weighted
Average Grant-Date Fair Value
|
Non-vested
at December 31, 2015
|
103,646
|
$
50.54
|
Granted
|
—
|
—
|
Vested
|
(35,155
)
|
50.54
|
Forfeited
|
—
|
—
|
Non-vested
at December 31, 2016
|
68,491
|
50.54
|
Granted
|
840,222
|
1.89
|
Vested
|
(34,252
)
|
48.65
|
Forfeited
|
(42,235
)
|
2.10
|
Non-vested
at December 31, 2017
|
832,226
|
$
3.88
|
There
were no shares of restricted stock issued during the year ended
2016; however, 35,155 restricted stock units have vested relating
to restricted stock units granted in 2015 to directors, officers,
employees and consultants. During 2017, 34,252 shares of restricted
stock units vested upon the one-year anniversary of restricted
stock units granted to the Company’s directors and
officers. Accordingly, 21,464 shares were issued and the
Company withheld 11,283 shares for the employee portion of taxes
and remitted $177,823 to the tax authorities in order to satisfy
tax liabilities related to this issuance on behalf of the
officers. In July and August of 2016, 2,403 shares were
issued to outside consultants upon vesting of previously issued
restricted stock units. As of December 31, 2016, there were 68,491
non-vested restricted stock units remaining
outstanding.
During
the year ended December 31, 2017, 840,222 shares of restricted
stock units were issued to directors, officers, employees and
consultants which will vest in January 2018 and 34,252 restricted
share units have vested relating to restricted stock units granted
in 2015 to directors, officers, employees and consultants. As of
December 31, 2017, there were 832,226 non-vested restricted stock
units remaining outstanding.
During
the year ended December 31, 2017, the Company has recognized
$1,381,969 in stock based compensation expense related to
restricted stock units. As of December 31, 2017, and 2016,
unamortized compensation expense related to restricted stock grants
amounted to $530,232 and $2,214,859, which is expected to be
recognized over a weighted average period of .02 and 2.27 years,
respectively.
Valuation Assumptions
The
Company used the Black-Scholes-Merton option valuation model to
determine the stock-based compensation expense for stock options
recognized under ASC 718 and ASC 505. The Company’s expected
stock-price volatility assumption was based solely on the weighted
average of the historical and implied volatility of comparable
companies whose share prices are publicly available. The expected
term of stock options granted was based on the simplified method in
accordance with Staff Accounting Bulletin No. 110, or SAB 110,
as the Company’s historical share option exercise experience
did not provide a reasonable basis for estimation. The risk-free
interest rate was based on the U.S. Treasury yield for a period
consistent with the expected term of the stock award in effect at
the time of the grant.
|
|
|
|
|
Risk-free interest
rate
|
|
|
Dividend
yield
|
0%
|
0%
|
Expected
volatility
|
|
|
Expected life of
options, in years
|
|
|
Weighted average
grant date fair value
|
$
1.53
|
$
3.16
|
Because
the Company had a net operating loss carryforward as of
December 31, 2017 and 2016, no tax benefits for the tax
deductions related to stock-based compensation expense were
recognized in the Company’s consolidated statements of
operations. Additionally, there were no stock option exercises in
the corresponding period of 2017.
Management Bonus Plan and Compensation for Non-Employee
Directors
On
February 16, 2016, our Compensation Committee approved a new
management bonus plan outlining maximum target bonuses of the base
salaries of certain of our executive officers. Under the terms of
this 2016 management bonus plan, the Company's Chief Executive
Officer shall receive a maximum target bonus of up to 50% of his
annual base salary, and the Chief Financial Officer and each of the
Company's Vice Presidents shall receive a maximum target bonus of
up to 30% of their annual base salary.
On
February 16, 2016, the Compensation Committee of the Board of
Directors of the Company approved the following
amendments to Company's policy for compensating non-employee
members of the Board:
●
The
initial equity grant upon first appointment (or election) of future
non-employee directors to the Board shall be a 10-year option to
purchase 2,253 shares of the Company's common stock, under the
Company's Second Amended and Restated 2014 Equity Incentive Plan
with 3-year annual vesting and a strike price equal the closing
price of the Company's common stock on the effective date of the
appointment (or election);
●
The
annual cash retainer for each non-employee director, paid
quarterly, is increased by $1,000 per calendar quarter to a total
of $7,000 per quarter, effective April 1, 2016; and
●
The
additional annual cash retainer for the chairperson of each of the
Audit, Compensation, and Nominating and Governance Committees, paid
quarterly, is increased by $1,000 per calendar year, such that each
chairperson retainer shall be as follows, effective April 1, 2016:
Audit Committee: $13,000; Compensation Committee: $9,000;
Nominating and Governance Committee: $6,000.
On August 25, 2016,
the Compensation Committee of the Board of Directors of the Company
approved the following amendments to Company's policy for
compensating non-employee members of the Board:
●
The
initial equity grant upon first appointment (or election) of future
non-employee directors to the Board shall be a 10-year option to
purchase 8,334 shares of the Company's common stock, under the
Company's Second Amended and Restated 2014 Equity Incentive Plan
with 3-year annual vesting and a strike price equal to the closing
price of the Company's common stock on the effective date of the
appointment (or election); and
●
The
additional automatic annual option grant to each non-employee
director on the date of the Company's annual meeting shall be a
10-year option to purchase 5,834 shares of the Company's common
stock, under the Company's Second Amended and Restated 2014 Equity
Incentive Plan with 1-year vesting and a strike price equal to the
closing price of the Company's common stock on the date of the
annual meeting.
On
February 6, 2017, the Compensation Committee of the Board of
Directors of the Company approved the following amendments to
Company's policy for compensating non-employee members of the
Board:
●
The
initial equity grant upon first appointment (or election) of future
non-employee directors to the Board shall be a 10-year option to
purchase 10,000 shares of the Company's common stock, under the
Plan with 3-year annual vesting and a strike price equal to the
closing price of the Company's common stock on the effective date
of the appointment (or election); and
●
The
additional automatic annual option grant to each non-employee
director on the date of the Company's annual meeting shall be a
10-year option to purchase 6,667 shares of the Company's common
stock, under the Plan with 1-year vesting and a strike price equal
the closing price of the Company's common stock on the date of the
annual meeting.
Effective
with the Company’s pay period ending August 10, 2017, and
without changing their employment agreements dated July 1, 2017,
several members of management volunteered to defer receiving
portions of their salaries for the remainder of 2017. The voluntary
deferral of cash payments was intended to help with the
Company’s cash flow for the remainder of the year, with
voluntary reductions by the management team committed to remain in
effect until the earlier of completing a successful financing of at
least $8.0 million, a business transaction that represents, or
business transactions in the aggregate that represent, an amount of
$10.0 million or greater, or the end of the year, whichever occurs
first.
On
August 14, 2017, the Chairman of the Compensation Committee, acting
on behalf of the Board of Directors sent a letter to each executive
of the Company stating that the Board deems it in the best
interests of the Company to request that the executive voluntarily
defer a portion of his regular salary to help with cash flow of the
Company, and that the employment agreements between the Company and
each executive were being modified to reduce the terms of their
employment agreements from three years to two years from the
effective date of each applicable agreement. On August 16 and
August 21, 2017, Paul Resnick, M.D. and Paul Maffuid, Ph.D.,
respectively, gave notice of good reason (as that term is defined
in their employment agreements or “Good Reason”) for
termination of their employment, primarily because of concerns of a
potential permanent loss of salary and that nothing in writing had
been provided as possible equity compensation. The Company cured
each executive’s concerns within the 30-day cure period
provided under their employment agreements, by reinstating the
deferred salary for Dr. Resnick in one instance, and in granting
restricted stock to all executives with vesting over time, as
disclosed in the filings of Form 4s following approvals by the
Board of Directors. Both executives rescinded their notices of good
reason for termination on September 7, 2017, and the employment
agreements with the Company remain unchanged.
Common Stock Reserved for Future Issuance
Common
stock reserved for future issuance consists of the following at
December 31, 2017:
Common
stock reserved for conversion of preferred stock and
warrants
|
6,645,559
|
Common
stock options outstanding
|
953,937
|
Authorized
for future grant or issuance under the Stock Plan
|
1,521,481
|
Unvested
restricted stock
|
832,224
|
Total
|
9,953,201
|
11. Net Loss per Share
The
Company calculates basic and diluted net loss per share using the
weighted average number of shares of common stock outstanding
during the period. When the Company is in a net loss position, it
excludes from the calculation of diluted net loss per share all
potentially dilutive stock options, preferred stock and warrants,
and the diluted net loss per share is the same as the basic net
loss per share for such periods. If the Company was to be in a net
income position, the weighted average number of shares used to
calculate the diluted net income per share would include the
potential dilutive effect of in-the-money securities, as determined
using the treasury stock method.
The
table below presents the potentially dilutive securities that would
have been included in the calculation of diluted net loss per share
if they were not antidilutive for the periods presented. The
securities were antidilutive because the Company incurred a loss in
both 2017 and 2016. Including the securities in the diluted net
loss per share would have resulted in the loss per share being less
than it would without including the securities.
|
|
|
|
|
Stock
options
|
953,937
|
283,845
|
Preferred
stock
|
6,222,872
|
991,808
|
Unvested
restricted stock
|
832,224
|
68,493
|
Warrants
to purchase common stock
|
422,687
|
1,708,048
|
Total
|
8,431,720
|
3,052,194
|
12. Contracts and Agreements
Memorial Sloan Kettering
We have licensed
from MSK the exclusive world-wide developmental and commercial
rights to receive biological materials from vaccinated clinical
trial participants enrolled in any of the clinical trials involving
the vaccines licensed to us, allowing us to discover human
monoclonal antibody-based therapeutics. MSK has issued patents or
has pending patent applications on the vaccine antigen conjugates,
mixtures of vaccine antigen conjugates and methods of use. This
patent portfolio includes 12 issued patents in the
U.S. We own all monoclonal antibodies produced by the
antibody discovery program and we generally file patent
applications directed to these antibodies once their potential
therapeutic utility has been sufficiently demonstrated in animal
models. United States and an foreign patent applications for each
of the anti-sLea antibodies and the anti-GD2 antibodies described
in this document have been filed. Within these filings, one U.S.
patent has issued for each of the anti-sLea antibodies and the
anti-GD2 antibodies.
Life Technologies Licensing Agreement
On
September 24, 2015, we entered into a licensing agreement with Life
Technologies Corporation, a subsidiary of ThermoFisher Scientific
(“Life Technologies”). Under the agreement
we agreed to license certain cell lines from Life Technologies to
be used in the production of recombinant proteins for our clinical
trials. The amount of the contract is for $450,000 and
was fully expensed during 2015. We paid $225,000 during
2015 related to this contract with the remaining amount paid in
2016.
Rockefeller University Collaboration
In July 2015, we
entered into a research collaboration agreement with Rockefeller
University's Laboratory of Molecular Genetics and Immunology
(“Rockefeller”). We provided antibody material to
Rockefeller, which is exploring the mechanism of action of constant
region (Fc) variants of the HuMab 5B1 in the role of tumor
clearance. The agreement allowed researchers at Rockefeller to
conduct research on antibodies discovered by us with the objective
of improving their ability to kill cancer cells. If a
viable drug candidate emerges from this collaboration, we have the
right to enter into negotiations with Rockefeller for the right to
exclusively license the technology used to improve our antibody for
clinical and commercial development. If we and
Rockefeller fail to reach agreement on terms for a license to the
drug candidate that contains the combined technologies, Rockefeller
does not have the right to license the drug candidate to a third
party without our consent because the drug candidate contains our
intellectual property embodied in the antibody. The research
collaboration agreement expired in July of 2017 but the provisions
of confidentiality and right to enter negotiations for certain
technology remain in place.
Patheon Biologics LLC Agreement
On
April 14, 2014, the Company entered into a development and
manufacturing services agreement (the “Services
Agreement”) with Patheon (f.k.a. Gallus Biopharmaceuticals)
to provide a full range of manufacturing and bioprocessing
services, including cell line development, process development,
protein production, cell culture, protein purification,
bio-analytical chemistry and quality control, or QC,
testing. Total amount of the contract is estimated at
approximately $3.0 million. For the years ended December
31, 2017 and 2016, the Company recorded $55,845 and $0 of expense,
respectively, associated with the Services Agreement. During 2016,
the Company negotiated a reduction in the amount previously
recorded and owed to Patheon related to manufacturing batches that
have failed, resulting in the reduction in R&D expenses of
approximately $363,000 during the third quarter of
2016.
Juno Therapeutics Option Agreement
On
August 29, 2014, the Company entered into an option agreement (the
“Option Agreement”) with Juno Therapeutics, Inc.
(“Juno”) in exchange for a one-time up-front option fee
in the low five figures. Pursuant to the Option Agreement, the
Company granted Juno the option to obtain an exclusive, world-wide,
royalty-bearing license authorizing Juno to develop, make, have
made, use, import, have imported, sell, have sold, offer for sale
and otherwise exploit certain patents the Company developed with
respect to fully human antibodies with binding specificity against
human GD2 or sialyl-Lewis A antigens and certain Company controlled
biologic materials. As of June 30, 2016, the Option Agreement
expired and Juno no longer has a contractual right for use of the
Company’s binding domains for use in the construction of CAR
T-cells.
During
the years ended December 31, 2017 and 2016, no revenues had been
earned under the Option Agreement.
13. Commitments and Contingencies
Capital Leases
On
March 21, 2016, the Company entered into a lease agreement with
ThermoFisher Scientific (“Lessor”). Under
the terms of the agreement, the Company agreed to lease two pieces
of equipment from the Lessor, a liquid chromatography system and an
incubator, totaling in cost of $91,941. The term of the
lease is five years (60 months), and the monthly lease payment is
$1,867. In addition, there is a $1.00 buyout option at the end of
the lease term.
Minimum
future annual capital lease obligations are as follows as of
December 31, 2017:
2018
|
$
22,402
|
2019
|
22,402
|
2020
|
22,402
|
2021
|
5,601
|
Less
interest
|
(9,140
)
|
Principal
|
63,667
|
Less
current portion
|
(17,810
)
|
Noncurrent
portion
|
$
45,857
|
Operating Leases
In
connection with the Merger, the Company recorded a $590,504
contingent lease termination fee, related to the termination of the
master lease and sublease of the Porter Drive Facility by MabVax
Therapeutics Holdings (f.k.a. Telik, Inc.), which is payable to
ARE-San Francisco No. 24 (“ARE”) if the Company
receives $15 million or more in additional financing in the
aggregate. The additional financing was achieved in 2015 and the
termination fee is reflected on the balance sheet as an accrued
lease contingency fee.
On September 2, 2015,
the Company
entered into a lease (the
“Lease”) with AGP Sorrento Business Complex, L.P., for
certain premises of office and laboratory space in buildings
located at 11535 Sorrento Valley Rd., San Diego, California, to
serve as the Company’s corporate offices and laboratories
(the “New Premises”). Due to the fact that
certain tenant improvements needed to be made to the New Premises
before the Company could take occupancy, the term of the Lease did
not commence until the New Premises were ready for occupancy, on
February 4, 2016. The Lease terminates six years after
such term commencement date, unless earlier terminated in
accordance with the Lease. Pursuant to the terms of the Lease, the
monthly base rent will be $35,631, subject to annual increases as
set forth in the Lease.
The
Company has an option to extend the Lease term for a single,
five-year period. If the Lease term is extended for the
optional five-year period, the monthly base rent will be adjusted
based on fair market rental value. In addition to rent,
the Company agreed to pay a portion of the taxes and utility,
maintenance and other operating costs paid or accrued in connection
with the ownership and operation of the property.
The
Company previously leased its corporate office and laboratory space
under an operating lease that, as amended on August 1, 2010,
expired on July 31, 2015.
We
recognize rent expense on a straight-line basis over the term the
lease. Rent expense of $460,952 and $433,397 was recognized in the
years ended December 31, 2017 and 2016,
respectively.
Minimum
future annual operating lease obligations are as follows as of
December 31, 2017:
2018
|
$
451,409
|
2019
|
464,951
|
2020
|
478,900
|
2021
|
493,267
|
Thereafter
|
82,612
|
Total
|
$
1,971,139
|
14. Employee Benefit Plans
401(k) Plan
Effective
January 1, 2017, the Company initiated a safe harbor contribution
program for the benefit of the Company’s Contribution Benefit
plan (the “Plan”) whereby, for all employees who were
eligible to participate in the Plan in compliance with
Section 401(k) of the Internal Revenue Code, the Company
contributed 3% of each participant’s salary to the Plan
which vested immediately. For the year ended December 31, 2017, the
Company paid $116,888 to the Plan.
15. Income Taxes
The components of
the provision for income taxes for the years ended December 31,
2017 and 2016 is as follows:
|
|
|
Deferred:
|
|
|
Federal
|
$
3,451,500
|
$
(5,745,300
)
|
State
|
(2,869,600
)
|
(990,400
)
|
|
581,900
|
(6,735,700
)
|
Less valuation
allowance
|
(581,900
)
|
6,735,700
|
|
|
|
Income tax
expense
|
$
—
|
$
—
|
Deferred income
taxes reflect the net tax effects of temporary differences between
the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes.
Significant components of the Company’s net deferred tax
assets are as follows as of December 31, 2017 and
2016:
|
|
|
Deferred tax
assets:
|
|
|
Net operating loss
carryforwards
|
$
17,638,000
|
$
20,169,000
|
Tax
credits
|
6,222,000
|
5,065,000
|
Accrued expenses
and other
|
3,460,000
|
2,667,900
|
Total deferred tax
assets
|
27,320,000
|
27,901,900
|
Less valuation
allowance
|
(27,320,000
)
|
(27,901,900
)
|
|
|
|
Net deferred tax
assets
|
$
—
|
$
—
|
The Company has
evaluated the available evidence supporting the realization of its
gross deferred tax assets, including the amount and timing of
future taxable income, and has determined that it is more likely
than not that the deferred tax assets will not be realized. Due to
such uncertainties surrounding the realization of the
Company’s deferred tax assets, the Company maintains a
valuation allowance of $27,320,000 against its deferred tax assets
as of December 31, 2017. Realization of the deferred tax assets
will be primarily dependent upon the Company’s ability to
generate sufficient taxable income prior to the expiration of its
net operating losses.
During the year
ended December 31, 2017, the Company had a net decrease in deferred
tax asset of $581,900. This change is a result of current year
activity as well as a change in the federal tax rates. The change
as a result of current year increase in deferred tax assets is
$7,425,100 offset by a $8,007,000 decrease due to a remeasurement
of the deferred tax asset based on new tax rates established
through the Tax Cuts and Jobs Act passed December 22, 2017. The
remeasurement is a provisional estimate under SAB 118 that could be
revised based on any additional guidance issued by the U.S.
Treasury Department, the U.S. Internal Revenue Service, and other
standard-setting bodies. On December 22, 2017, H.R.1, known as the
Tax Cuts and Jobs Act, was enacted. This new law did not have a
significant impact on the Company’s consolidated financial
statements for the year ended December 31, 2017 because the company
maintains a valuation allowance on the entirety of its deferred tax
assets. However, the reduction of the U.S. federal corporate tax
rate from 35% to 21% resulted in a remeasurement of the deferred
tax asset reflected in the tax rate reconciliation below as well as
the deferred tax asset listed above.
Given the
significant impact of the Tax Cuts and Jobs Act, the SEC staff
issued Staff Accounting Bulletin (“SAB”) 118 which
provides guidance on accounting for uncertainties of the effects of
the Tax Act. Specifically, SAB 118 allows companies to record a
provisional estimate of the impact of the Tax Act during a one year
“measurement period”. The company has recognized the
provisional tax impact related to the revaluation of deferred tax
assets and liabilities and included these amounts in its
consolidated financial statements for the year ended December 31,
2017. The ultimate impact may differ from these provisional
amounts, due to, among other things, additional analysis, changes
in interpretations and assumptions the Company has made, and
additional regulatory guidance that may be issued.
During the year
ended December 31, 2014, MabVax Therapeutics, Inc. merged with
Telik, Inc. in a tax-free reorganization. As a result of the
merger, all components of Telik’s deferred tax assets are now
included as deferred tax assets of MabVax Therapeutics, Inc. These
pre-merger deferred tax assets are net operating loss carryforwards
of $1,588,000, research and development credit carryforwards of
$4,457,000, in total equaling $6,045,000. The current year change
in these assets have been reflected in the provision for income
taxes.
As of December 31,
2017, the Company had net operating loss carryforwards of
approximately $62,885,000 and $63,463,000 for federal and state
income tax purposes, respectively. These may be used to offset
future taxable income and will begin to expire in varying amounts
in 2028 to 2037. The Company also has research and development
credits of approximately $744,500 and $6,934,000 for federal and
state income tax purposes, respectively. The federal credits may be
used to offset future taxable income and will begin to expire at
various dates beginning in 2030 through 2037. The state credits may
be used to offset future taxable income, such credits carryforward
indefinitely.
For all years
through December 31, 2017, the Company generated research and
development credits but has not completed a study to document the
qualified activities. This study may result in an adjustment to the
Company’s research and development credit carryforwards;
however, until a study is complete and any adjustment is known, no
amounts are being presented as an uncertain tax position. A full
valuation allowance has been provided against the Company’s
research and development credits, and if an adjustment is required
this adjustment would be offset by an adjustment to the valuation
allowance. Thus, there would be no impact to the balance sheets or
statements of operations and comprehensive loss if an adjustment
were required.
The Company is
subject to taxation in the U.S. and California jurisdictions.
Currently, no historical years are under examination. The
Company’s tax years ended December 31, 2017 and 2016 are
subject to examination by the U.S. and state taxing authorities due
to the carryforward of unutilized net operating losses and research
and development credits.
Utilization of the
Company’s net operating loss carryforwards and research and
development credit carryforwards may be subject to a substantial
annual limitation due to an “ownership change” that may
have occurred, or that could occur in the future, as defined and
required by Section 382 of the Internal Revenue Code of 1986, as
amended (the “Code”), as well as similar state
provisions. These ownership changes may limit the amount of net
operating loss carryforwards and research and development credit
carryforwards, and other tax attributes that can be utilized
annually to offset future taxable income and tax, respectively. Any
limitation may result in the expiration of a portion of the net
operating loss carryforwards or research and development credit
carryforwards before utilization. The net operating loss
carryforwards and research and development credit carryforwards
inherited as a result of the merger with Telik, Inc. have been
severely limited under these rules and will likely not be
realized.
In general, an
“ownership change” results from a transaction or series
of transactions over a three-year period resulting in an ownership
change of more than 50% of the outstanding stock of a company by
certain stockholders or public groups. The Company intends to
complete a study in the future to assess whether an ownership
change has occurred or whether there have been multiple ownership
changes since the Company’s formation, and will complete such
study before the use of any of the aforementioned
attributes.
The provision for
income taxes differs from the amount computed by applying the U.S.
federal statutory tax rate (34% in 2017 and 2016) to income taxes
as follows:
|
|
|
Tax benefit
computed at 34%
|
$
(6,466,500
)
|
$
(6,004,000
)
|
|
|
|
State tax
provision, net of federal tax benefit
|
(1,092,444
)
|
(989,344
)
|
|
|
|
Change in valuation
allowance
|
(581,900
)
|
6,735,600
|
Change in valuation
allowance due to overall Federal rate change
|
8,007,000
|
-
|
Other
|
133,844
|
257,744
|
Tax provision
(benefit)
|
$
—
|
—
|
The Company has adopted ASC 740-10-25. This
interpretation clarifies the criteria for recognizing income tax
benefits under ASC 740,
“Accounting for Income
Taxes”,
and requires
additional disclosures about uncertain tax positions. Under ASC
740-10-25 the financial statement recognition of the benefit for a
tax position is dependent upon the benefit being more likely than
not to be sustainable upon audit by the applicable taxing
authority. If this threshold is met, the tax benefit is then
measured and recognized at the largest amount that is greater than
50 percent likely of being realized upon ultimate
settlement.
16. Subsequent Events
Overview
of 2018 Private Placements
Between February 2
and February 10, 2018, the Company entered into separate purchase
agreements with investors pursuant to which the Company sold (i)
shares of its common stock, (ii) shares of its convertible
preferred stock
,
and
(iii) warrants to purchase shares of common stock (the
“February 2018 Private Placements”). From April 30 to
May 2, 2018, the Company entered into separate purchase agreements
with investors pursuant to which the Company agreed to sell shares
of its common stock and convertible preferred stock
(the “May 2018 Private
Placements”)
. No financial advisor was used in
connection with the February 2018 Private Placements nor the May
2018 Private Placements.
The securities
issued in connection with the February 2018 Private Placements and
the May 2018 Private Placements were offered and sold solely to
accredited investors in reliance on the exemption from registration
afforded by Rule 506 of Regulation D and Section 4(a)(2) of the
Securities Act. The Company entered into separate registration
rights agreements with each of the investors in the February 2018
Private Placements and the May 2018 Private Placements, pursuant to
which the Company agreed to undertake to file a registration
statement to register the resale of the shares of common stock and
the shares of common stock underlying the warrants and preferred
stock. The Company also agreed to use reasonable best efforts to
cause such registration statement to be declared effective and to
maintain the effectiveness of the registration statement until all
of such shares of common stock have been sold or are otherwise able
to be sold pursuant to Rule 144 under the Securities Act, without
any restrictions.
February
2018 Private Placements
In connection with
the February 2018 Private Placements, the Company sold (i) an
aggregate of 555,562 shares of its common stock for an aggregate
purchase price of $1,250,000, or $2.25 per share, (ii) 5,000 shares
of its newly designated 0%
Series M Convertible Preferred Stock
(the “Series M Preferred Stock”) for an aggregate
purchase price of $1,500,000, or $300.00 per share,
and
(iii) warrants to purchase up to an aggregate of 855,561 shares of
common stock each with an exercise price of $2.70 per share. The
net proceeds of the February 2018 Private Placements were
$2,700,000 after transaction costs of $50,000.
May
2018 Private Placements
In connection with
the May 2018 Private Placements, the Company agreed to sell (i)
218,182 shares of common stock at an aggregate purchase price of
$240,000, or $1.10 per share, and (ii) 5,363.64 shares of newly
designated 0%
Series N
Convertible Preferred Stock (the “Series N Preferred
Stock”) at an aggregate purchase price of $590,000, or
$110.00 per share
.
Under the terms of
the May 2018 Private Placements, the Company was required to offer
an aggregate of 12,777.77 shares (the “May 2018 Inducement
Shares”) of newly designated 0% Series O Preferred Stock (the
“Series O Preferred Stock”) to investors who previously
purchased securities in the February 2018 Private Placements and
who also purchased securities in the May 2018 Private Placements
with an aggregate purchase price of at least 40% of their
investment amounts in the February 2018 Private Placements. Based
on the closing of the offering, and participation of certain prior
investors who invested an aggregate of $830,000 (the “May
2018 Inducement Investors”), the Company issued an aggregate
of 10,605.56 May 2018 Inducement Shares in the form of Series O
Preferred Stock convertible into an aggregate of 1,060,556 shares
of common stock.
The May
2018 Private Placements closed on May 15, 2018, with the Company
receiving gross proceeds totaling $830,000
.
Series
L Convertible Preferred Stock Conversions
Between January 16
and January 26, 2018, an aggregate of 12,500 shares of Series L
Preferred Stock were converted into 694,445 shares of common
stock.
Series
I Convertible Preferred Stock Conversions
On February 12,
2018, Grander Holdings, Inc. 401K, a holder of Series I Convertible
Preferred Stock (“Series I Preferred Stock”), converted
152,820 shares of Series I Preferred Stock into 50,940 shares of
common stock.
Reverse
Stock Split
On February 14,
2018, the Company filed a certificate of amendment to its Amended
and Restated Certificate of Incorporation with the Secretary of
State of the State of Delaware to effectuate another reverse stock
split of the Company's issued and outstanding common stock on a
1-for-3 basis, effective on February 16, 2018. All share and per
share amounts, and number of shares of common stock into which each
share of preferred stock will convert, in the financial statements
and notes thereto have been retroactively adjusted for all periods
presented to give effect to the reverse stock split, including
rounding for fractional shares and reclassifying any amount equal
to the reduction in par value of common stock to additional paid-in
capital.
Compensation Committee Decisions
On
February 21, 2018, the Compensation Committee of the Company made
the following decisions.
Review of
Management Compensation
–
The Compensation Committee determined that no bonus payments would
be made for 2017 performance. Further, the Compensation Committee
determined that in order to continue to conserve cash resources,
management’s base salaries would remain unchanged from
current levels.
The
Compensation Committee granted stock options with an exercise price
based on the closing price of the shares of common stock on
February 21, 2018, or $2.04, to the following officers of the
Company:
J.
David Hansen
|
President
and Chief Executive Officer
|
290,000
stock options
|
Paul
W. Maffuid
|
Executive
Vice President of Research and Development
|
195,000
stock options
|
Gregory
P. Hanson
|
Chief
Financial Officer
|
195,000
stock options
|
Paul
F. Resnick
|
Vice
President and Chief Business Officer
|
80,000
stock options
|
The
stock options will vest at 25% of the total number granted at the
six-month anniversary of the commencement date, with the balance in
equal monthly installments of 4.167% of the number of shares for 18
months, such that 100% of the options will be vested after two
years from the grant date.
Review of
Board of Directors Compensation
– The Compensation Committee granted 35,000
stock options to each non-executive member of the Board of
Directors, with vesting on a monthly basis until the options are
fully vested at one year from the grant date, in lieu of cash
compensation for 2018. The Compensation Committee increased the
automatic annual grant on the next annual meeting date from 16,667
shares to 20,000 shares with the same monthly
vesting.
On
July 9, 2018, the Compensation Committee of the Company made the
following decision.
Review of
Board of Directors Compensation
– The Compensation Committee authorized the
re-instatement of fees to each non-executive member of the Board of
Directors of $3,000 per month, effective July 1,
2018.
Amendments
to Articles of Incorporation or Bylaws
Amendment to Amended and
Restated Certificate of Incorporation –
On February 14, 2018,
the Company filed a certificate of amendment to its amended and
restated certificate of incorporation to effect a 1-for-3 reverse
stock split effective as of 9:00 a.m. Eastern Standard Time on
February 16, 2018 (the “Effective Date”). On the
Effective Date, every three shares of MabVax common stock issued
and outstanding immediately prior to the Effective Date
automatically converted into one share of MabVax common
stock.
Certificate of
Designations, Preferences and Rights of the 0% Series N Convertible
Preferred Stock –
On April 30, 2018, the
Company filed a Certificate of Designations, Preferences and Rights
of the 0% Series N Convertible Preferred Stock (the “Series N
Certificate of Designations”) with the Secretary of State of
the State of Delaware, designating 20,000 shares of preferred stock
as Series N Preferred Stock.
The
shares of Series N Preferred Stock are convertible into shares of
common stock based on a conversion calculation equal to the stated
value of the Series N Preferred Stock, plus all accrued and unpaid
dividends, if any, on such Series N Preferred Stock, as of such
date of determination, divided by the conversion price. The stated
value of each share of Series N Preferred Stock is $110 and the
initial conversion price is $1.10 per share, each subject to
adjustment for stock splits, stock dividends, recapitalizations,
combinations, subdivisions or other similar events.
The Series N
Certificate of Designations includes a 4.9% beneficial ownership
conversion blocker, a 19.99% blocker provision until
stockholders have approved any or all
shares of common stock issuable upon conversion of the Series N
Preferred Stock, and price protection for so long as the holder
owns the Series N Preferred Stock. All shares of the
Company’s capital stock will be junior in rank to the Series
N Preferred Stock, with respect to the preferences as to dividends,
distributions and payments upon the liquidation, dissolution and
winding-up of the Company, except for the Company’s Series D
Preferred Stock, Series E Preferred Stock, Series I Preferred
Stock, Series J Preferred Stock, Series K Preferred Stock, Series L
Preferred Stock and Series M Preferred Stock.
In the event of liquidation, the holders of Series
N Preferred Stock shall be entitled to receive in cash out of the
assets of the Company, whether from capital or from earnings
available for distribution to its shareholders (the
“Liquidation Funds”), before any amount shall be paid
to the holders of any of shares of capital stock, an amount per
Series N Preferred Share equal to the greater of (a) the par value
thereof on the date of such payment, and (b) the amount per share
such holder would receive if such holder converted such Series N
Preferred Stock into common stock immediately prior to the date of
such payment; provided, however, that, if the Liquidation Funds are
insufficient to pay the full amount due to the holders and holders
of shares of parity stock (stock ranking equal to the Series N
Preferred Shares), then each holder of Series N Preferred Stock and
each holder of parity stock shall receive a percentage of the
Liquidation Funds equal to the full amount of Liquidation Funds
payable to such holder and such holder of parity stock as a
liquidation preference, in accordance with their respective
certificate of designation (or equivalent), as a percentage of the
full amount of Liquidation Funds payable to all holders of Series N
Preferred Stock and all holders of shares of parity stock. All the
preferential amounts to be paid to the holders of Series N
Preferred Stock shall be paid or set apart for payment before the
payment or setting apart for payment of any amount for, or the
distribution of any Liquidation Funds of the Company to the holders
of shares of junior stock in connection with
the
liquidation, dissolution or winding up of the affairs of the
Company, whether voluntary or involuntary, or a consolidation or
merger of the Company with or into any other corporation or
corporations, or a sale of all or substantially all of the assets
of the Company, or the effectuation by the Company of a transaction
or series of transactions in which more than 50% of the voting
shares of the Company is disposed of or conveyed.
The
Company is prohibited from effecting a conversion of the Series N
Preferred Stock to the extent that, as a result of such conversion,
the holder would beneficially own more than 4.99% of the number of
shares of common stock outstanding immediately after giving effect
to the issuance of shares of common stock upon conversion of the
Series N Preferred Stock, which beneficial ownership limitation may
be increased by the holder up to, but not exceeding, 9.99%. Each
holder is entitled to vote on all matters submitted to stockholders
of the Company, and shall have the number of votes equal to the
number of shares of common stock issuable upon conversion of such
holder’s Series N Preferred Stock, but not in excess of the
beneficial ownership limitations, and except that the holder may
not vote for approval of shares of common stock issuable upon
conversion of Series N Preferred Stock at any meeting of the
Company's stockholders.
Correction to Certificate
of Designations, Preferences and Rights of the 0% Series N
Convertible Preferred Stock –
On May 2, 2018,
the Company
filed a correction to the Series N Certificate of
Designations.
The inaccuracy or
defect in the Series N Certificate of Designation was that the
Series N Certificate of Designation inadvertently stated a specific
number of shares in Section 4(f) “19.99% Conversion
Blocker.” The Series N Certificate of Designation
was
corrected by amending and restating
Section 4(f) in its entirety to remove such
inadvertent inclusion.
Certificate of
Designations, Preferences and Rights of the 0% Series O Convertible
Preferred Stock –
On April 30, 2018, the
Company filed a Certificate of Designations, Preferences and Rights
of the 0% Series O Convertible Preferred Stock with the Secretary
of State of the State of Delaware, designating 20,000 shares of
preferred stock as Series O Preferred
Stock.
The
shares of Series O Preferred Stock are convertible into shares of
common stock based on a conversion calculation equal to the stated
value of the Series O Preferred Stock, plus all accrued and unpaid
dividends, if any, on such Series O Preferred Stock, as of such
date of determination, divided by the conversion price. The stated
value of each share of Series O Preferred Stock is $0.01 and the
initial conversion price is $0.0001 per share, each subject to
adjustment for stock splits, stock dividends, recapitalizations,
combinations, subdivisions or other similar events. The Company is
not permitted to issue any shares of common stock upon conversion
of the Series O Preferred Stock until the Company obtains the
approval of its stockholders.
In the event of a liquidation, dissolution or
winding up of the Company, each share of Series O Preferred Stock
will be entitled to a per share preferential payment equal to the
stated value on the date of such payment.
All shares of capital
stock will be junior in rank to Series O Preferred Stock with
respect to the preferences as to dividends, distributions and
payments upon the liquidation, dissolution and winding-up of the
Company, except for the Company’s Series D Preferred Stock,
Series E Preferred Stock, Series I Preferred Stock, Series J
Preferred Stock, Series K Preferred Stock, Series L Preferred
Stock, Series M Preferred Stock and Series N Preferred
Stock.
The holders of Series O
Preferred Stock will be entitled to receive dividends if and when
declared by the Company’s board of directors. The Series O
Preferred Stock shall participate on an “as converted”
basis, with all dividends declared on the Company’s common
stock. In addition, if the Company grants, issues or
sells any rights to purchase its securities pro rata to all record
holders of the Company’s common stock, each holder will be
entitled to acquire such securities applicable to the granted
purchase rights as if the holder had held the number of shares of
common stock acquirable upon complete conversion of all Series O
Preferred Stock then held.
The
Company is prohibited from effecting a conversion of the Series O
Preferred Stock to the extent that, as a result of such conversion,
the holder would beneficially own more than 4.99% of the number of
shares of common stock outstanding immediately after giving effect
to the issuance of shares of common stock upon conversion of the
Series O Preferred Stock, which beneficial ownership limitation may
be increased by the holder up to, but not exceeding, 9.99%. Each
holder is entitled to vote on all matters submitted to stockholders
of the Company, and shall have the number of votes equal to the
number of shares of common stock issuable upon conversion of such
holder’s Series O Preferred Stock, but not in excess of the
beneficial ownership limitations, and except that the holder may
not vote for approval of shares of common stock issuable upon
conversion of Series O Preferred Stock at any meeting of the
Company's stockholders.
Sublicense Grant to Y-mAbs Therapeutics, Inc.
On June 27, 2018, the Company granted an exclusive
sublicense to Y-mAbs Therapeutics, Inc., a privately held clinical
stage biopharmaceutical company (“Y-mAbs”), for a
bi-valent ganglioside-based vaccine intended to treat
neuroblastoma, a rare pediatric cancer (the “Y-mAbs
Sublicense”). Total value of the transaction to MabVax is
$1.3 million plus a share of a Priority Review Voucher (as defined
in the sublicense agreement) if granted by the FDA to Y-mAbs on
approval of the vaccine and the Priority Review Voucher is
subsequently sold. Additionally, Y-mAbs will be responsible for all
further development of the product as well as any downstream
payment obligations related to this specific vaccine to
Memorial Sloan Kettering Cancer Center
(“MSK”) that were specified in the
original MabVax-MSK license agreement dated April 30, 2008. If
Y-mAbs successfully develops and receives FDA approval for the
neuroblastoma vaccine, it is obligated to file with the FDA for a
Priority Review Voucher. If the voucher is granted to Y-mAbs and
subsequently sold, then MabVax will receive a percentage of the
proceeds from the sale of the voucher by Y-mAbs. Upon entering the
Y-mAbs Sublicense, the Company received an upfront payment of
$700,000 and will receive an additional $600,000 upon the one-year
anniversary of entering into the agreement (assuming the agreement
is still in effect).
The
Y-mAbs
Sublicense
contains termination provisions allowing for the
termination of the agreement (i) upon material breach if the
breaching party fails to cure the breach within 60 days of notice
by the non-breaching party, (ii) by Y-mAbs at any time upon 90
days’ advance notice to MabVax, or (iii) the expiration or
termination of the underlying license from MSK to MabVax, provided
that MSK will assume the agreement if Y-mAbs is in material
compliance with the agreement upon the termination of the
MSK-MabVax license
. There were no
continuing obligations on the part of the Company in connection
with the agreement other than one-time administrative matters that
were completed within thirty (30) days of signing the
agreement.
Letter Agreement with MSK
On
June 27, 2018, the Company entered into a letter agreement with MSK
(the “MSK Letter”) in connection with obtaining the
consent from MSK for the Company to enter into the Y-mAbs
Sublicense and allow Y-mAbs to “step into the shoes” of
the obligations that the Company would have had to pay MSK if the
Company had continued development of the neuroblastoma vaccine,
including future payment obligations of the Company regarding
future milestones. As part of the agreement, the Company and MSK
agreed that MabVax would receive 100% of both the $700,000 upfront
payment and $600,000 upon the one-year anniversary of the Y-mAbs
Sublicense, and the Company would pay an aggregate of $398,534 to
MSK in connection with prior expenses incurred by MSK in relation
to MSK’s longstanding relationship and collaboration with the
Company.
Amendments
and Notices Related to Oxford Finance Loan Agreement
On July 3, 2018,
the Company and Oxford Finance signed the Second Amendment to Loan
and Security Agreement whereby Oxford Finance has (i) consented to
the Company’s license and sale to Boehringer Ingelheim
(defined below)
of the
Acquired Assets and release of any encumbrances under the Loan
Agreement that relate to the Acquired Assets, (ii) payments of
advisory fees to Greenhill & Company of $385,000 over the
course of six months in equal monthly payments, and (iii) deferred
principal payments under the Loan Agreement for six months starting
with the July 2018 payment, in exchange for the Company granting
such additional collateral that was not pledged previously or in
which security interest was not granted prior to the Second
Amendment. The Company is obligated to pay a fully earned and
non-refundable amendment fee of $5,000 to Oxford Finance, which
shall become due and payable upon the earlier of: (i) the maturity
date of the term loans, (ii) the acceleration of any term loan, or
(iii) the prepayment of the term loans pursuant to the Loan and
Security Agreement.
As a result of the
deferred principal payments under the Loan Agreement, the future
principal payments under notes payable for the Loan Agreement as of
July 1, 2018 are as follows:
Years ending
December 31:
|
|
2018
(remaining)
|
$
-
|
2019
|
2,380,952
|
2020
|
396,826
|
Notes payable,
balance as of July 1, 2018
|
2,777,778
|
Unamortized
discount on notes payable
|
(235,560
)
|
Notes payable, net,
balance as of July 1, 2018
|
2,542,218
|
Current portion of
notes payable as of July 1, 2018, net
|
(1,190,476
)
|
Non-current portion
of notes payable as of July 1, 2018, net
|
$
1,351,742
|
On August 14, 2018,
the Company received a letter from Oxford Finance (the
“Notice”) asserting certain events of default under the
Loan Agreement had occurred as a result of certain events the
Company reported as having occurred, including, without limitation,
(i) the resignation of the Company’s external auditor,
effective August 3, 2018, and its withdrawal of its audit reports
for the years 2014 through 2017, (ii) the resignation of four
members of the Board of Directors, effective as of July 31, 2018,
and (iii) the delisting of the Company’s common stock from
The Nasdaq Stock Market LLC on July 11, 2018 (collectively, the
“Alleged Default Events”). The Company has informed
Oxford Finance that it disputes the Alleged Default Events
individually or collectively constitute a “Material Adverse
Change” or other event of default under the Loan Agreement.
In addition, the Company has already engaged a new auditor, Haskell
& White LLP, effective August 22, 2018, and on September 20,
2018, the Court ratified the Delaware Petition. The Company also
intends to apply for listing on the OTCQB Venture Marketplace (the
“OTCQB Marketplace”) once it meets the requisite
eligibility requirements, which are subject to appointing at least
one independent member to the Board of Directors, with the second
independent member to be placed on the Board of Directors within 30
days of uplisting to the OTCQB Marketplace.
Asset
Purchase and License Agreement with Boehringer
Ingelheim
On July 6, 2018,
the Company entered into an
Asset
Purchase Agreement and License Agreement
(the “Asset Purchase
Agreement”)
with Boehringer Ingelheim International
GmbH (“Boehringer Ingelheim”)
centered on MabVax's program
targeting a glycan commonly overexpressed on multiple solid tumor
cancers. Boehringer Ingelheim has acquired all rights in and to the
program. MabVax received $4 million upon signing the agreement and
will receive an additional $7 million in connection with near-term
milestones and downstream regulatory milestone payments plus
further earn-out payments. The asset acquisition is separate and
distinct from other programs under development at MabVax, enabling
MabVax to retain all rights to its lead HuMab-5B1 antibody program
which is in Phase 1 clinical trials as a therapeutic product
candidate and as a diagnostic product candidate, as well as other
antibody discovery programs from the Company's antibody discovery
portfolio targeting other cancer antigens.
Cold
Spring Harbor Laboratory License Agreement
On September 8,
2018, the Company entered into an agreement with Cold Spring Harbor
Laboratory (“CSHL”), a nonprofit New York State
education corporation, whereby the Company licensed the exclusive
worldwide rights to certain technology including interest in
certain patent applications by the Company for a new indication for
MVT-5873. The Company paid $20,000 as an upfront license fee and
will pay to CSHL a nonrefundable annual license maintenance fee of
the same amount beginning on January 1, 2020 and continuing each
year thereafter during the term of the agreement and will increase
to $50,000 a year upon issuance of the first patent in connection
with the technology. The annual license fee will be reduced for any
patent prosecution and maintenance costs and will be fully
creditable against any royalties or milestone payments earned
during the year. Future milestone payments are in the aggregate
less than $2.5 million, with royalties that range from 0.25% if no
valid claim to patents, to 2.5% if there is a valid claim of the
patent in the territory of sales.
Legal
Proceedings
SEC
Complaint and SEC Action
On January 29,
2018, the Company
received notice from
the SEC of an investigation (along with the SEC Complaint, defined
below, the "SEC Action"). We believe the SEC is investigating (i)
potential violations by the Company and its officers, directors and
others of Section 10(b) of the Exchange Act and Section 17(a) of
the Securities Act; and (ii) potential violations by multiple
holders of the Company’s preferred stock who are among those
included in the Aggregated Investors (as defined in Part III, Item
12,
“
Security
Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters
”
of
Form 10-K/A, filed with the SEC on October 15, 2018) of the
reporting and disclosure requirements imposed by Section 13(d) of
the Exchange Act and pursuant to Schedules 13D and 13G. The Company
further believes the SEC Action pertains to the Company’s
relationships with certain of the Aggregated Investors, including
(i) the circumstances under which those certain Aggregated
Investors invested in the Company and whether certain Aggregated
Investors have acted as an undisclosed group in connection with
their investment; (ii) the manner with or in which those
individuals and entities may have sought to control or influence
the Company and its leadership since their respective investments
(and the extent to which those efforts to control or influence have
been successful); and (iii) the Company’s prior disclosures
regarding the control of the Company and beneficial ownership of
the Company’s common and preferred stock included in its
registration statements filed in 2017 and 2018 and in the
Company’s Exchange Act reports.
On September 7,
2018, the SEC filed the SEC Complaint in the U.S. District
Court for the Southern District of New York against the following
Aggregated Investors: Barry C. Honig, John Stetson, Michael
Brauser, John R. O'Rourke III, Mark Groussman, Phillip
Frost, Alpha Capital Anstalt, ATG Capital LLC, Frost
Gamma Investments Trust, GRQ Consultants, Inc., Grander
Holdings, Inc., Melechdavid, Inc., OPKO Health, Inc., HS Contrarian
Investments, LLC, and Southern Biotech, Inc. (collectively,
the “Investor Defendants”), and against others who
the Company believes have not made any investment in the Company,
SEC v. Honig et al.
, No.
1:18-cv-01875 (S.D.N.Y. 2018). In the Complaint, the SEC alleges a
variety of misconduct with respect to the Investor
Defendants’ transactions and/or relationships with three
public issuers, including a public issuer identified as
“Company C,” which the Company understands to be MabVax
Therapeutics Holdings, Inc. With respect to “Company C”
in particular, the SEC alleges certain of the Investor Defendants
manipulated the price of the Company’s securities by writing,
or causing to be written, false or misleading promotional articles,
and a variety of other manipulative trading practices. The SEC
further alleges certain of the Investor Defendants filed false
reports of their beneficial ownership or failed to file reports of
their beneficial ownership when required to do so. The SEC claims
that, by engaging in this and other alleged actions in the SEC
Complaint, the Investor Defendants and other defendants violated
the anti-fraud and many other provisions of the Exchange Act, the
Securities Act, and SEC Rules promulgated thereunder. The SEC
Complaint does not assert any claims against the Company or any of
its directors or officers, nor otherwise allege that the Company or
any of its directors or officers were culpable participants in the
misconduct allegedly undertaken by the Investor
Defendants.
The
Company has cooperated with the SEC in connection with the SEC
Action. Although the SEC has not asserted claims against the
Company or any of its directors or officers, the Company cannot
predict whether the SEC Action ultimately will conclude in a manner
adverse to the Company or any of its directors and officers, or in
a manner adverse to the Investor Defendants or other of the
Company’s current or former stockholders. The Company also
cannot predict when the SEC Action or any related matters may
conclude, or how any such matters or resolution may impact how the
Company is perceived by the market, potential partners and
potential investors in the Company’s securities. In the past,
the SEC informed us it would not declare effective any registration
statements registering the Company’s securities effective
during the pendency of the SEC Action.
Company Filed Complaint Against Sichenzia Ross Ference
LLP
On September 10, 2018, the Company
filed, in the Superior Court of California, County of San Diego, a
complaint (the “Sichenzia Complaint”) against Sichenzia
Ross Ference LLP, a law firm that previously represented the
Company in certain corporate, securities, and SEC matters
(“Sichenzia”), and eight current Sichenzia partners,
and one former Sichenzia partner, Harvey Kesner,
MabVax
Therapeutics Holdings, Inc. v.
Sichenzia Ross Ference LLP et al.,
No.
37-2018-00045609-CU-PN-CTL.
The Sichenzia Complaint asserts claims
for negligent professional practice, breach of fiduciary
duty, breach of contract,
unjust enrichment, deceit, and fraud by the defendants. The Company
is evaluating additional claims it may have against others in
connection with the same or similar subject
matter.
Delaware
Order Granting Petition for Relief
On September 20,
2018, the Court entered an order validating (i) issuances of common
stock upon conversions of the Company’s preferred stock
occurring between June 30, 2014 and February 12, 2018, and (ii)
stockholder approval of corporate actions presented to the
Company’s stockholders from June 30, 2014 to February 12,
2018. In so doing, the Court granted the Delaware Petition, filed
on July 27, 2018, in order to rectify the uncertainty regarding
whether shares of the Company’s common stock were validly
issued upon conversion of the Company’s preferred stock from
June 30, 2014 to February 12, 2018.
Class Action and Derivative Complaints
In re MabVax Therapeutics
Securities Litigation
,
Case
No. 18-cv-1160-BAS-NLS.
On June 4, 2018, and August 3,
2018, two securities class action complaints were filed by
purported stockholders of the Company in the United States District
Court for the Southern District of California (the “U. S.
District Court”) against the Company and certain of its
current officers. On September 6, 2018, the U.S. District Court
consolidated the two actions and appointed lead plaintiffs. On
October 10, 2018, lead plaintiffs filed their consolidated
complaint, which, in addition to naming the Company and certain
current officers as defendants, also names certain investors as
defendants. The consolidated complaint alleges, among other things,
that the defendants violated Sections 10(b) and 20(a) of the
Exchange Act, and Rule 10b-5 thereunder, by misleading investors
about problems with the Company’s internal controls, improper
calculation of its beneficial ownership, and improper influence by
certain investors. The consolidated complaint also alleges that
some of the investor defendants violated Section 9 of the Exchange
Act by manipulating the Company’s stock price. The
consolidated complaint seeks unspecified damages, interest, fees
and costs. The current deadline to respond to the consolidated
complaint is December 6, 2018.
Liesman v. Hansen et
al.
,
Case No. 18-cv-2237-BTM-WVG
.
On September
26, 2018, a shareholder derivative complaint was filed in the
United States District Court for the Southern District of
California. The complaint arises from similar allegations as
In re MabVax Therapeutics
Securities Litigation
but asserts a state law breach of
fiduciary duty claim against certain of the Company’s current
and former directors and officers. In particular, the
complaint alleges that the defendants breached their fiduciary
duties by failing to implement the necessary controls to ensure
that certain financial disclosures and disclosures concerning stock
ownership were accurate. Plaintiff seeks, on behalf of the
Company, damages, fees, costs, and equitable relief.
Jackson v. Hansen et
al.
,
Case No.
18-cv-2302-BAS-MSB-BGS
.
On October 4,
2018, a shareholder derivative complaint was filed in the United
States District Court for the Southern District of
California. The complaint arises from similar allegations as
In re MabVax Therapeutics
Securities Litigation
and
Liesman v. Hansen et al.
but, in
addition to a breach of fiduciary duty claim, also includes causes
of action for unjust enrichment, abuse of control, gross
mismanagement and waste of corporate assets. Plaintiff seeks,
on behalf of the Company, damages, fees, costs, and equitable
relief. The deadline to respond to the complaint is December 21,
2018.
Nasdaq
De-listing and Intent to Apply for Listing on the OTCQB
Marketplace
On July 2, 2018,
the Listing Qualifications Department of the Nasdaq Stock Market
(the “Staff”) notified the Company of its determination
to delist the Company’s securities. In this notice, the Staff
indicated their determination was based upon the Company’s
failure to timely file all required reports with the SEC per Nasdaq
listing rule 5250(c)(1), and for the Company’s non-compliance
with the $2.5 million stockholders’ equity requirement per
Nasdaq listing rule 5550(b)(1). The Company elected not to appeal
the Staff’s decision and, as a result, on July 2, 2018, the
Company received a letter from the Staff indicating trading of the
Company’s common stock would be suspended on Nasdaq Capital
Market at the open of business on Wednesday, July 11, 2018. On July
11, 2018, the Company’s common stock began trading on the OTC
Pink, continuing under the symbol MBVX. The Hearing Department of
the Nasdaq Stock Market notified us on September 24, 2018, that it
would announce the delisting of our common stock. On September 26,
2018, the Nasdaq Stock Market issued a press release and posted a
notice to its website announcing it would delist our common stock
and file a Form 25 with the SEC to complete the delisting. The
delisting becomes effective ten (10) days after the Form 25 is
filed with the SEC.
The Company
currently intends to apply for listing on the OTCQB Marketplace
once the Company meets the requisite eligibility requirements for
the OTCQB Marketplace.
Resignation and Appointment of Members of the
Board of Directors
Effective July 31, 2018, Paul Maier,
Jeffrey E. Eisenberg, Thomas C. Varvaro and Kenneth Cohen, resigned
as members of
the Company’s Board of Directors. There
were no disagreements between the resigning members of the Board of
Directors and management.
Following the
resignations, in a separate action, the Company’s Board of
Directors appointed the Company’s Chief Financial Officer,
Gregory Hanson, as a member of the Board of Directors. Mr. Hanson
has served as the Company’s Chief Financial Officer since
July 2014, and of its subsidiary, MabVax Therapeutics, Inc., since
February 2014.
Mr. Hanson
has over 30 years' experience serving as the CFO, financial
executive and director of public and private life sciences and
hi-tech companies. Since October 2016, he has served as a member of
the board of directors of a private pharmaceutical contract
research organization.
PROSPECTUS
, 2018